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ABSTRACT OF THE DISSERTATION
LIFESTYLE AND BIOLOGICAL RISK FACTORS FOR LIVER FIBROSIS IN THE
MIAMI ADULT STUDIES ON HIV (MASH) COHORT:
AN HIV INFECTED AND HIV/HCV CO-INFECTED POPULATION
by
Tiffanie S. Stewart
Florida International University, 2016
Miami, Florida
Professor Adriana Campa, Major Professor
Liver disease is now a leading cause of non-AIDS related morbidity and mortality
in people living with HIV (PLWH). The present study investigated the interplay between
adverse lifestyle factors that are prevalent in PLWH, biological mediators of liver
pathogenesis, and a non-invasive measure of liver fibrosis (FIB-4 index) in HIV monoand HIV/HCV co-infected individuals.
The results of this investigation in the Miami Adult Studies of HIV (MASH)
cohort show that the odds of liver fibrosis progression significantly increased over two
years for HIV mono-infected participants who drank alcohol hazardously (OR 3.038,
P=0.048), and had BMI ≥ 28kg/m2 (OR 2.934, P=0.027). Cocaine use reduced the odds
of advancing one stage of liver fibrosis (OR 0.228, P=0.038), but an interaction between
high BMI and cocaine use slightly raised the odds by 4.8% of liver fibrosis progression
(P=0.072). HIV/HCV co-infected participants showed interactions between cocaine use
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and high BMI with increased FIB-4 stage (OR 4.985, P= 0.034), however no lifestyle
factors could independently predict FIB-4 stage in this group.
Biological mediators previously associated with liver pathogenesis were
associated with higher FIB-4 index over 2 years in a subset of (n=65) HIV mono-infected
participants. Plasma measures of oxidative stress (% oxidized glutathione: OR 4.342, P=
0.046), hepatocyte-specific apoptosis (Cytokeratin-18 (CK-18): OR 1.008, P=0.021), and
microbial endotoxin (lipopolysaccharide (LPS): OR 1.098, P= 0.097) were associated
with having higher odds of progressing at least one stage of FIB-4 over 2 years.
The same biological mediators were also associated with liver fibrosis within HIV
infected people who also had a harmful lifestyle characteristic. FIB-4 index was
significantly associated with % oxidized glutathione in obese subjects (β=0.563,
P=0.018), TGF-β1 in cocaine users (β=0.858, P=0.027), and CK-18 in HIV infected
individuals without any adverse lifestyle factors (β=0.435, P=0.015).
Taken together, the findings of these studies describe interrelationships between
HIV disease status, lifestyle, and biological mediators of liver fibrosis. The results show
interactions between lifestyle conditions and the mediators of liver fibrosis may account
for higher rates of liver disease in HIV infection. Research is warranted to develop
personalized therapeutics for PLWH to curb the burden of liver disease.
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CHAPTER I: INTRODUCTION
Statement of Problem
The use of combined antiretroviral therapy (ART) to treat HIV infection has
prolonged lifespan by reducing opportunistic infections, 1 but brings new challenges for
survival. 2 Liver disease is now a major cause of morbidity and mortality in HIV infection
in the United States and Europe. 3-7 In addition to adverse lifestyle factors (obesity,
alcohol dependence, and cocaine use) 5,8-11 that contribute to liver fibrosis, co-infection
with the hepatitis C virus (HCV) has become an important prognostic factor of liver
disease in people living with HIV (PLWH). 12 The risk of liver-related mortality is
predominantly attributed to HIV/HCV co-infection; however, HIV mono-infected
persons are at higher risk for liver disease than non-infected persons. 13,14 Several studies
suggest that HIV may directly interact with liver cells, even infecting hepatocytes,
suggesting that liver disease is a rising issue for both HIV mono- and HIV/HCV coinfected persons. 15 Other studies suggest that by reducing HCV-specific CD4 T-cell
counts in HIV/HCV co-infected people, HIV infection supports a strong response of
HCV-specific interferon-gamma (IFN-α) producing CD8 T-cells, which favor the
destruction of HCV-infected hepatocytes and may play a role in accelerating liver
fibrosis. 16-20
Liver fibrosis is a cellular mechanism initiated by presence of injury to hepatocytes.
It can be classified into sequential phases based on the activation of hepatic stellate cells
(HSCs): initiation phase and perpetuation phase. 21 The initiation phase refers to early
events that render the quiescent HSCs responsive to a range of growth factors. 21
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Important fibrogenic stimuli in this stage include: reactive oxygen species, leading to
oxidative stress; apoptotic fragments, generated from hepatocyte cell death, and the
bacterial endotoxin lipopolysaccharide (LPS), resulting from bacterial products crossing
from the gut into the blood stream. 21 The perpetuation phase involves proliferation and
migration of HSCs to the extra cellular matrix (ECM), where they synthesize and secrete
elevated levels of collagen and fibronectin, promoting fibrosis. 22,23
The upregulation of the cytokine transforming growth factor beta-1 (TGF-β1) is
characteristic of the perpetuation phase because it is released by Kupffer cells, platelets,
and HSCs themselves in the presence of fibrogenic stimuli. 24 TGF-β1 is a key regulator
of liver fibrosis because it is required by HSCs to lay down fibrotic tissue. 25 Anti-TGFβ1 strategies have been proposed to reduce liver fibrosis by blocking its fibrogenic
properties, 26 including direct neutralization of TGF-β1 and indirectly reducing TGF-β1
by targeting biological risk factors such as oxidative stress, 27 microbial translocation, 28
and apoptosis. 29 For example, neutralizing activated TGF-β1 could potentially reduce
fibrosis by preventing the activation of HSCs. 26 These biological risk factors for liver
fibrosis may be different within the lifestyle risk factors of obesity, 9 alcohol dependence,
9,30

and cocaine use, 10,11 thus there is a need to identify mediators within these lifestyle

conditions.
Fibrosis can be resolved in both the initiation phase and the perpetuation phase when
fibrogenic stimuli are cleared and degrading enzymes remove fibrotic tissue from the
ECM. 31 However, HIV mono- and HIV/HCV co-infection expose hepatocytes to
continuously higher levels of fibrogenic stimuli, which propagates the development of
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fibrosis. Higher levels of oxidative stress, 32 microbial translocation, 33 TGF-β1, 34 and
hepatocyte apoptosis 35 are observed in HIV infection, and have been proposed as factors
that accelerate liver disease in HIV/HCV co-infection. 8,35,36 Lifestyle factors such as high
body mass index, 9,37,38 hazardous alcohol use, 9,30 and cocaine use 10,11 further increase
risk of liver fibrosis. It is important to understand, first, how lifestyle factors affect liver
fibrosis in HIV mono- and HIV/HCV co-infection, and then investigate which biological
factors pose a greater risk for liver fibrosis within adverse lifestyle conditions.
The relationship between oxidative stress, 39,40 microbial translocation, 41-43 TGF-β1
22,44,45

and hepatocyte-specific apoptosis 46-48 has been established in cell and animal

models, however, relationships between these factors have not been thoroughly
investigated in HIV+ patients with lifestyle conditions that put them at risk for liver
fibrosis. More recent pharmaceutical developments in direct acting antivirals (DAAs)
may potentially provide high cure rates (between 67% to 84% in initial trials) 49 for
HIV/HCV co-infected participants, making lifestyle factors and biological mediators of
liver fibrosis even more relevant factors to study in people living with HIV. However,
access to newly developed DAAs remains limited in PLWH who often experience
barriers to health care. 50,51 As such, the study’s aim was to characterize adverse lifestyle
factors (alcohol use, body mass index, and cocaine use) associated with liver fibrosis in
HIV mono- and HIV/HCV co-infection, respectively. Secondly, we sought to identify
biological factors that may contribute to liver fibrosis within the adverse lifestyle factors
for HIV mono-infection cross-sectionally, and overtime.
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Summary
Cellular and animal studies elucidate possible mediators contributing to liver fibrosis,
22,39-43,45-48

however, these may not necessarily explain the pathophysiology of liver

fibrosis in humans with adverse lifestyle conditions. The increased morbidity associated
with progressive liver fibrosis in HIV mono-infected and HIV/HCV co-infected persons,
52,53

combined with lack of access to the new effective HCV therapies for the study

population, 50,51,54 highlight the importance of identifying significant etiological drivers of
liver fibrosis (both lifestyle and biological factors) to identify potential therapeutic targets
that may prevent or delay liver fibrosis in a population at high risk for rapid advancement
to liver disease. The Miami Adult Studies on HIV (MASH) Cohort is unique because it
provides a large sample (n=464) followed for two to four years with 25% of the cohort
co-infected with HIV/HCV. The aim of this study was to examine the biological
mediators (oxidative stress, microbial translocation, hepatocyte apoptosis, and TGF-β1)
related to lifestyle factors (obesity, alcohol dependence, cocaine use) that contribute to
liver fibrosis in a cohort of HIV-infected persons in Miami, FL.
Specific Aims and Hypotheses
Specific Aim 1: Examine the effects of lifestyle factors (high BMI, alcohol use, and
cocaine use) on liver fibrosis in HIV mono- and HIV/HCV co-infection subjects crosssectionally, and investigate whether high baseline measures of BMI, alcohol intake, and
cocaine use affect liver fibrosis progression over time.
Rationale for Specific Aim 1: Hepatitis C infection may not fully account for liver
fibrosis development in HIV infection. This study examined lifestyle factors that
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contribute to liver fibrosis and identified useful lifestyle changes that can be made by this
population to prevent or delay liver fibrosis development.
Hypothesis 1: Adverse Lifestyle factors (High BMI, alcohol use and cocaine use) are
associated with higher liver fibrosis measured with FIB-4, in HIV-mono and HIV/HCV
co-infection.
Specific Aim 2: Examine the effect of biological factors at baseline and on changes in
liver fibrosis over time.
Rationale for Specific Aim 2: Biomarkers at baseline may predict onset of liver fibrosis
over time. Although a cross-sectional biomarker may not correlate to fibrosis, it may
predict liver fibrosis over time. This study aimed to identify important biomarkers that
may lead to early therapeutic targets before the progression of liver fibrosis.
Hypothesis 2: Increased oxidative stress, microbial translocation, hepatocyte apoptosis,
and TGF-β1 independently increase the risk of liver fibrosis over time (2 years) in HIV
mono-infected individuals.
Specific Aim 3: Explore the potential biological factors associated with individual
lifestyle factors that contribute to liver fibrosis at baseline.
Rationale for Specific Aim 3: Lifestyle factors that contribute to liver fibrosis may have
different underlying biological mechanisms to promote liver fibrosis. This aim identifies
whether there exists different types of biomarkers linked to liver fibrosis in people with
high BMI, who drink alcohol hazardously, use cocaine.
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Hypothesis 3: Oxidative stress, microbial translocation, hepatocyte apoptosis, and TGFβ1 are increased in participants living with HIV who have high BMI, drink or abuse
alcohol, or use cocaine compared to controls.
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Table 1: Methods and statistical analyses for each hypothesis.
Hypothesis
Methods
1. High BMI, alcohol use
We set cut-off points to identify participants with lifestyle
and cocaine use are
factors linked to liver fibrosis:
associated with higher liver
High Body Mass Index: ≥ 28 kg/m2
fibrosis measured with FIB- Alcohol: AUDIT score ≥ 8 indicated hazardous/binge
4, in HIV-mono and
drinking
HIV/HCV co-infection.
Cocaine use: Self-report and/or positive urine.
Dependent variable:
FIB-4 index: calculated by patient lab values using
[(AgeXAST)/(PlateletsX√(ALT))]
FIB-4 is categorized as follows:
None/mild fibrosis = FIB-4 <1.45
Moderate fibrosis = 1.45≤ FIB4 ≤3.25
Advanced fibrosis/cirrhosis = FIB-4 >3.25

2. Increased oxidative
stress, microbial
translocation, hepatocyte
apoptosis, and TGFβ1
independently increase the
risk of liver fibrosis over
time (2 years) in HIV monoinfection.

3. Oxidative stress,
microbial translocation,
hepatocyte apoptosis, and

Baseline cut-off points for independent variables to grouped
participants as having low/high biomarkers. We assigned
participants to groups who decreased, stayed the same, or
increased in FIB-4 category over time (2 years).
Variables:
Biological mediators
Microbial translocation, oxidative stress, TGFβ1, apoptosis.
Liver fibrosis
FIB-4 is categorized as follows:
None/mild fibrosis = FIB-4 <1.45
Moderate fibrosis = 1.45≤ FIB4 ≤3.25
Advanced fibrosis/cirrhosis = FIB-4 >3.25
We categorized participants into groups of lifestyle factors
(see methods in hypothesis 1 for categorization): High BMI
group, Alcohol group, Cocaine group, Control group to assess
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Statistical Analysis
T-test and one-way ANOVA with post-hoc analysis were
used to analyze differences between groups with two and
three levels, respectively. Multiple linear regression
analyzed each lifestyle factor independently for significance
on FIB-4 index as the dependent variable controlling for age,
gender, ART use, CD4 cell count, and HIV viral load.
Logistic regression analyzed the odds of progressing at least
on stage of fibrosis over 24 months based on having a risky
lifestyle factor (i.e., high BMI, alcohol use, or cocaine use).
3-way ANOVA was used to investigate associations
between lifestyle factors and FIB-4 index. Analysis will
include interactions between lifestyle factors.
Logistic Regression were used to measure the odds of
progressing at least one FIB-4 category over 2 years, for
those with high levels vs. low levels of independent
variables at baseline.
Proportion test determined the proportion of participants that
progressed in each group.
Logistic Regression measured the odds of progressing at
least one FIB-4 category over 2 years, for those with high
levels vs. low levels of independent variables at baseline.
GEE models analyzed repeated measured to describe
relationships with biological factors, FIB-4 (continuous)
with time (three time points) as an interaction.

Student’s T-test directly compared the mean of each
biological factor within a lifestyle group to the control
group.

TGFβ1 are increased HIVinfected participants who
have high BMI, drink or
abuse alcohol, or use
cocaine compared to
controls.

biological factors between groups.
Variables:
Biological mediators
Oxidative stress measured by malondialdehyde (MDA)
Colorimetric TBARS assay (Northwest Life Science) and
% Oxidized Glutathione Colorimetric assay (Arbor Assays).
Microbial Translocation measured by LPS Colorimetric
Lonza Limulus assay (Lonza).
Hepatocyte-specific apoptosis measured by CK-18 protein
ELISA assay, M30 Apoptosense kit (Peviva®).
TGFβ1 measured by Quantikine ELISA (R&D Systems).
Liver fibrosis
FIB-4 index calculated by patient lab values using
[(AgeXAST)/(PlateletsX√(ALT))].
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One-Way ANOVA with post-hoc analysis established
differences in biological factors between lifestyle groups and
the control group.
Three-way ANOVA was employed to assess interactions
between lifestyle groups for each biological factor.
Multivariate linear regression run with control variables
determined which biological factors were associated with
liver fibrosis within lifestyle groups.
Logistic regression was used to associate odds of having an
adverse lifestyle with high biological mediators of fibrosis.
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CHAPTER II: LITERATURE REVIEW
The Centers for Disease Control and Prevention estimates that approximately 1.2
million people are infected with HIV in the United States.1 Those most seriously affected
by HIV in the recent years are African American men who have sex with men (MSM).1
According to the Florida Department of Health, the State of Florida ranked third in 2013
with the highest number of people living with HIV, and first in the US in incidence of
HIV.2 Miami-Dade specifically bears the highest burden in the State in number of new
cases (n=1,411), and is listed among the top ten in the nation for metropolitan divisions
with new cases of HIV in 2013.2
HIV remains a heavy burden on the health care system. An earlier study found
that direct economic costs of HIV in the United States in the era of antiretroviral therapy
(ART) is approximately $36.4 billion annually.3 Co-morbidities account for productivity
losses and direct medical costs, and liver fibrosis is a leading co-morbidity in HIVinfection.4-7 The prevalence of liver fibrosis in HIV infection is apparent by the
substantial increase in liver-related morbidity, accounting for 14-18% of all deaths in
HIV+ patients.8,9 While hepatitis C plays a major role in contributing to liver fibrosis, it
does not account for all of the liver fibrosis cases. A study conducted in 2010 of 432
HIV mono-infected patients found that 8.3% developed severe liver fibrosis and
suggested that future studies explore the mechanisms of fibrosis in HIV mono-infection.10
Miami-Dade is an excellent location to study the relationship between liver fibrosis and
HIV since it has high rates of HIV/HCV co-infection (over 2,000 cases reported in
2014),11 and county services offer access to care for both HIV mono- and co-infected
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individuals. More recently, direct acting antivirals against hepatitis C show high cure
rates in HIV/HCV co-infection are being developed.12,13 Although they are not widely
available to the HIV community,14 their development justifies more research into the
pathogenesis of liver disease in HIV mono-infection as well as HIV/HCV co-infection.
Lifestyle and Risk Factors in Liver Fibrosis
Pathogenesis of liver disease. Liver fibrosis is an important stage of liver disease
because it serves as the main determinant of prognosis and of most therapeutic
decisions.15 Liver fibrosis is part of a series of stages of liver disease which include fatty
liver (steatosis), inflammation combined with fatty liver (steatohepatitis), liver fibrosis
(varying degrees), cirrhosis, and possibly hepatocarcinoma (Figure 1).
There are several liver conditions associated to fibrotic changes: Non Alcoholic
Fatty Liver Disease (NAFLD) is associated with early stages of liver pathogenesis
(steatosis) that cannot be attributed to heavy alcohol use, and Non Alcoholic
Steatohepatitis (NASH) is associated with inflammation of the liver.16 Alcoholic Liver
Disease (ALD) encompasses more than one stage of liver pathogenesis, and its etiology is
attributed to excessive alcohol consumption.16,17
HIV destroys the immune system, and is associated with chronic immune
activation18,19 and systemic inflammation.20 The virus itself is able to infect hepatocytes,
potentially causing damage to liver cells.21,22 HIV itself may be a potential risk factor for
fatty liver,23 and HIV-infected persons are prone to accumulating known epidemiological
risk factors for NAFLD (and subsequent fibrosis), such as lipodystrophy, increased
triglycerides, glucose abnormalities, microbial translocation, and immune
dysregulation.24,25
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Figure 1. Stages of liver damage

Source credit: National Institute of Diabetes and Digestive and Kidney Diseases26
High Body Mass Index. Obesity is a major cause of liver fibrosis in the general
population, commonly leading to non-alcoholic fatty liver disease NAFLD.27 According
to the Centers for Disease Control and Prevention, obesity is characterized by BMI
greater or equal to 30 kg/m2, and is associated with the development of liver disease.28
However, a lower BMI may also be associated with liver fibrosis. The development of
the BARD score uses a BMI cutoff of 28 kg/m2 to assess liver fibrosis development in the
general population.29 Considering other fibrogenic contributing factors in HIV such as
increased inflammation, poor immune function, ART and oxidative processes, the BMI
cutoff may even be lower. In fact, a cohort study of 1176 patients found that a BMI
range of 25-29 significantly contributed to liver fibrosis in HIV infection.30 In HIV
mono-infected patients on ART, high BMI, waist-to-hip ratio, and glucose intolerance
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were strongly associated with liver pathology than HIV-specific parameters, suggesting
that obesity may be a significant driver of fibrosis in this population.31 In the era of ART,
different from the pre-ART times, HIV-infection is associated with higher rates of
obesity,32 a condition that could further put patients at risk for liver disease. Examining
the range in which BMI contributes to liver fibrosis in HIV may serve as an indicator for
establishing a cutoff for a population at risk of liver fibrosis.
The mechanisms by which obesity causes liver fibrosis are mainly due to altered
fatty acid metabolism and the development of hepatic steatosis.33,34 The liver is involved
in manufacturing, storing, and exporting lipids.35 Chronically increased levels of
circulating free fatty acids (FFAs) in obese patients accounts for a build up of lipids in
liver, leading to hepatic steatosis in NAFLD.36 Lipid accumulation in the liver is followed
by proinflammatory mediators to induce inflammation, hepatocellular injury, leading to
fibrosis.37
Oxidative stress is associated with increased hepatic fatty acid storage and
obesity. A study in 31 NAFLD patients with increased BMI showed decreased
antioxidant capacity and increased oxidative stress.38 A similar study showed higher
levels of lipid peroxidation and lower levels of reduced glutathione in patients with
NAFLD compared to controls, regardless of obesity, type II diabetes, and
hyperlipidemia.39 Mouse models show a link between obesity, oxidative stress and liver
fibrosis. In obese mice fed a high fructose diet, increased oxidative stress markers were
associated with lipogenesis and hepatic fibrosis, whereas antioxidant supplementation
attenuated fibrotic markers.40 In Ldlr knockout mice (a model of NAFLD) fed a Western
diet, mRNA expression of oxidative stress genes Nrf2, Hmox1, and NADPH oxidase

17

subunits and hepatic fibrosis were increased compared to controls.41 TGF-β1 was also
induced in these mice compared to controls.41
TGF-β1 is a pro-fibrogenic cytokine involved in inflammatory signaling
associated with fibrosis.42-44 It is suggested that in both HIV and obesity, TGF-β1 levels
are elevated,45-47 making it an important cytokine to investigate in the context of liver
fibrosis. Microarray gene expression in 38 obese patients with and without fibrosis
showed that those with fibrosis displayed significantly higher expression of fibrotic
cytokines, including TGF-β1 expression, compared to controls.48 While studies in
humans are limited, circulating TGF-β1 in plasma has not consistently shown to reflect
the hepatic microenvironment; one study in obese patients shows that plasma TGF-β1
does not correlate to degree of fibrosis using the Brunt’s system of fibrosis
classification.49 On the other hand, in an HCV infected cohort, BMI was significantly
correlated to TGF-β1 levels.50 However, in HIV, TGF-β1 has mixed uses as a biomarker
of fibrosis. In a small study (n=66), higher levels of TGF-β1 were associated with
disease progression in HIV-infected patients,51 and impaired immune function could lead
to liver dysfunction.52 Sanvisens et al.53 showed that serum TGF-β1 was not predictive of
fibrosis measured by liver biopsy in HIV/HCV co-infected patients, and Rallon et al.54
found that elevated TGF-β1 levels were, in fact, associated with lower liver fibrosis.54
Both studies were conducted cross-sectionally in HIV/HCV co-infected cohorts with
relatively small samples sizes (n=69, n=88 respectively). To date, there are no human
studies that investigate TGF-β1 in HIV mono-infection to predict liver fibrosis and the
role that obesity plays in its development.
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Recently, new insights into the gut microbiome links obesity to increased
microbial dysfunction leading to microbial translocation. Microbial translocation is the
crossing over of endotoxin and bacterial antigens into the blood stream that elicits an
immune response.54 The liver serves as a first pass of venous blood from the intestine,
and is highly exposed to microbial translocation products,55 which can induce liver
fibrosis by binding Toll-like receptors (TLR-4) on hepatic stellate cells and Kupffer cells
in the liver, inducing a pro-fibrogenic response. A popular marker of microbial
translocation is lipopolysaccharide (LPS) and its surrogate markers LPS binding protein
(LBP) and soluble CD14 (sCD14), which are used as markers of microbial translocation
in plasma. A study in morbidly obese patients (n=40) found that obesity alone can
induce high levels of LBP, and it was correlated with markers of liver inflammation.56 A
similar study found elevated levels of LPS and gut permeability in 16 obese patients
compared to12 healthy controls, and these levels were significantly associated with liver
disease.57 These studies offer evidence that microbial translocation markers are elevated
in those with high BMI. HIV and obesity both contribute to downregulation of tight
junctions in gut mucosa, which leads to an increase in gut permeability.58 HIV also
specifically depletes CD4+ T cells in the gastrointestinal tract, rendering the gut
associated lymphoid tissue more permeable to microbial products.59 However, few
studies have investigated the dual role of HIV and obesity on liver fibrosis in relation to
microbial translocation in humans.
It is hypothesized that as a result of increased oxidative stress,60 TGF-β1,61 and
microbial translocation,62 apoptotic cascades are eventually triggered, and apoptotic
fragments further increase hepatic fibrosis.63 The association between hepatic apoptosis
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and liver fibrosis has been linked to obesity.64 In a group of 62 patients categorized as
having BMI in obese range, a serum marker of hepatic fibrosis and hepatic apoptosis,
cytokeratin-18 fragment level (CK-18), a protein secreted by liver cells undergoing cell
death and a validated surrogate marker of hepatocyte apoptosis, was correlated with
increased degree of liver fibrosis.65 A cross-sectional study conducted in 229 obese youth
looked at liver biopsies separated by ethnicity. Results showed that CK-18 levels are
significantly associated with steatosis in obese Caucasian and Hispanic youth, but not in
African American youth, suggesting that apoptosis is associated with liver damage and
may be affected by race/ethnicity.66 In HIV, the gp120 viral protein independently
induced apoptosis in hepatocytes.67 HIV infection increased hepatocyte apoptosis in an
HCV model.68
Alcohol Use. It is well established that excessive alcohol consumption causes liver
disease, commonly known as alcoholic liver disease (ALD).17 Alcohol is the second most
common cause of liver disease after hepatits C, accounting for 20-25% of the cases in the
US.69 ALD is characterized by a spectrum of pathological conditions, including steatosis,
steatohepatisis, which can progress to hepatic fibrosis that may lead to cirrhosis, and
hepatocellular carcinoma.70 Liver fibrosis is often the main determinant of prognosis and
of most therapeutic decisions.15 A commonly used tool to classify alcohol use is the
Alcohol Use Disorders Identification Test (AUDIT), developed by the World Health
Organization to screen for excessive alcohol consumption and to help health-care
professionals identify individuals who would benefit from abstinence or reduction.71,72
AUDIT scores range from 0 to 40, and can classify alcohol consumption from
abstinence/no drinking (score of 0), mild/moderate drinking (score < 8), hazardous/binge
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drinking (score ≥ 8), to alcohol dependence (score ≥ 13 in women and ≥ 15 in men).72-74
Higher AUDIT scores have been associated with liver pathogenesis. For example, an
early study to validate the AUDIT tool found that a cutoff ≥ 8 could predict liver disease
and gastrointestinal bleed in an ambulatory setting (n=350) with a sensitivity of 63% and
a specificity of 74%.75 AUDIT is often used to study the effects of alcohol in HIV
infection because of the extra burden placed on the liver by the disease, increasing
fibrotic events and rapid progression of ALD pathogenesis, including fibrosis.76,77 A
large-scale study of the Veterans Aging Cohort (701 HIV/HCV co-infected, 1410 HIV
mono-infected, 296 HCV infected, and 1158 uninfected adults) associated higher odds of
having liver fibrosis with higher AUDIT category in HIV mono-infection, HIV/HCV coinfection, and HCV infection compared to non-infected controls.77 Even low levels of
alcohol consumption were associated with advanced hepatic fibrosis in these groups
suggesting that small quantities of alcohol may lead to liver fibrosis in HIV and
HIV/HCV infection compared to uninfected controls.77
Mechanisms of liver pathogenesis are described in cell and animal models.
Decreased glutathione antioxidant capacity is also a consequence of excessive alcohol
consumption, leading to greater reactive oxygen species (ROS) in murine models.78-81
Excessive alcohol consumption that creates ROS triggers elevated lipid peroxidation
products,82 such as malondialdehyde (MDA), and these products lead to activation of
hepatic stellate cells (HSCs) and the TGF-beta system that initiates fibrosis.83-85 Alcohol
use influences cross-talk among intracellular events in the liver involving TGF-β1
signaling in the perpetuation phase of fibrosis.86 More specifically, when cultured HSCs
are treated with acetaldehyde, a by-product of alcohol metabolism, it stimulates
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activation of TGF-β1 and induces its expression, upregulating collagen expression that
leads to fibrosis.87 HSCs are the key regulators of liver fibrosis because they produce the
intracellular matrix required for fibrotic tissue.44 Cell and animal models of alcoholic
liver disease (ALD) also show endotoxin (LPS) plays a significant role in liver fibrosis.
Treating Caco2 cells (a model for colorectal epithelial cells) with acetaldehyde opens
tight junctions, suggesting a mechanism for increased gut permeability for microbial
endotoxins.88 Rat HSCs treated with combined LPS, ethanol and its metabolite
acetaldehyde showed high levels of oxidative stress and collagen deposition, compared to
single ethanol, acetaldehyde, or LPS exposure.89 Another study conducted in vivo
suggested that LPS potentiates the fibrotic effects of alcohol through increasing oxidative
stress levels, activating HSCs, and increasing collagen production.90 Apoptosis is also
investigated as a mechanism of fibrosis in mouse models of ALD.91 Alcohol infusion in
the mouse for 4 weeks lead to a marked increase in the number of apoptotic nuclei in the
liver compared to controls.92
Human studies investigating the relationship between oxidative stress, TGF-β1,
LPS and apoptosis in liver fibrosis show similar trends. Grasselli et al.93 showed that
alcohol dependence is associated with higher BMI, increased levels of oxidative stress
measured by the TBARS assay, and more severe steatosis, which could lead to liver
fibrosis, in 60 alcoholic subjects compared to 58 controls.93 A study matching HIV- and
HIV+ alcohol users (n=10) compared oxidative stress levels measured by
oxidized/reduced glutathione.94 HIV+ alcohol users had higher oxidative stress levels
than HIV- alcohol users, suggesting that the combined effect of HIV and alcohol may
lead to failure of antioxidant systems to maintain crucial redox homeostasis.94 These
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investigators also reported that oxidative stress was associated with the CYP2E1 system,
which is involved in alcohol metabolism that generates alcohol-induced oxidative stress
in the liver.95 Higher levels of oxidative stress in people living with HIV who drink
excessive alcohol suggest that oxidative stress may be one of the mechanism to advance
fibrosis in this population.
Circulating TGF-β1 is not always a reliable correlate to liver fibrosis in humans;
however, a study showed that 41 patients with alcohol dependence had significantly
higher levels of circulating TGF-β1 than healthy controls.96 Notably, within the alcohol
dependent group, those with or without liver pathology showed no difference in TGF-β1
levels, suggesting that TGF-β1 may be higher in alcohol users with or without the
presence of liver damage.96 Alcohol disrupts gut permeability and LPS is associated with
alcohol intake in human studies. A small study of healthy volunteers (n=25) showed that
acute binge drinking significantly increased circulating LPS within hours of intake, and
triggered an inflammatory cascade via the TLR-4 system.97 A larger study in patients
with liver cirrhosis found that microbial endotoxin levels were significantly higher in
patients with alcoholic cirrhosis compared to patients with non-alcoholic cirrhosis.98 The
results indicate that alcohol abuse contributes to endotoxemia and may exacerbate
alcohol-induced liver disease.98 HIV adds a level of complexity to this phenomenon, as it
also destroys the protective barrier in the gut by specifically depleting Th17 CD4+ Tcells and tight junctions.58,99A cross-sectional study examined whether unhealthy
drinking influenced microbial translocation in people living with HIV before initiating
ART. The study revealed significantly higher sCD14, a surrogate marker of immune
activation by endotoxin, in HIV+ patients with unhealthy alcohol use compared to those
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who did not drink alcohol, indicating that the combined effect of HIV and heavy alcohol
use increases microbial translocation in patients.100
In HIV/HCV co-infected women (n=44), sCD14 was higher in those who
progressed from no fibrosis to cirrhosis or liver-related death, compared to nonprogressors.101 This finding remained significant after controlling for alcohol use.101 The
relationship between circulating LPS, alcohol intake, liver fibrosis in HIV mono-infection
and HIV/HCV co-infection warrants further investigation in human populations. Another
variable that warrants further investigation in HIV+ alcohol user is liver-related
apoptosis. As previously discussed, mouse models show that alcohol increases apoptotic
bodies in the liver.92 In humans, circulating CK-18, a marker for hepatic apoptosis, is
elevated in heavy alcohol drinkers with fibrosis compared to those without fibrosis.102 A
study compared hepatic apoptosis in 134 HIV/HCV co-infected patients and 130 HCV
mono-infected patients using liver biopsies.103 The results indicated that HIV/HCV coinfection had the highest odds of increasing hepatic apoptosis compared to HCV alone,
and low CD4 cell counts contributed to apoptosis.103 Heavy alcohol consumption was
slightly associated with apoptosis in the entire cohort (p=0.06); however, within the
HIV/HCV group, significance was lost, which the authors attributed to unreliable
interview methods.103
Alcohol use warrants investigation in the MASH cohort because it is prevalent
among people living with HIV.104,105 Alcohol is associated with a multitude of comorbidities, and is a risk factor for lack of viral control and non-adherence to ART,106
accelerated liver disease in HCV infection,57 and HIV liver-related mortality.107
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Cocaine Use. According to the National Institute on Drug Abuse, in 2013 there were 1.5
million cocaine and/or crack-cocaine users in the US.108 In the same year, Miami-Dade
had the highest number of cocaine-related deaths (n=238) among the State’s metropolitan
areas.109 Collecting drug use data can be accomplished through self-report or toxicology
screening. Self-reporting is effective during in-person interviews in a private and
confidential setting, and that data are more robust when it is confirmed by toxicology.110
Cocaine is known to have deleterious effects in HIV infection. In cell models, cocaine
can facilitate HIV-1 progression by impairing macrophage and CD4 T-cell function,
modulating the levels of cytokines and increasing the level of viral replication.111 Mice
that expressed human leukocytes displayed higher HIV replication when exposed to
cocaine compared to HIV-infected mice not exposed to cocaine, suggesting that there is
an interaction between HIV, cocaine, and immunity in vivo.112 Early studies with cocaine
showed that it significantly depresses the immune system of mice, specifically
thymocytes and leukocytes in a dose-dependent manner.113 While few studies
investigating the effects of cocaine have been conducted in HIV populations, its use is
associated with poor outcomes. Parikh et al.114 used multivariate modeling to show that
cocaine use alters cytokine profiles, leading to an imbalance in Th1/Th2 T-cells in
African Americans and may decrease CD4 cell counts and increase viral load over
time.114 Analysis of a large HIV+ cohort for all-cause mortality indicates that cocaine
users are at a higher risk for ART non-adherence (2.60 times higher odds, p<0.001), and
that hard drug use (cocaine, heroine, amphetamine) had significant risk (2.58, p=0.03) of
an AIDS outcome or death.115 In this multi-center HIV+ cohort, cocaine was the most
prevalent drug used in those who used hard drugs.
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In the MASH cohort, Baum et al.116 reported that crack-cocaine accelerates HIV
disease progression in HIV+ drug users. The cohort of 222 drug users showed that only
crack-cocaine use was associated with time-to-event (CD4 decline to 200 cells/mL) with
a relative risk of 2.145, p=0.029.116 The current MASH cohort preliminary data describes
that cocaine use increases mitochondrial DNA oxidative damage in HIV, which is
positively correlated to liver fibrosis.117 Oxidative stress may trigger hepatic fibrosis by
activating hepatic stellate cells and increasing TGF-beta systems.83,84 In a small cross
sectional study, HIV+ cocaine users have dysfunctional microbial profile compared to
non-users, which may induce microbial translocation. The authors attribute microbial
dysfunction to food insecurity among their HIV+ drug cocaine users.118 Exposure to the
microbial endotoxin (LPS) augments cocaine’s hepatotoxicity. In mice pre-exposed to
cocaine, those exposed to LPS showed higher levels of hepatic nitric oxide and ROS
compare to controls, leading to liver damage.119 Only when nitric oxide was neutralized
were the effects reversed, suggesting that cocaine sensitizes the liver to the hepatotoxic
effects of LPS.119 Cocaine is processed in the liver to norcocaine by the cytochrome
CYP2E1 system that generates oxidative stress and lipid peroxidation in
hepatocytes.120,121 The oxidative stress generated from CYP2E1 has been linked to
apoptosis in hepatocytes in cell models, which could lead to fibrosis.122,123 Preliminary
data of the MASH cohort presented at the International AIDS conference showed that
HIV+ frequent cocaine users (at least 3-4 times/week) were 5.5 times more likely to have
higher hepatocyte apoptosis (CK-18), compared to those who used it less frequently.124
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Antiretroviral Treatment (ART). A confounding factor for fibrogenesis in people
living with HIV is the chronic use of ART and its related hepatotoxicity. A number of
studies have highlighted the hepatotoxic effect of ART in this population;125-129 however,
ART use in advanced HIV disease has been associated with lower levels of hepatic
fibrosis.130 Another part of this problem is that a large proportion of patients in the United
States do not adhere to ART,131which needs to be considered in future studies.
Biological Risk Factors in Liver Fibrosis
Oxidative Stress. A family of established mediators in liver fibrosis includes reactive
oxygen species (ROS) leading to increased oxidative stress. Oxidative stress occurs when
ROS generated from exogenous sources (i.e., alcohol) and endogenous sources (i.e., liver
enzyme P-450 system and mitochondrial oxidative phosphorylation) are not balanced by
endogenous and exogenous antioxidants.132 High levels of oxidative stress contribute to
the development of liver fibrosis by disrupting lipids, proteins, and DNA, inducing
necrosis and apoptosis, amplifying the inflammatory response, and stimulating HSCs to
initiate fibrosis.133,134 Oxidative stress may also contribute to the perpetuation phase of
liver fibrosis through the enhancement of TGF-β1 as observed in an HCV cell culture
model,135 a relationship that has not been investigated in humans.
Markers of oxidative stress are present in fibrotic areas of the liver, linking ROS
directly to liver damage.136 Specifically, in biopsies from 39 patients with liver disease
showed malondialdehyde (MDA), a marker of lipid peroxidation associated with ROS, is
significantly associated with areas of hepatic steatosis (p<0.04) and fibrosis (p<0.05).137
Notably, circulating markers of oxidative stress suggested to be indicative of the hepatic
microenvironment because they are highly correlated with liver fibrosis. For example,
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titers of antibody against circulating albumin with MDA adducts in 167 NAFLD patients
showed that having high levels of MDA independently predicted advanced liver
fibrosis/cirrhosis compared to those within the control range.138 These findings, along
with those of other investigators,139,140 suggest that circulating markers of oxidative stress
correlate with liver fibrosis.
Prior studies report that HIV infection is associated with higher levels of oxidative
stress, and HIV/HCV co-infection increases oxidative stress levels even more.141
Common measures of oxidative stress include lipid peroxidation (MDA levels),142 redox
status (i.e., oxidized:reduced glutathione ratio),142 and protein modifications.143
Circulating levels of MDA and glutathione are relatively inexpensive commercial kits
that have been validated and are readily available for measurement in human plasma. In
experimental models, circulating MDA correlates to liver MDA levels in the presence of
liver fibrosis. Intra-abdominal sepsis rat model showed that circulating MDA levels
correspond to tissue MDA levels in liver.144 Another study showed that liver MDA in
hamsters who were fed a high cholesterol fibrogenic diet correlated significantly with
levels of circulating MDA (raw data in Chen YY, 2015).145 Circulating glutathione is
another biomarker that correlates well with liver glutathione levels. In patients with
chronic hepatitis C, the levels of hepatic glutathione, plasma glutathione, and PBMC
glutathione, were highly correlated and significantly depleted in HIV/HCV co-infected
patients.146 In summary, MDA and glutathione are good measures of oxidative stress in
the MASH cohort because they reliably and significantly correlate with liver fibrosis, and
represent the microenvironment of the liver.
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Microbial Translocation. HIV damages the gastrointestinal mucosal barrier99 and
facilitates microbial translocation147 into the bloodstream from the gut. Microbial
translocation increases sensitivity of HSCs to fibrotic mediators, such as oxidative stress
and the cytokine TGF-β1.148-150 In cell models, the bacterial endotoxin lipopolysaccharide
(LPS) induces oxidative stress that leads to liver injury.151 In mice, the presence of LPS
enhances production of TGF-β1 from Kupffer cells and primes HSCs to secrete TGF-β1,
leading to increased fibrogenesis.149,152 People living with HIV have high levels of LPS
due to the depletion of gut-associated lymphoid tissue.153 Few human studies have
investigated the impact of LPS on liver fibrosis in HIV infection, although a compelling
study conducted by Balagopal et al.148 showed that HIV/HCV co-infected subjects with
elevated plasma LPS had a 2.7-fold higher risk of liver disease, and in the overall cohort
(n=28 HIV/HCV co-infected, n=88 HCV mono- and n=60 uninfected controls) elevated
LPS was associated with 18.7-fold higher risk of cirrhosis when adjusting for
confounding factors.148 Although microbial translocation can be measured by multiple
methods, such as 16S rDNA, sCD14, and lipoprotein binding protein (LBP), LPS is
considered the cardinal and most direct measure of endotoxin.154 Recently, measurement
of LPS in plasma has been debated because of an inhibitory effect that has yet to be
identified. However, the inhibitory effect can be overcome by processing the plasma
with heat-inactivation155 and by diluting plasma to mitigate inhibitory effects.154 LPS is a
direct stimulus for liver fibrosis, by binding to the TLR-4 receptor on hepatic
macrophages (known as Kupffer cells) that activate HSCs to produce a matrix rich in
collagen leading to fibrosis.62 It is the most direct measure of endotoxin and an acute
stimulus of liver fibrosis.

29

TGF-β1. The fibrogenic cytokine TGF-β1 is one of the key regulators of liver
fibrosis.156,157 During times of tissue injury, elevated levels of TGF-β1 are produced in
the liver by hepatic stellate cells (HSCs), Kupffer cells and platelets. The presence of
TGF-β1 activates HSCs to proliferate and migrate to the ECM where they synthesize and
secrete elevated levels of matrix proteins, promoting fibrosis.44,158 Thus, circulating TGFβ1 has been suggested as a biomarker and target in the treatment of liver fibrosis because
it is elevated in HIV and HCV infection,159 and because it is a potent inducer of
fibrogenesis.42,86 The TGF-β1 producing polymorphism is associated with increased
fibrosis, supporting the hypothesis that increasing TGF-β1 will increase fibrosis in the
liver microenvironment.160
Serum levels of TGF-β1 do not always reflect liver the hepatic
microenvironment,49 because a number of studies show an inconsistent relationship
between circulating TGF-β1 and degree of liver fibrosis. Nonetheless, it is often cited as a
biomarker of liver fibrosis.161,162 TGF-β1 levels are often high in early stages of liver
fibrosis, in patients who are at risk of developing liver disease, such as HIV,51 and
HIV/HCV54 so it may be an important predictor of hepatic fibrosis.
Apoptosis. Elevated levels of cytokines that induce liver fibrosis are associated with
hepatocyte apoptosis, or programmed cell death. Apoptotic fragments released from
hepatocytes are fibrogenic in cultured HSCs,63 and hepatocyte apoptosis in experimental
animals has also been shown to be fibrogenic, and induces HSCs to secrete TGF-β1.163 In
cell models, TGF-β1 induces hepatocyte cell death,61 generating pro-fibrogenic apoptotic
fragments that may further increase TGF-β1, leading to a cycle of increasing fibrosis. The
association between hepatic apoptosis and liver fibrosis has been linked to obesity64 and
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heavy alcohol drinking,102 in people without HIV, and exposure to cocaine in mice.164 A
validated biomarker of hepatocyte-specific apoptosis is the protein cytokeratin-18 (CK18).64,165 During the apoptotic process, intracellular caspases cleave a number of
substrates, including CK-18, a major intracellular filament in hepatocytes, resulting in the
characteristic and morphologic changes of apoptosis.166 The specificity of the filament
coming from hepatocytes makes it a reliable biomarker of hepatocyte-specific apoptosis.
Several studies have associated CK-18 with fibrosis. A multicenter validation study in
patients with NAFLD showed that the odds of having liver fibrosis based on biopsy was
significantly associated with plasma CK-18 levels.64 Circulating CK-18 was also an
independent predictor of NASH after adjusting for variables for variables associated with
NASH.64 Plasma CK-18 can also predict liver fibrosis in heavy alcohol drinkers, and is
especially sensitive at predicting severe fibrosis in this population.102 In HIV/HCV
populations, CK-18 predicts liver fibrosis, especially when CD4 cells count is low, most
likely due to poor adherence to ART or pre-ART administration.130,167
Literature Review Summary
HIV is a disease that destroys the immune system and is associated with disease
states that contribute to liver dysfunction such as chronic immune activation,36,37 systemic
inflammation,38 and direct hepatocyte infection by HIV.39,40
The literature identifies obesity,44,31 alcohol drinking,81,83,90 and cocaine use130-134
as significant factors contributing to liver fibrosis. The interplay between lifestyle and
biological factors on liver fibrosis have not thoroughly been studied in human patients
with HIV mono- and HIV/HCV co-infection. While hepatitis C infection significantly
increases the risk of advancing the degree of liver fibrosis, hepatitis C virus itself cannot
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account for all of the liver damage,168,169-170 nor can it account for liver disease
progression in HIV mono-infection.33
Theoretical Model: Liver Fibrosis Development in HIV Involving Lifestyle Factors
Based on the literature review, we developed a conceptual model that explains the
development of liver fibrosis through lifestyle factors, and the associated biological
factors. The model was adapted from graphical interpretations in the scientific literature.
The basis of this figure was developed from Meyer et al.171 because it contained many of
the core variables of interest. However, we modified and added microbial endotoxin,
Kupffer cells, and the specific biomarkers we are measuring: oxidized GSH, MDA, TGFβ1, LPS, and CK-18. We also added the lifestyle factors of interest to the model.

Figure 2: Theoretical model of liver fibrosis development in HIV infection
Image adapted from: TGF-beta signaling in alcohol induced hepatic injury171
There is evidence that these lifestyle conditions advance liver fibrosis through
biological factors that include oxidative stress, microbial translocation, hepatocyte
apoptosis, and TGF-β1 to perpetuate fibrosis.33,172,173 This study identified the effect of
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lifestyle factors on the development of liver fibrosis in HIV mono- and HIV/HCV coinfection in the MASH cohort. It also characterized important biomarkers of liver
fibrosis linked to lifestyle factors and associated biomarkers with fibrosis in an HIV
infected population.
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Table 1: Literature Review: Lifestyle Factors Associated with Increased Liver Fibrosis.
Author/Study
Study Purpose
Population/Methods
design
HIGH BODY MASS INDEX

Findings

Harrison SA
et al., 200829

Develop and validate a
simple NAFLD clinical
scoring system for
identifying patients without
Retrospective advanced disease.
study

827 patients with biopsy evidenced to have
NAFLD (no infection or heavy alcohol use)
were categorized based on NASH diagnosis,
and then fibrosis stage. Demographic and
metabolic factors were analyzed as
determinants for liver fibrosis.

When comparing people with no
fibrosis or mild fibrosis, to
advanced fibrosis, being older
(>50 years), having a higher
aminotransferase ration (≥0.8),
having diabetes and BMI ≥28
kg/m2 were individually
associated with an odds ratio of
≥2.4 for advanced fibrosis.

Kirk GD et
al., 201330

1176 current and former injection drug users
with antibodies to HCV enrolled
longitudinally. Fibrosis was measured with
transient elastography and compared to
demographic, hematological, and metabolic
factors.

Liver fibrosis was associated
with older age and was greater in
persons with HIV than those
without HIV. Having a BMI
greater than 25 kg/m2 is a
significant determinant of liver
fibrosis.

Investigate whether persons
with HIV develop
hepatitis-related liver
disease at younger ages
Prospective, than similar persons
observational without HIV.

34

Morse CG et
al., 201531
Crosssectional,
observational

Videla LA et
al., 200438
Case control,

Examine the prevalence
and clinical correlates of
antiretroviral-associated
liver disease, including
steatosis, steatohepatitis,
and fibrosis.

Sixty-two HIV-infected participants with no
previous hepatitis infection who displayed
elevated liver enzymes for ≥6 months while
receiving ART underwent metabolic
laboratory testing.

NAFLD was found in 73% of
liver biopsies in HIV monoinfected participants on ART
with elevated liver enzymes.
Higher BMI (29.1 kg/m2), waistto-hip ratio (1.01), and risk
factors for diabetes (glucose
fasting, OGTT, hemoglobin
A1C).

Investigate the molecular
mechanism underlying
liver oxidative stress in
NAFLD in patients.

Thirty-one patients ranging from 18-55 years
old who underwent gastric bypass surgery
enrolled as case subjects and twelve patients
with healthy BMI who had anti-reflux
surgery enrolled as controls. Liver biopsies
were obtained at the time of surgery. Both
liver and plasma samples generated
oxidative stress samples.

Patients with NAFLD and high
BMI exhibited substantial prooxidant condition in the liver
compared to normal weight
controls. This finding is also
significant in the plasma.

Determine the specific
intrahepatic gene
expression profiles
associated with histological
severe NASH.

Obese patients with NASH (n=38) with liver
biopsies and categorized as NASH with
fibrosis, without fibrosis, and with obese
patients without NASH (control group).

Patients with NASH, but without
fibrosis, showed increased
expression of pro-apoptotic and
inflammatory genes. However,
patients with NASH and fibrosis
also showed an elevated
expression of the TGF-beta1
gene.

Crosssectional
study
Cayon A et
al., 200848
Crosssectional
study
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Farhadi A et
al., 200857
Case control,
Crosssectional
study

Civera M et
al., 201065
Crosssectional
study
Santoro N et
al., 201366
Crosssectional
study

Study gut leakiness in
morbidly obese NASH
patients versus morbidly
obese patients without
NASH and determine its
association with liver
disease.

Gastrointestinal permeability was measured
using lactulose/mannitol (L/M) ratio in urine
samples (n=16 NASH patients, n=12
“healthy” patients), and was repeated after
challenge with aspirin to measure whether
gut leakiness is affected by a slight challenge
to GI tract. Circulating LPS was also
measured in a subgroup of patients. Liver
biopsy diagnosed histological damage using
the Brunt system.

Serum endotoxin levels (LPS)
were significantly higher in
patients with NASH. L/M ratio
was significantly higher in
patients with NASH after the
aspirin challenge. Results
suggest endotoxin serves as a
second hit after altered lipid
metabolism that leads to liver
damage.

Investigate the relationship
between insulin resistance
and caspase-generated CK18 fragments in patients
with severe obesity.

Sixty-two patients selected for bariatric
surgery were categorized based on liver
histology (degree of fibrosis) and 70th
percentile of insulin resistance (based on
HOMA).

Patients with greater HOMA had
significantly higher CK-18
fragments. There was a
significant correlation between
CK-18 fragments and degree of
liver fibrosis.

Explore association
between hepatosteatosis
and circulating CK-18
fragments, and assess the
impact of ethnicity, insulin
resistance and SNPs
associated with steatosis.

Two-hundred and twenty-nine obese youths
with various ethnicities underwent MRI, oral
glucose tolerance test, and CK-18 level
measurements.

CK-18 levels are significantly
associated with hepatic steatosis
in obese Caucasian and Hispanic
youth, but not in African
American youth, suggesting that
apoptosis associated with liver
damage may be affected by
ethnicity.

ALCOHOL USE
Conigrave

Examine the performance

A cohort of 330 subjects was followed for 236

Cutoff point of 7 and lower

KM et al.,
199575
Prospective,
observational

Lim JK et al.
201477
Crosssectional
study

Grasselli EE
et al. 201493
Case control,
Crosssectional
study
Ande A et al.
201594

of the AUDIT
questionnaire as a predictor
of harm, over the full range
of its scores.

3 years to study the prevalence of alcohol
consumption. The baseline interview
consisted of medical questionnaires and an
AUDIT score. The follow-up interviews
examined alcohol-related harm with
endpoints including social problems, alcoholrelated hospitalizations, liver disease,
gastrointestinal bleeding, and established
cutoff points to maximize discrimination.

predicted most alcohol-related
disorders with maximum
discrimination. For more
serious and specific alcoholrelated problems, cutoffs of 15
and 22 provided higher
specificity, although lower
sensitivity.

Evaluate associations
between alcohol use
AUDIT categories and
advanced hepatic fibrosis
by HIV and chronic HCV
status.

The Veterans Aging Cohort Study enrolled
participants who reported alcohol
consumption (n=3565; 701 HIV/HCV coinfected, 1410 HIV mono-infected, 296 HCV
mono-infected, 1158 uninfected). FIB-4
index >3.25 defined advanced fibrosis.
AUDIT cutoffs determined nonhazardous
drinking or hazardous drinking.

Within HIV/HCV co-infected
group, advanced hepatic fibrosis
increased as alcohol used
category increased. Both HIV
mono- and HCV mono-infection
showed associations between
advanced liver fibrosis and
higher AUDIT categories
compared to healthy individuals.

Investigate the correlation
between oxidative stress
and antioxidant proteins in
serum related to liver
steatosis grade.

A total of 118 cases (60 alcoholic subjects
and 58 controls) were assessed for BMI, lever
steatosis (using ultrasound), and blood
chemistry. Oxidative stress was determined
by TBARS assay and MDA analysis.
Antioxidant status measured of superoxide
dismutase activity. Alcohol consumption was
assessed by trained interview.

Alcoholic subjects had a higher
BMI and moderate/severe
hepatic steatosis. Alcoholic
subjects had higher TBARS and
SOD activity, indicating
increased production of
oxidative stress in alcoholic
individuals.

Examine the effects of mild HIV+ alcohol users (n=4) who reported
to moderate alcohol use on mild/moderate alcohol use, and HIV37

Compared to HIV- alcohol
users, HIV+ alcohol users had

Case control,

oxidative stress and the
CYP2E1 pathway in HIV+
ART-naïve patients.

mild/moderate alcohol users (n=6) had
oxidative stress (DNA 8-oxo-dG, % oxidized
glutathione),serum alcohol levels, mRNA of
antioxidant enzymes, and CYP2E1 mRNA
levels measured.

increased oxidative DNA
damage, and increased %
oxidized glutathione. HIV+
individuals had lower levels of
plasma alcohol levels, and
higher levels of CYP2E1,
suggesting that there is
significantly enhanced
antioxidant requirements for
HIV+ alcohol users to maintain
homeostasis.

Verify the relationship
between alcohol
dependence and TGFbeta1.

Alcohol use was assessed in 41 healthy and
41 alcohol dependent males using DSM-IV
criteria. Demographics and anthropometrics
were collected, and circulating TGF-beta1
levels were analyzed using ELISA. Liver
fibrosis was measured by ultrasonography
after consultation with a physician.

Patients with alcohol
dependency showed
significantly higher circulating
TGF-beta1 than healthy
controls, however, within the
alcohol dependent group, those
with or without liver fibrosis did
not show a difference in TGFbeta1 levels, suggesting that
TGF-beta1 may be higher in
alcohol users with or without the
presence of liver damage.

Evaluate the presence of
endotoxemia in peripheral
blood in alcoholic cirrhotic
patients compared to nonalcoholic cirrhotic patients.

Patients with liver cirrhosis (88 with
alcoholic cirrhosis “AC”, and 42 with nonalcoholic cirrhosis “NAC” had endotoxemia
evaluated by LPS. History of alcohol use
was obtained and patients were categorized
into subgroups based on acute and chronic

Higher levels of LPS were
found more frequently in
patients with AC compared to
NAC. Acute alcohol
consumption in patients without
chronic liver disease lead to an

Crosssectional
study

Kim YK et
al. 200996
Case control,
Crosssectional
study

Bode C et al.
198798
Case control,
Crosssectional
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study

Lavallard VJ
et al. 2011102
Crosssectional
study

Quantify and correlate the
circulating levels of CK-18
to liver disease severity in
heavy alcoholics.

liver disease.

increase of LPS, however when
measured 5-8 days after the
consumption, no LPS could be
measured. This suggests that
heavy alcohol use leads to
transient endotoxemia, which
may aggravate liver disease.

CK-18 was evaluated in the serum of 143
heavy alcoholics. All patients were HIV and
hepatitis B and C negative. Liver disease was
evaluated by biopsy.

Circulating CK-18 is elevated in
heavy alcohol drinkers who
have liver fibrosis, compared to
heavy alcohol drinker without
fibrosis. AUROC score of CK18 predict liver fibrosis is 0.84,
suggesting that it is a useful
biomarker.

Subjects were assessed at baseline, week 4,
week 8, then at 8-32 week intervals until the
end of the study at week 512. Data was
collected for medical history, drug and
alcohol use, cardiovascular events, DC4 cell
counts, HIV viral loads, and ART
medications. Drug use was assessed by
frequency and heavy use, and by drug type.

HIV+ cocaine users are at a
higher risk of ART nonadherence and hard drug use.
They also had significant risk of
an AIDS outcome or death.
Cocaine was the most prevalent
drug of choice of the hard drugs
used.

A cohort of 222 HIV-infected drug users
were recruited for a 30-month study. Medical
history and blood draws were taken biannually. Drug use (type, frequency, mode

The use of crack-cocaine
significantly predicted a decline
in CD4 and an increase in viral
load, independent of other risk

COCAINE USE
Cohn SE et
al. 2011115
Prospective,
longitudinal
cohort study

Describe the impact of selfreported alcohol and drug
use in HIV+ patients on
ART enrolled in a
longitudinal study.

Baum, MK et Evaluate the relationship
al. 2009116
between substances of
abuse and HIV disease
Prospective,
progression in a cohort of
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longitudinal
cohort study

HIV+ active drug users.

Labib R et al. Examine the role of
2009119
Kupffer cells and the
modulating effects of nitric
oxide and reactive oxygen
species on the LPS
In vivo,
potentiation of cocaineanimal
mediated hepatotoxicity.
Experimental

of administration) was assessed by trained
staff using a questionnaire. CD4 cell count
and viral load were the main outcomes to
determine disease progression.

factors (i.e., other drugs, age,
gender, years since diagnosis,
ART use). This suggests that
cocaine may have physiological
action unrelated to ART
adherence that accelerates
disease progression in HIV
infected individuals.

Four groups of mice, consisting of 4 mice in
each group (total n=16) were exposed to LPS,
cocaine, cocaine+LPS, or no exposure
(control).

Mice exposed to LPS showed
higher levels of hepatic nitric
oxide and reactive oxygen
species compared to controls.
Cocaine exacerbated these
effects in the presence of LPS.

Cocaine was administered for 5 consecutive
days, LPS was given intraperitoneally.
Glutathione, antioxidant status, nitric oxide,
and liver damage were determined 18 hours
after final LPS administration.

40

Table 2: Literature Review: Biological Factors Associated with Increased Liver Fibrosis.
Author/Study design
Study Purpose
Model or Population
MacDonald GA et al.
Assess the distribution of
Thirty-nine patients with hepatic steatosis, and
2001137
lipid peroxidation in
no history of heavy alcohol drinking or any
association with these
form of hepatitis were enrolled in the study.
Cross-sectional study
factors and the relationship Liver biopsies were taken to confirm fibrosis
of this to the fibrogenic
staging and MDA-adduct staining.
cascade.
Barbaro G et al. 1996146 Quantitate the amount of
One hundred and five patients with hepatitis C
hepatic and plasma
(HCV) were recruited and categorized as being
Cross-sectional,
glutathione (GSH) in
HIV+ or HIV- based on serological markers.
convenience sample
patients with chronic
GSH concentrations were measured by HPLC.
hepatitis who were HIV+
Liver biopsies were obtained to measure degree
or HIV- and examine
of fibrosis. Circulating GSH levels were also
correlations between
measured in a healthy control group.
activity of liver disease

Balagopal A et al,
2008148
Retrospective, casecontrol study

Study the effect of
microbial translocation on
liver disease in HIV and
hepatitis C infection using
a repository of samples.

Findings
Levels of MDA, a marker of
lipid peroxidation, are
significantly associated with
areas of hepatic steatosis and
liver fibrosis in situ.

Antioxidant GSH
concentrations were
significantly reduced in
patients with chronic hepatitis
C compared to healthy
controls. Circulating GSH
significantly correlated to
hepatic GSH levels in
HIV/HCV co-infected
patients. Lower levels of
GSH were significantly
associated with higher liver
fibrosis in HIV/HCV.
One-hundred consecutive samples with paired
HIV infection itself increases
liver biopsies were chosen. Cases were defined microbial translocation
as having end stage liver disease or cirrhosis,
compared to uninfected
and controls had no or minimal fibrosis.
controls, however HCV
mono-infection does not.
Microbial translocation was defined by
measuring LPS in plasma using the Lonza LAL HIV/HCV co-infected
assay and sCD14 using ELISA.
subjects with elevated plasma
LPS had a 2.7-fold higher risk
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Sanvisens A et al.
200953
Cross-sectional,
convenience sample
Rallon N et al. 201154
Case-control,
Cross-sectional study

Connoy A et al. 2011130
Cross-sectional study

of liver disease, and in the
overall cohort elevated LPS is
associated with 18.7-fold
higher risk of cirrhosis when
adjusting for confounding
factors.
Analyze the prognostic
Sixty-nine consecutive HIV/HCV co-infected
TGF-beta1 was not predictive
value of hyaluronic acid
patients had liver fibrosis assessed using
of fibrosis in HIV/HCV coand TGF-beta1 for liver
Sheuer’s fibrosis score. Serum hyaluronic acid infected patients treated with
fibrosis using liver biopsies and TGF-beta1 were assessed as diagnostic
HAART. The levels of TGFin HIV/HCV co-infection. markers using AUROC curves.
beta1 dropped in the later
stages of fibrosis.
Examine the levels of T42 HIV/HCV co-infected patents, 20 HCV
There was an inverse
regulatory cells and
mono-infected patients, and 26 HIV- and HCV- correlation between liver
circulating TGF-beta1 in
seronegative control subjects had T-reg cells
stiffness and TGF-beta1,
HCV mono-infected and
measured using flow cytometry and circulating however, it was not
HIV/HCV co-infected
TGF-beta1 levels measured using ELISA.
statistically significant. High
according to the stage of
Liver fibrosis was measured using Fibroscan
levels of TGF-beta1 was
liver fibrosis.
transient elastography.
significantly associated with
not having advanced liver
fibrosis.
Test the expression of
Samples from 50 subjects (10 patients in each
Hepatocyte apoptosis was
serum markers of
group) were collected: HIV ART naïve, HIV
higher and significantly
inflammation and apoptosis on ART, HCV mono infected HIV/HCV ART
associated with markers of
and explore their
naïve, and HIV/HCV on ART. M30
liver fibrosis in patients with
relationship with hepatic
apoptosense measured circulating CK-18 for
HIV who were not taking
fibrosis in HIV infected
heapatic apoptosis. Liver fibrosis was
antiretroviral medication, and
patients.
characterized by expression of the fibrotic
had lower CD4 cell counts.
enzymes MMP-2 and TIMP-1.
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CHAPTER III: METHODS
Study Participants
Participants recruited from the Borinquen Health Care Center in Miami, FL, who
participated in the observational Miami Adult Studies on HIV (MASH) cohort funded by
R01 AA018011 and R01 DA 023405 (P.I. Marianna K. Baum) were included in this
study. After assessing for eligibility criteria for the parent study and obtaining informed
consent, baseline and follow-up data for demographics, drug use, alcohol use, medication
use and ART adherence, along with 24-hour dietary recall and anthropometrics were
collected by trained interviewers, and were used in this study. In a cohort of 464 people
living with HIV (PLWH), 25.4% (118/464) were HIV/HCV co-infected, and none of the
participants were HBV infected. The remainder of the cohort (346 participants) consisted
of HIV mono-infected participants. HIV, HBV and HCV status were collected using
proof of positive test in medical records. Subjects were referred to Borinquen Health
Center for HIV or hepatitis testing if they did not have proof of viral status. The FIU
Institutional Review Board approved this proposed study, and study participants agreed
during baseline consent to have their data and lab specimens used for future research. The
investigator only used de-identified data and specimens linked by a code number.
Variables Obtained by the MASH Cohort:
Demographics, anthropometrics (including BMI), and ART use were obtained from
the parent MASH study.
Alcohol use information was gathered during patient interviews using the Alcohol Use
Disorders Identification Test (AUDIT) tool. AUDIT was developed by the World Health
Organization to screen for alcohol consumption.1,2 Moderate alcohol use or abstinence is
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AUDIT score < 8, while scores ≥ 8 indicate hazardous drinking and ≥ 13 in women and
15 in men indicates possible dependence.2,3This tool was used in the parent study to
assess alcohol use.
Body Mass Index was obtained by measuring height using a stadiometer and weight on a
calibrated scale when subjects were dressed in light clothing and after removing shoes.
Height was recorded at the baseline visit only, and weight was collected at each visit
throughout the study to measure BMI in kg/m2.
Cocaine use was determined by a self-report questionnaire that included type and
frequency of drug of abuse and was confirmed by urine toxicology.
FIB-4 index is a non-invasive measure of liver fibrosis. Although liver biopsy is the
current gold standard for liver fibrosis staging using METAVIR scores, it is highly
invasive and it is not feasible to obtain for research purposes.4 Specifically in HIV
patients, it is contraindicated because of the increased risk of internal hemorrhage due to
thrombocytopenia.4,5 FIB-4 index was calculated using results collected by the parent
study from common laboratory reports generated by a commercial laboratory using the
formula: [(AgeXAST)/(PlateletsX√(ALT))]. It has been used in previous studies in HIV
and validated in HCV6,7 and HIV/HCV6 with specificity of 94.7% and 90%, and
sensitivity of 74.3% and 70%, respectively. METAVIR categories of liver fibrosis using
FIB-4 values are as follows: F0-F1 (FIB-4 <1.45) none/mild fibrosis, F2 (1.45≤ FIB4
≤3.25) moderate fibrosis, and F3-F4 (FIB-4 >3.25) advanced fibrosis/cirrhosis.6,7
Control variables included factors known to impact liver fibrosis: age, gender, CD4 cell
count (baseline), HIV viral load (baseline), ART use, lifestyle factors (obesity, alcohol
use, cocaine use) and HCV disease status, when appropriate.
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Laboratory Sample Analysis Performed for this Study:
Laboratory tests for oxidative stress, microbial translocation, TGF-β1, and hepatocytespecific apoptosis were generated specifically for this study. Whole blood samples were
collected at baseline and annually for the participants in the MASH cohort, and
transported to the FIU laboratory for processing and storage within 4 hours of collection.
All laboratory tests were performed in plasma samples. The assays used in this analysis
required that plasma samples were collected and processed within 4 hours of
venipuncture for accurate results. After separating plasma from red blood cells and the
buffy coat by centrifugation in vacutainers with an anticoagulant, approximately 8 X 1
mL aliquots were stored in cryovials at -80C for future research. This study did not use
samples that had undergone repeated freeze-thaw cycles.
i. Malondialdehyde (MDA)
MDA is widely accepted as a marker of lipid peroxidation, indicating oxidative stress,
and correlates well with liver fibrosis in other populations.8-10 MDA was measured using
a Thiobarbituric Acid Reactive Substance (TBARS) assay (Northwest Life Science
Specialties, Portland, OR, USA). The test principle is based on the reaction between
MDA and thiobarbituric acid (TBA), forming a stable MDA-TBA adduct that absorbs
light strongly at 532nm, and can be read spectrophometrically. Samples that were
“cloudy” upon thawing were centrifuged at 3,000 X g for 5 minutes prior to the addition
of reagents. All reagents were reconstituted according to manufacturer’s protocol.
Butylated hydroxytoluene (BHT) with excess precipitate in solution was warmed in a
water bath at 60 C for 1 minute. Ten microliters of BHT preservative was added to 250
uL of plasma sample or a known standard (provided by Northwest Life Science) in
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microcentrifuge tubes. Acid reagent (250 uL) and TBA (250 uL) were added to the
sample or standards and vortexed vigorously for 5 seconds, then incubated in a water
bath at 60C for 60 minutes. After incubation, tubes were centrifuged at 10,000 X g for 3
minutes. Each sample was transferred into a disposable cuvette and Absorbance was read
individually at 532nm in a spectrophotometer (Beckman Coulter DU530). A calibration
curve generated a linear equation from which concentration of samples were estimated.
ii. Glutathione (GSH)
The reduced form of GSH, is the most abundant endogenous intracellular antioxidant,
and it directly participates in quenching harmful peroxide radicals as well as recycling
other antioxidants.11 GSH represents antioxidant status by measuring the ratio of oxidized
glutathione to total glutathione (oxidized GSSG + reduced GSH). Measuring levels of
reduced GSH alone does not indicate oxidative stress levels, however, a higher ratio of
oxidized glutathione to total glutathione is indicative of higher oxidative stress. Healthy
values of oxidized glutathione are under 10% of the total glutathione pool.12 Percent
oxidized glutathione is measured using DetectX colorimetric assay that measures total
and oxidized glutathione (Arbor Assays, Ann Arbor, MI, USA). The principle behind
DetectX colorimetric assay is to bind the free thiol groups in oxidized GSSG to yield a
highly colored product.
Prior to long term storage of plasma for glutathione analysis, the samples were treated
with equal parts 5% sulfosalicylic (SSA) solution and centrifuged at 14,000 RPM for 5
min at 4C to prevent further oxidation of the sample by precipitating proteins that may
cause damage. Then samples were aliquoted and stored at -80C until use. To prepare
samples for the assay, each sample was diluted in assay buffer to 1:5 as per
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manufacturer’s instruction and 50uL was distributed in two 96 well plates in duplicate
(i.e. 2 X 50 uL diluted sample in plate 1, and 2 X 50 uL sample in plate 2). Plate 1
represented % oxidized GSH, and plate 2 represented total GSH measurement. A
standard curve was created by making six serial dilutions of the provided standard in each
plate. Before adding the colorimetric reagent, 1.2 uL of 2-vinylpyridine was added to
each well in plate 1 only to block reduced GSH from binding to the colorimetric
substrate. Colorimetric reagent was added (25 uL) and subsequently, 25 uL of the
reaction mixture was added using a multichannel pipette. The sides of the plates were
tapped gently to mix the samples and incubated at room temperature for 20 minutes then
immediately read using a microplate reader at 405nm using Gen5 Software (BioTek,
EL800). Absolute values of reduced and total GSH were estimated using standard curves.
In order to generate the final values for % oxidized GSH, the values of oxidized GSH
were divided by 2 because each thiol group in the GSSG disulfide bond, can bind to the
colorimetric agent, generating twice the absorbance of the original GSH molecule. The
equation to calculate % oxidized GSH was
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Both MDA and %

oxidized glutathione kits have been used in previous MASH cohort studies and results
were presented in publications.13,14
iii. Lipopolysaccharide (LPS)
The bacterial endotoxin LPS is a major component of Gram-negative bacterial cell
walls and can be quantitatively assessed to determine the degree of microbial
translocation.15 Plasma LPS levels are directly associated with the degree of intestinal
permeability following invasive surgery.16 The limulus amebocyte lysate (LAL) assay
has been widely used for the detection of endotoxin for approximately 30 years,17 and in
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HIV-related research.15,18-20 Recently, methods have been developed to measure LPS
using the LAL Lonza kit in plasma of HIV+ patients.18 Circulating LPS was measured
using the Endpoint Chromogenic LAL Assay (Lonza, Walkersville, MD, USA) that
utilizes Factor C, a protease zymogen that is cleaved and activated in the presence of
endotoxin. The assay utilizes the cascade to ultimately activate a synthetic chromogenic
peptide that exhibits a yellow color and can be read at 405 nm. A greater absorbance
directly corresponds to a higher level of LPS endotoxin present in samples. Plasma
samples require extra processing for this assay. Samples were thawed and diluted 1:5 in
LAL reagent water, then heated to 70C in a heating block for 15 minutes to inactivate
proteins. Samples were aliquoted into a microplate on a pre-warmed heating block to
37C. A series of endotoxin standard dilutions was used as a reference curve, and LAL
water served as a blank. All samples and standards were plated in duplicate on 96 well
plates. At time zero, 50 uL of LAL reagent water was added using a microchannel
pipette. After 10 minutes of incubation at 37C, the pre-warmed (37C) chromogenic
substrate was added in the same order as the LAL reagent water and incubated at 37C for
16 min. The stop solution (25% acetic acid) was added to stop the reaction in the same
order as the previous reagents, and the samples were read on a microplate reader at
405nm (BioTek EL800) using Gen5 software. A “best fit” linear standard curve was
generated to estimate the values of LPS in the samples.
iv. Transforming Growth Factor-Beta 1 (TGF-β1)
Measurement of the fibrogenic cytokine TGF-β1 uses ELISA methods from a
commercially available kit. The Quantikine ELISA kit (R&D Systems, Minneapolis,
MN, USA) measures the activated form of TGF-β1 circulating in plasma samples, and
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has been used on previous studies in human plasma.21,22 Although circulating TGF-β1
shows mixed results when correlating with FIB-4 index,23 its levels are often high in the
early stages of fibrosis.24,25 The sandwich ELISA assay quantifies TGF-β1 using precoated wells with monoclonal antibodies that specifically bind to TGF-β1 in samples and
standards. After washing away excess sample, the bound TGF-β1 is immobilized by the
antibody and treated with and enzyme-linked polyclonal antibody to bind with TGF-β1 in
the well, the excess is washed away. Finally, a substrate solution that reacts to the
presence of the enzyme of the polyclonal antibody is introduced to generate a color
proportional to the quantity of TGF-β1in the well. For plasma samples, latent TGF-β1
was activated by adding 20 uL of 1N HCl to 40 uL of plasma and vortexed for 3 counts.
After 10 minutes of incubation at room temperature, 1.2 NaOH/0.5 M HEPES was added
to neutralize the mixture. The sample was diluted with the calibrator diluent to a final
dilution factor of 40 based on the manufacturer’s protocol. A standard curve was
generated with several serial dilutions, and the calibrator diluent served as a blank. Fifty
microliters of assay diluent was added to each well using a multichannel pipette, then 50
uL of sample, standard, or blank was added to each individual well. The well plate was
covered and placed inside a foil pouch during a 2 hour incubation period at room
temperature. The wells were washed manually with a squirt bottle using 400 uL of wash
buffer with complete removal of liquid and bubbles at each step. TGF-β1 conjugate (100
uL) was added to each well and incubated in the foil pouch with gentle rocking at room
temperature for 2 hours. The wash step was repeated, then 100 uL of substrate solution
was added to each well and the plate was incubated at room temperature for 30 minutes
and protected from light. Stop solution (100 uL) was added and plate was tapped gently
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to ensure mixing. The absorbance of each sample was measured (in duplicate) at 450 nm
on a microplate reader (BioTek EL800) using Gen5 software. TGF-β1 values were
estimated from the linear equation generated by the standard curve (blank 450nm).
v. Cleaved Cytokerain-18 protein (CK-18)
Programmed cell death, or apoptosis, in hepatocytes has been suggested as a
mechanism for liver fibrosis because apoptotic bodies initiate inflammation and activate
hepatic stellate cells.26Hepatocyte-specific apoptosis was quantified using Apoptosense
ELISA assay (Peviva, Nacka, Sweden) that uses the M30 antibody specific for the
cleaved cytokeratin-18 (CK-18) protein. Hepatocyte cells undergoing cell death produce
cleaved CK-18 and an increase circulating levels are associated with hepatic injury and
fibrosis.27-32The protocol for the sandwich ELISA assay requires 25 uL of plasma in
duplicate. Standards provided in kit (did not require dilutions) were pipetted in 96 well
plate along with a “high” control and “low” control. Samples were dispensed directly
into wells, and 75 uL of the conjugate solution was added to the plate using a
multichannel pipette. The plate was sealed and incubated for four hours at room
temperature on a shaker. After, the wells were rinsed with a squirt bottle (400 uL with
overflow) using the wash solution 4-5 times. TMB substrate (200 uL) was added to each
well and the plate was incubated at room temperature for 20 minutes with no exposure to
light. Fifty microliters of the stop solution was added and the plate was placed on the
shaker for 5 minutes before reading the absorbance on the microplate reader at 450 nm
using Gen5 software. The standard curve provided a linear estimate of CK-18 values.
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Acceptable results for all sample analyses had coefficient of variation (CVs) within 10%,
that is, the value of each duplicate must be within 10% of the mean for that sample,
indicating a small variance between replicates; otherwise the samples were reanalyzed.
Statistical Methods
A convenience sample from the parent study was included in this analysis. We
selected participants that had complete liver enzyme and platelet information to calculate
FIB-4 index, and with BMI, AUDIT, and drug use information completed. The
laboratory data for hypothesis 2 was conducted in a subset of the mono-infected
population to factor out any deleterious effects from hepatitis C virus on liver fibrosis.
Data were generated at three time points throughout the parent study (baseline, 12
months, and 24 months) with n=60 participants included in the analysis. The participants
included for hypothesis 3 testing were selected based on completeness of data and
comprehensive laboratory data at baseline. A total of n=65 participants met this criteria
and were included in the analysis.
Sample Size: Sample size was calculated using G*Power Program for all hypotheses.
The first hypothesis analyzing lifestyle factors had the largest sample size (464
participants), mainly because it had the most complete data. The sample for hypothesis 2
included HIV mono-infected participants only to increase power and exclude the
powerful confounder of hepatitis C infection. We reduced the sample size to 65
participants and included 3 time points for a more robust analysis of the biological
samples (65 participants X 3 time points = 195 samples analyzed). A post-hoc power
analysis of 65 HIV-mono infected participants generated 80% power to detect an alpha of
0.05 with three time points (baseline, 12 months, 24 months) with a correlation between
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variables at r=0.2. Therefore a sample size of 65 participants for hypothesis 2 provided
80% power to detect predictive value of biomarkers. When calculating the power for
logistic regression with a samples size of n=65, we had 80% power to see a statistically
significant difference when the odds of fibrosis progressing one stage of fibroses
increases by a factor of 2.3 times.
Statistical Analysis: The variables that required transformations to meet normality of
distribution for the study included log10 transformation for the absolute HIV viral load,
squaring CD4 cell count, and log10 TGF-β1. All other variables met the requirements of
normal distributions. Descriptive characteristics for each hypothesis were generated
using chi-square tests to compare categorical variables, and continuous variables were
compared using student’s t-test for two groups or one-way ANOVA for multiple groups.
Multivariate linear regression was used to assess independent predictor variables on FIB4 for specific aim 1, and for biological factors in specific aim 2 and 3. Logistic
regression examined the odds of progressing at least one category of FIB-4 over two
years when being at risk for a lifestyle factor at baseline (high BMI, drinking alcohol,
using cocaine) for specific aim 1, or for having a high level of a fibrogenic biomarker
(oxidative stress, LPS, TGF-β1, hepatocyte apoptosis) for specific aim 2. When sample
size permitted, analyses were conducted separately in HIV mono- and HIV/HCV coinfected participants to avoid confounding effects of the HCV virus on liver fibrosis. P <
0.05 set the significance level for all analyses. Statistical analysis were performed using
SPSS software versions 21 and 22.
Statistics for Specific Aim 1: Examine the effect of lifestyle factors (high BMI,
alcohol use, and cocaine use) on liver fibrosis in HIV mono- and HIV/HCV co65

infection cross-sectionally, and investigate whether high baseline measures affect
liver fibrosis progression over time. Lifestyle groups were separated based on cutoff
points generated by AUROC analyses of body mass index, alcohol AUDIT score, and
cocaine use frequency. A BMI cutoff of BMI≥28 kg/m2, an AUDIT cut off of ≥8 and
positive cocaine use (self-reported cocaine use in the past 6 weeks or a positive urine test)
were the cutoff values that best fit the data and were used as cutoff points in the analysis.
Three-way ANOVA investigated associations between lifestyle factors and FIB-4 index
and included interactions between lifestyle factors. Significant interactions were further
investigated with supplementary statistics, by stratifying the data and including plots to
evaluate interaction on FIB-4 index. T-test and one-way ANOVA with post-hoc analysis
was used to determine differences between groups with two and three levels,
respectively. Multiple linear regression was run to analyze each lifestyle factor
independently for significance on FIB-4 index as the dependent variable controlling for
age, gender, ART use, CD4 cell count, and HIV viral load. Logistic regression was used
to analyze the odds of progressing at least on stage of fibrosis over 24 months based on
having a risky lifestyle factor (i.e., high BMI, alcohol use, or cocaine use).
Statistics for Specific Aim 2: Examine the effect of biological factors at baseline on
changes in liver fibrosis over time. Sixty-five HIV-mono infected participants were
selected for longitudinal analyses to test whether high levels of biomarkers at baseline
predict liver fibrosis progression over two years. Biomarkers were separated into tertiles,
and biomarkers that fell into higher tertile value was considered “high”. FIB-4 values for
participants were evaluated from baseline to 24 months and categorized as (1)
nonprogressor – did not advance in FIB-4 category, and (2) progressor – progressed at
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least one FIB-4 category in two years. A test of proportions was initially conducted to
determine the proportion of participants that progressed in each group biomarker group
(high vs. low). The odds of progressing at least one category of fibrosis (FIB-4 index)
based on having a high fibrogenic biomarker (oxidative stress, LPS, TGF-β1, or CK-18),
was examined using logistic regression, and controlled for variables associated with liver
fibrosis. Mixed model analysis used repeated measures to describe the associations
between biological factors and liver fibrosis (FIB-4 index) with time as an interaction.
Statistics for Specific Aim 3: Exploring the biological factors within lifestyle factors
that contribute to liver fibrosis cross-sectionally. Participants were selected based on
having one identifying lifestyle factor (i.e. only high BMI, or only hazardous drinking, or
only using cocaine) in order to isolate any association between a specific lifestyle factor
and biomarkers associated with liver fibrosis. Student’s T-test compared the mean of
each biological factor within a lifestyle group to a control group (no adverse lifestyle
factors). One-way ANOVA was used to determine whether the means of biological
factors were significantly different between each (High BMI vs. Hazardous drinking vs.
Cocaine use vs. Control Group). Post-hoc analysis revealed specific differences between
groups. Three-way ANOVA assessed interactions between lifestyle groups for each
biological factor. Multiple linear regressions determined associations between individual
biomarkers and FIB-4 within lifestyle groups, controlling for covariates known to affect
liver fibrosis.
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CHAPTER IV: HAZARDOUS ALCOHOL USE, HIGH BODY MASS INDEX,
AND COCAINE USE ARE ASSOCIATED WITH LIVER FIBROSIS IN
HIV MONO- AND HIV/HCV CO-INFECTED ADULTS
Abstract
Objective: Liver fibrosis is a leading cause of morbidity and mortality in people living
with HIV (PLWH). Co-infection with HIV and Hepatitis C (HCV) is a major contributor
to liver disease progression, because of the ability of HCV and HIV to specifically infect
hepatic stellate cells. Adverse lifestyle factors that are prevalent in PLWH include
hazardous alcohol use, high body mass index (BMI), and illicit drug abuse, such as
crack/cocaine use also may be significant contributors to liver fibrosis in HIV disease.
This research aims to investigate harmful lifestyle factors that contribute to liver fibrosis
using FIB-4 index as a non-invasive indicator in an HIV mono- and HIV/HCV coinfected people.
Methods: Baseline data was collected in 310 HIV mono-infected and 134 HIV/HCV coinfected participants in the Miami Adults Studies on HIV (MASH) cohort in Miami, FL.
Longitudinal data was collected in a subset of participants to evaluate liver fibrosis
progression after 24 months of study enrollment. Hazardous drinking was assessed by
AUDIT score ≥ 8, high BMI was considered ≥ 28 kg/m2, and positive cocaine use was
collected using participant self-report, and confirmed with urine toxicology test.
Participants were grouped into categories of liver fibrosis at baseline according to their
FIB-4 score generated by the equation that uses common laboratory values:
[(AgeXAST)/(PlateletsX√(ALT))]. FIB-4 index < 1.45 ruled out advanced stage of
hepatic fibrosis (METAVIR stage F0-F1), FIB- 4 score that fell between 1.45 and less
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than 3.25 was considered and indeterminate score (METAVIR stage = F2), and severe
hepatic fibrosis or cirrhosis was defined by FIB-4 index ≥ 3.25 (METAVIR ≥ F3-F4).
Multivariate linear regressions were used to find associations between lifestyle factors
and FIB-4 index cross-sectionally. Univariate and multivariate analyses were used to
assess whether hazardous alcohol use, high BMI, and/or positive cocaine use were
significantly associated with increased liver fibrosis. A longitudinal analysis explored
odds ratios of increasing one category of hepatic fibrosis after completing 2 years of
study enrollment and having an adverse lifestyle factor. Interactions between lifestyle
factors were explored in the analyses.
Results: Within the HIV mono-infected group, higher AUDIT score was independently
associated with increasing FIB-4 index at baseline in regression models (P=0.023) and
multivariate analysis of variance (P=0.023), after adjusting for age, gender, HIV viral
load, CD4 cell count, and ART use. The odds of progressing at least one stage of hepatic
fibrosis in HIV mono-infected participants was independently associated with high BMI
(≥ 28 kg/m2), after adjusting for covariates (P=0.015). Hazardous drinking was also
associated with a 3 times increased odds of liver fibrosis progression over 2 years when
controlling for covariates and high BMI (P=0.048). Cocaine use significantly decreased
the odds of progressing in hepatic fibrosis stage when controlling for BMI (P=0.034),
however, significance was lost in participants with low BMI, whereas CD4 cell count
predicts FIB-4 in HIV mono-infected participants with lower BMI. There is an
interaction between BMI, cocaine use, and liver fibrosis progression in both HIV monoand HIV/HCV co-infection (P=0.072 and P=0.034, respectively). Hepatic fibrosis was
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associated to clinical outcomes in HIV/HCV co-infected participants. Age (P= 0.004)
was the major predictor of higher FIB-4.
Conclusions: Adverse lifestyle factors in HIV mono-infection associated with hepatic
fibrosis may account for the high prevalence of liver disease not directly related to
HIV/HCV co-infection. Hazardous drinking was associated with higher FIB-4 index in
HIV mono-infection. BMI increased the odds of progressing FIB-4 category over 2 years.
There was an interaction between cocaine use and BMI in both HIV mono- and
HIV/HCV co-infected participants, and CD4 cell count may play a protective role in HIV
mono-infected participants at risk for liver fibrosis with lower BMI.
Keywords: HIV infection, HIV/HCV co-infection, liver fibrosis, alcohol, AUDIT,
cocaine, body mass index, FIB-4 index
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Introduction
Liver fibrosis is a leading cause of morbidity and mortality in people living with
HIV (PLWH).1-3 Co-infection with HIV and Hepatitis C (HCV) is a major contributor to
liver disease progression, because of the ability of HCV and HIV to specifically infect
hepatic stellate cells.4,5 This is evidenced by poor HIV disease status association with
more advanced liver disease.6,7 People living with HIV in the United States may also be
exposed to adverse lifestyle factors that further contribute to the development of liver
disease,8-11 and in the United States harmful lifestyle factors that are prevalent in PLWH
include hazardous alcohol use,12,13 high body mass index (BMI),8,12,14 and illicit drug
abuse, such as crack/cocaine use.15-17 Alcohol use is studied in HIV infection because of
the extra burden it places on the liver, and leads to rapid progression of alcoholic liver
disease in PLWH.18 Hazardous drinking is associated with binge drinking and not
necessarily alcohol dependence.19,20 Binge drinking alcohol can lead to mechanisms of
liver damage in healthy individuals,21 so it is believed that hazardous alcohol use is
associated with liver fibrosis in HIV mono- and HIV/HCV co-infection.11 According to
recent NHANES data, 2 in 5 HIV- infected women and 1 in 5 HIV-infected men are
obese (BMI≥ 30kg/m2) in the United States. Obesity and being overweight is associated
with advanced liver fibrosis in the general population, leading to conditions such as nonalcoholic fatty liver disease (NAFLD)22,23 Illicit drug use is associated with HIVinfection, and there is a growing prevalence of non-injection drug users who use
crack/cocaine in PLWH.24 Cocaine is also associated with hepatotoxicity25 through
oxidative mechanisms26 that cause liver fibrosis.
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These lifestyle factors are associated with liver disease, and their association with
increased liver fibrosis is also observed in the general population,22,23,27,28 and may
significantly affect liver fibrosis in HIV infection.
Stage of liver fibrosis serves as an important prognostic factor for liver disease
because it defines the extent of liver disease advancement for therapeutic decisions.29
FIB-4 is a non-invasive index of liver fibrosis. Liver biopsy is the current gold standard
for liver fibrosis, it is highly invasive, carries a high risk for research purposes.30
Specifically in PLWH, it is contraindicated because there is an increased risk of internal
hemorrhage due to thrombocytopenia.30,31 Therefore, non-invasive methods of
determining liver fibrosis, such as FIB-4 index32,33 have been used. Sterling et al.34 have
described the FIB-4 index, which consists of alanine aminotransferase (ALT) level, AST
level, PLT counts, and age, for assessing fibrosis in a large cohort of patients with
HIV/HCV co-infection. The FIB-4 index has also been validated as an inexpensive and
accurate marker of fibrosis in the context of HCV mono-infection with a sensitivity of
74.3% and specificity of 80.1% (FIB-4 cut off< 1.45 to rule out advanced liver fibrosis).35
This noninvasive index constitutes an inexpensive yet accurate prediction of hepatic
fibrosis and can be correlated with liver biopsy METAVIR stage of F0-F1 based on a
FIB-4 value <1.45, representing no/mild fibrosis, and METAVIR stage ≥F2 (FIB-4≥
1.45) representing advanced fibrosis and METAVIR stage F3-F4 (FIB-4 ≥ 3.25)
representing advanced fibrosis/cirrhosis.6,36,37
Most studies have attributed the advancing liver fibrosis in PLWH to high rates of
HIV/HCV co-infection, however, with an effective use of antiretroviral therapy, PLWH
are aging,38 and this is accompanied by an increase in co-morbidities (e.g. cardiovascular
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disease and liver fibrosis) both due to aging, risky lifestyle factors as well as the HIV and
HCV virus infections.39,40 Due to the strong confounding impact that HCV infection has
on liver disease,41-43 it is important to investigate factors associated with liver fibrosis in
both HIV mono- and HIV/HCV co-infection as separate populations. This research aims
to investigate harmful lifestyle factors that contribute to liver fibrosis using FIB-4 as a
non-invasive indicator in an HIV mono- and HIV/HCV co-infected people.
Methods
The aim was to determine the association of harmful lifestyle factors with liver
fibrosis in HIV mono-infected and HIV/HCV co-infected subjects participating in the
Miami Adult Studies on HIV (MASH) cohort.
Study design and setting
A total of 454 HIV-infected adults, a subsample of MASH, participated in the
study and were followed for two years. Data analysis was conducted separately for HIV
mono-infected and HIV/HCV co-infected people as indicated in the results section. All
participants gave written consent and completed each clinic visit with trained
interviewers who also collected anthropometrics at each time point. Blood was collected
annually via venipuncture by the study nurse and sent to a central laboratory (Quest
Diagnostics, Miami, FL) for analysis and blind reporting. Participants visited the clinic
every three months for follow-up interviews that included data collection for information
on lifestyle, risk factors for disease, and blood samples for laboratory assessment. The
study was approved by the Institutional Review Board at Florida International University.
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Measurements
Dependent variable. Laboratory data to obtain FIB-4 index was sent to a central
laboratory (Quest Diagnostics, Miami, FL) for blinded analysis. FIB-4 index was
calculated using the validated equation [(AgeXAST)/(PlateletsX√(ALT))].34,35 For
baseline groups, participants were categorized as having no/mild fibrosis (FIB-4 index
<1.45, METAVIR stage F0-F1), indeterminate fibrosis (1.45 ≥ FIB-4 < 3.25) or severe
(FIB-4 ≥ 3.25 METAVIR stage ≥ F3-F4).36 The absence of advanced fibrosis was
determined with the cut off value of FIB-4 < 1.45 (METAVIR stage F0-F1) for crosssectional and longitudinal analyses.7,35,44 A participant qualified as progressing in at least
one METAVIR stage or category of liver fibrosis if their baseline FIB-4 score increased
from < 1.45 to greater than 1.45, or from between 1.45 – 3.25 to ≥ after 2 years of study
enrollment.
Lifestyle factors. Interviewers collected information about alcohol consumption.
The Alcohol Use Disorders Identification Test (AUDIT), a questionnaire developed by
the World Health Organization to identify patients who drink hazardously or who are
alcohol dependent and may benefit from abstinence was used.45,46 AUDIT generates a
score from 0 to 40 and can classify patients into abstinence from alcohol (AUDIT = 0),
mild drinking habits (AUDIT < 8), hazardous drinking (AUDIT ≥ 8), and alcohol
dependence (AUDIT ≥ 13 in women and ≥ 15 in men).19,45,47 Body mass index (BMI)
was obtained by measuring height using a stadiometer and weight on a calibrated scale
when subjects were dressed in light clothing and after removing shoes. Height was
recorded at the baseline visit only, and weight was collected throughout the study.
Established cut off points of BMI for being overweight (BMI ≥ 25kg/m2) and obese (BMI
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≥ 30kg/m2) were used since they are associated with liver fibrosis,14,48however, previous
research suggests that using a BMI cut off ≥ 28kg/m2 predicted fibrosis.23,49 The
interviewer utilized a drug-frequency questionnaire to obtain self-reported crack/cocaine
use, and the information was confirmed with urine toxicology.
Covariates. Age, gender, and ART use, along with HIV disease parameters (HIV
viral load, and CD4 cell count) were obtained from interviews and primary care
physicians with the consent of the participants at each visit.
Statistical Analysis
Descriptive statistics were used to describe the overall study sample in HIV
mono- and HIV/HCV co-infected groups. Baseline characteristics were compared across
groups using Chi-square/Fisher’s exact test for categorical variables and analysis of
variance for continuous variables. Receiver Operating Curve (ROC) analysis guided
decisions to choose cut off points for primary analyses of harmful lifestyle factors with
FIB-4 index. Using statistical analyses we evaluated (1) the associations between
drinking (AUDIT score), anthropometrics (body mass index), and crack/cocaine use
(self-report and/or urine sample) with liver fibrosis (FIB-4 index) and (2) whether
participants experienced a progression in liver fibrosis over two years. Analyses were
controlled for covariates that are known to affect liver fibrosis (age, gender, HIV viral
load, CD4 cell count, and ART use). Spearman’s correlations were used to evaluate
potential collinearity between covariates. No pair of covariates included in the same
regression model were highly correlated (r>0.50). Multivariate linear regressions were
used to evaluate associations between AUDIT scores, BMI, and cocaine use
independently with FIB-4 index. Univariate and Multivariate ANOVA models were
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used to test the effect of adverse lifestyle groups on FIB-4 index. Three-way ANOVA
Levene’s test failed, but univariate analysis modeling is robust to heterogeneity, which
allowed three-way ANOVA to proceed because the ratio of variance between the largest
group and the smallest group was less than 3. Associations between the odds of
progressing at least one category of FIB-4 index and having an adverse lifestyle were
evaluated using logistic regression models. Lifestyle groups were evaluated in statistical
models as independent factors, and subsequent analyses identified the impact of
interactions between lifestyle groups on liver fibrosis. HIV viral load was log
transformed, CD4 cell count was transformed by square root to meet assumptions of
normality. The assumptions of linearity, independence of errors, homoscedasticity, and
normality of residuals were met and independent variables showed no multicollinearity.
A P-value < 0.05 was considered statistically significant.
Results
Characteristics of study population (Table 1)
In the MASH cohort, HIV mono-infected individuals were younger, had lower
HIV viral load but no difference in CD4 cell count or ART use, and had slightly higher
BMI. As expected, HIV/HCV co-infected participants had significantly higher FIB-4
index, which places them in a higher clinical category of liver fibrosis compared to those
who are HIV mono-infected (advanced fibrosis or METAVIR stage ≥ F2 vs. mild fibrosis
or METAVIR stage F0-F1, respectively).
Factors associated with categories of fibrosis (Table 2a and 2b)
ANOVA analysis revealed that mean FIB-4 value fell within clinical range for
mild, indeterminate and severe liver fibrosis in HIV mono-infection (mild 0.96±0.26, vs.
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indeterminate 1.83±0.38, vs. severe 5.32±3.44) and HIV/HCV co-infection (mild 1.09 ±
0.25 vs. indeterminate 2.07 ± 0.51, vs. severe 4.66 ± 1.84). Only 5.6% of HIV monoinfected participants qualified as having severe liver fibrosis at baseline visit compared to
18.9% in the co-infected group. A higher percent of the HIV mono-infected participants
with higher stages of liver fibrosis at baseline were men (77% vs 58%, P<0.001, and
significantly older (44.5± 8.3 vs. 49.4± 4.9 years P=0.001). The mean BMI was in the
“overweight” category for all categories of liver fibrosis. In HIV/HCV co-infection,
only age differed significantly and HIV viral load trended towards significance between
FIB-4 categories such that participants in later stages of liver fibrosis tended to be older
(49.1±5.6 vs. 51.3±5.2 years, P=0.003) and had a higher proportion of uncontrolled HIV
viral load (55.4% vs. 80.0%, P=0.056) (Table 2b).
Cut off points in within lifestyle groups
Each lifestyle parameter had at least three useful cut off values that could be
potentially used for analysis. Figure 1a and b show ROC analysis curves that determined
the single best cut off point generated for each lifestyle variable to predict liver fibrosis
progression over 2 years. Body mass index (BMI) was the only variable in HIV monoinfection that had an acceptable AUROC value (0.650 ± 0.059, P=0.023). The cut off of
28 kg/m2 had the highest sensitivity and specificity combination (68.2% and 59.1%,
respectively). AUDIT score and cocaine frequency had poor AUROC curves, however,
the cut offs that showed the highest sensitivity and specificity were an AUDIT score of 8
and positive cocaine use (Table 3).

HIV/HCV co-infection showed no significant

AUROC curves, and similar sensitivity and specificity to HIV mono-infection values, so

80

the cut off values from HIV mono-infection were applied to HIV/HCV co-infection for
the analysis.
Due to the diverse etiologies of liver disease in HIV mono- and HIV/HCV coinfection, adverse lifestyle variables alone may not be associated with FIB-4 liver disease
progression. Even so, this analysis is necessary for the generation of cut off points to
investigate the relationship and interactions between lifestyle factors and other
confounding factors that affect liver fibrosis progression.
Factors associated with liver fibrosis in HIV mono-infection
After removing participants with missing data in the various categories of
variables used, analysis was conducted in HIV mono- and HIV/HCV co-infection,
respectively. Data from 300 HIV mono-infected participants were analyzed at baseline.
Simple correlations showed FIB-4 index was significantly correlated to alcohol
consumption (r= 0.118, P=0.021), BMI (r=-0.127, P=0.014), age (r=0.377, p<0.001),
and CD4 cell count (r= -0.152, P=0.004). Multivariate linear regression used lifestyle
factors (AUDIT score, BMI, cocaine use) as predictors of FIB-4 index and included
covariates known to influence liver fibrosis into the model (age, gender, HIV viral load,
CD4 cell count, ART use). The model significantly predicted FIB-4 index F(8, 300)=
5.202, P<0.001, adjusted R2 = 0.099; however AUDIT score was the only lifestyle factor
that was an independent predictor of liver fibrosis (β =0.003, P=0.023) when adjusting
for confounding factors. Regression coefficients are shown in Table 4.
Three-way ANOVA investigated the main effects and interactions of harmful
lifestyle factors on FIB-4 index as a continuous variable.
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The results for main effects of lifestyle factors (shown in Table 5) describe an
association between hazardous drinking and higher FIB-4 index when adjusting for age,
gender, viral load, CD4 cell count, and ART use F(6,300)=5.216, P=0.023.
Correspondingly, an alternative model that was adjusted for main effects and interactions
between lifestyle groups was significant F(7,300)=2.721, P=0.009, with a significant
association of increasing liver fibrosis with drinking hazardously, AUDIT score ≥8 F(1,
300)= 3.925, P=0.048, and with being overweight BMI ≥ 28 kg/m2 F(1, 300)= 4.429,
P=0.036. No significant association was found between liver fibrosis and cocaine use
F(1, 300)=1.955, P=0.163, however, there was interaction between BMI and cocaine use
F(1, 300)=4.509, P=0.035 that is shown graphically (Figure 2).
In the ANOVA model, HIV mono-infected participants who were overweight
(BMI ≥ 28kg/m2) and who engaged in hazardous alcohol drinking (AUDIT score ≥ 8)
had significantly higher liver fibrosis; however there was an inverse association
relationship between BMI and FIB-4 index in regression models. To explore alternative
factors leading to liver fibrosis in HIV mono-infection, we selected for participants with
healthy BMI (<28 kg/m2) and low AUDIT score (<8). In participant with healthy
lifestyle factors, having a low CD4 cell count was significantly associated with higher
FIB-4 value, (β= -0.227, P=0.037) adjusting for age, gender, and ART use. Interestingly,
the significant relationship between CD4 cell count and FIB-4 index is not present in
participants with high BMI (β= 0.115, P=0.173), which may be related to protective
effect that high BMI has on CD4 cell count, however, the fibrogenic effects of BMI
overshadows any protective effects of CD4 cell count on FIB-4 (Figure 3).
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A total of n=176 HIV mono-infected participants had complete data for baseline
and 24-month visits. Figure 4 describes the proportion of participants who progressed at
least one category of fibrosis over 2 years. Within BMI category, a significantly higher
proportion of participants progressed in liver fibrosis over 2 years compared to those with
low BMI (p<0.001).
Logistic regression analysis describes an association between liver fibrosis
progression of at least one fibrosis category over 24 months and high BMI (≥ 28 kg/m2)
at baseline (OR 2.934 [95% CI 1.132 -7.605]; P= 0.027, that became more significant
after adjusting for age, gender, HIV viral load, CD4 cell count, (OR 3.797 [95% CI 1.301
- 11.077]; P=0.015). Hazardous drinking and crack/cocaine use became significantly
associated with progressive liver fibrosis when adjusting for BMI in the model (alcohol ≥
8 (OR 3.038 [95% CI 1.010 - 9.135]; P=0.048) and crack/cocaine use (OR .228 [95% CI
0.057 - 0.918]; P=0.038).
On the other hand, crack/cocaine use was associated with a 4.39 lower odds of
progressing in liver fibrosis in the adjusted model that includes BMI. To further
investigate paradoxical relationship between crack/cocaine use and liver disease, the
participants were stratified by “high” BMI (≥ 28 kg/m2) and “low” BMI (< 28 kg/m2) and
the adjusted odd ratio was re-evaluated. When stratifying by BMI, the “protective” effect
of crack/cocaine was reversed although the finding was not significant (n= 95, OR 1.105
[95% CI 0.187 – 6.508]; P=0.912). In participants with “high” BMI, cocaine cannot
predict the odds of progressing in FIB-4 category with an insignificant and extremely low
odds ratio (n=80, OR <0.000 [95% CI 0.000 - <0.001]; P= 0.998. Liver fibrosis
progression is slightly associated with the interaction between BMI and crack/cocaine use
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(OR 0.959 [95% CI 0.913 – 1.006]; P=0.085; aOR 1.048 [95% CI 0.907 – 1.006]; P=
0.072), where the interaction between BMI and cocaine is associated with a 4.8%
increase in the odds of progressing in liver fibrosis. It is important to note that here is a
2.22 greater odds of having a lower BMI when using crack/cocaine (OR 0.450 [95% CI
0.229 – 0.889]; P=0.021) in HIV mono-infection.
Factors associated with liver fibrosis in HIV/HCV co-infection
A total of n=125 HIV/HCV co-infected participants had complete data at baseline.
Pearson correlation indicated FIB-4 index was significantly correlated to age (r=0.258,
p<0.002), HIV viral load (r= 0.144, P=0.051), and CD4 cell count (r= -0.152, P=0.004).
Multivariate linear regression significantly predicted FIB-4 index F(7, 125)= 2.883,
P=0.008, adjusted R2 = 0.09, however, unlike the results from the HIV mono-infected
group, no lifestyle factors were associated with FIB-4 index in HIV/HCV co-infection.
Age (β=0.296, P=0.001) was the only significant predictor of FIB-4 index in HIV/HCV
co-infection. Regression coefficients are listed in Table 7.
Multivariate analysis (three-way ANOVA) showed no interaction between
lifestyle factors and FIB-4 index in HIV/HCV co-infection, however age was
independently associated with FIB-4, F(1, 125)= 8.456, P=0.004. The results for main
effects of harmful lifestyle factors are shown in Table 8. The alternative model adjusting
for main effects and interactions between lifestyle groups was not significant F(7,125)
0.841, P=0.555.
Although there were no significant effect or statistically significant interactions of
FIB-4 with crack/cocaine use, when the data is plotted, an interaction between BMI and
cocaine use was observed (Figure 5). This graphical representation differs from HIV
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mono-infection because high BMI and cocaine use increase the estimated marginal
association with FIB-4 index in HIV/HCV co-infection, whereas this association is
attenuated in HIV mono-infection.
Age was the only significant factor that predicted liver fibrosis in HIV/HCV coinfection, therefore we performed the analysis stratifying subjects by age and running
regression analysis separately in HIV/HCV co-infected individuals with an age cut off of
51 years. In participants who were 51 years old or less, age remained a significant factor
that predicted FIB-4 value (β =0.022, P=0.016), after adjusting for gender, HIV viral
load, CD4 cell count, AUDIT score, BMI, and cocaine use. In HIV/HCV co-infected
participants older than 51 years old, age lost significance, but BMI significantly predicted
FIB-4 value (β=0.012, P=0.029) controlling for the same variables and with a
comparable sample size. Notably, BMI was not significantly different between the age
groups in HIV/HCV co-infection, however CD4 cell count was significantly lower in
younger age group (453 vs. 617, P=0.004) and AUDIT score was significantly higher (10
vs. 6, P=0.002).
A total of n=61 HIV/HCV co-infected participants had complete longitudinal data
for baseline and 24-month visits. Figure 6 shows that although there was a greater
proportion of cocaine users that progressed in at least one FIB-4 category, the result was
not statistically significant.
Table 9 shows the logistic regression analyses, adjusting for age, gender, HIV
viral load, CD4 cell count and ART use in HIV/HCV co-infection. None of the models,
including the full model containing all predictors was statistically significant, χ2(8,
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61)=5.071 P=0.750, indicating that the model could not distinguish between those who
progressed and those who did not progress one category of FIB-4.
Using the plotted interaction generated from the three-way ANOVA analysis,
further investigation with logistic regression analysis showed that liver fibrosis
progression was significantly associated with the interaction of BMI and crack/cocaine in
HIV/HCV co-infection. Being overweight BMI (≥ 28kg/m2) and using crack/cocaine had
a statistically significant association with odds of progressing in FIB-4 category (OR
3.800 [95% CI .982 – 14.698]; P=0.053; adjusted OR 4.985 [95% CI 1.130 – 21.993];
P= 0.034). Unlike HIV mono-infection, the interaction of BMI and crack/cocaine
increased the odds of progression of fibrosis by a factor of nearly five in the HIV/HCV
co-infected group.
Discussion
The findings from this study indicate that adverse lifestyle factors influence the
progression of liver fibrosis in both the HIV mono-infected and the HIV/HCV coinfected subjects in this study. Moreover, these findings support the premise that there is
a great amount of negative reinforcing interaction among these adverse influences.
A relatively small percentage of HIV mono-infected individuals in the MASH
cohort were categorized as having severe liver fibrosis at baseline (5.6%), however, when
combined with the number of participants with FIB-4 ≥ 1.45 liver fibrosis that percentage
increased to 25.5% of participants with advanced liver fibrosis or METAVIR stage ≥ F2.
In studies with comparable sample size, the prevalence of advanced liver fibrosis was
8.3%40 and 10.0%50 in HIV mono-infection, indicating that the MASH cohort has a
greater proportion of HIV mono-infected participants with advanced liver fibrosis
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compared to the findings from other studies. On the other hand, the literature for
HIV/HCV co-infected populations shows a prevalence of advanced liver fibrosis ranging
from 37.4% to 60.0%.37,51,52 HIV/HCV co-infected participants in the MASH cohort had
proportions of advanced liver fibrosis (58.8%) similar to a higher prevalence of advanced
fibrosis in HIV/HCV co-infected populations in the literature.
Choosing appropriate cut off values was important for conducting analysis of
variance and logistic regression. AUROC analysis indicated that an AUDIT score ≥ 8,
BMI ≥ 28kg/m2 and positive cocaine use were the best cut off points to predict
advancing liver fibrosis using the FIB-4 index in this cohort, and these values correspond
with cut off points associated with liver disease and poor HIV disease in the
literature.17,21,23 An AUDIT score ≥ 8 distinguishes between hazardous drinking, typically
associated with binge drinking that has been linked to liver damage.21 High BMI (≥
28kg/m2) may be a stronger predictor of liver fibrosis in HIV-infection than other
lifestyle factors. Initiation of ART improves HIV prognosis and is associated with
increasing BMI. A majority of the participants in this study were ART adherent (82.6%
in HIV mono-infected group and 82.7% in HIV/HCV co-infected group) which is
associated with higher BMI, better CD4 cell counts.53-55
Furthermore, BMI in HIV infection may have a paradoxical effect on liver
fibrosis because it has been shown to be protective of the immune response56 and it is
associated with better HIV disease outcomes,54 which in turn protects against liver
disease.40 Our results highlight the relationship between BMI, CD4 cell count and liver
fibrosis in HIV mono-infection because CD4 cell count is a significant predictors of liver
fibrosis only in those with lower BMI ≤ 28 kg/m2, and The relationship between CD4 cell
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count and FIB-4 index is lost in those who have higher BMI, indicating that the
protective effect that higher CD4 cell count has on the liver is negated in those who are
overweight/obese (β= 0.115, P=0.173).
Our results also show that BMI has a significant interaction with cocaine. In fact,
there are 2.22 greater odds of having a lower BMI when using crack/cocaine in HIV
mono-infection, which is likely attributed to the anorectic effect of cocaine in HIV
infection, and in non-infected populations, leading weight loss that may prevent odds of
developing liver fibrosis from being overweight (i.e. preventing non-alcoholic fatty liver
disease).57-59
We have found that alcohol use is associated with liver fibrosis in HIV monoinfection, but not in HIV/HCV co-infection, perhaps because the participants who tend to
have higher AUDIT scores in this population are younger, and the HIV/HCV co-infected
participants with advanced liver fibrosis tended to be older than 50 years.
The attenuation of the interaction of BMI and cocaine effects on FIB-4 index was
not seen in HIV/HCV co-infection. While an interaction existed between the two
variables, they significantly increased the odds of liver fibrosis progression by a factor of
nearly five. In this case, the combined effect of high BMI and cocaine use may damage
the liver because it is even more susceptible to higher levels inflammation and oxidative
stress resulting from cocaine use and being overweight, combined with the deleterious
effect of cocaine in CD4 cell count.17,60-62
Overall, BMI and cocaine showed a deleterious interaction on FIB-4 index in both
HIV mono- and HIV/HCV co-infected participants. Although the anorectic effects of
cocaine use initially masked harmful effect of BMI, the average of crack/cocaine users
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still fell into the “overweight” BMI category (Figure 7), and this study shows that
combined effects of cocaine use and being overweight are damaging to the liver.
Age is one of the most important factors associated with liver fibrosis in
HIV/HCV co-infected participants in the MASH cohort. When stratifying for age,
increased BMI was significantly associated with FIB-4 index in participants older than 51
years; however, it is important to note that BMI was not significantly different between
the age groups in HIV/HCV co-infection, but CD4 cell count was significantly lower in
younger age group (453 vs. 617, P=0.004) and AUDIT score was significantly higher (10
vs. 6, P=0.002), which may account for the effect on FIB-4 values. Although CD4 cell
count and AUDIT were independently significant in the model they contribute to the
overall direction of the relationship between BMI and FIB-4 in younger HIV/HCVinfected persons.
Conclusion
Adverse lifestyle factors prevalent in in HIV mono- and HIV/HCV co-infection may act
together to magnify their individual effect on liver fibrosis, and contribute independently
or through their interaction to advance liver fibrosis over time. Hazardous alcohol use,
high BMI, and the interaction between crack/cocaine use and BMI are adverse lifestyle
conditions that are associated with liver fibrosis, and are of concern in this population.
These findings will be useful to help guide future research into lifestyle factors that affect
the HIV population, and guide healthcare choices to prevent and ameliorate liver disease
as a comorbidity in people living with HIV.
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Tables and Figures
Table 1: Descriptive characteristics of HIV mono- and HIV/HCV co-infected groups at baseline.

Descriptive Characteristics
Age
Gender (%male)
Ethnicity
White Non-Hispanic
White Hispanic
Black Non-Hispanic
Black Hispanic
Other
HIV Parameters
Log10(HIV viral load)
CD4 cell count
HCV viral load
ART use (% yes)
Lifestyle Factors
AUDIT
BMI
Cocaine use (% yes)
Liver Fibrosis
FIB-4 index
FIB-4 ≥ 1.45 (% yes)
P-value <0.05 is significant.

HIV n=310
Mean±S.D. or %(n)
n=310
45± 7.8
64%(198)

HIV/HCV n=134
Mean±S.D. or %(n)
n=134
50± 5.2
62%(83)

6.0(19)
17.7(55)
68.1(211)
4.7(14)
3.7(11)

9.6(12)
18.4(25)
65.4(88)
5.1(7)
1.4(2)

2.68± 1.30
516.4± 424.6
N/A
82.6%(256)

2.76± 1.32
528.5± 335.4
12712808 (n=61)
82.7%(111)

0.587
0.617
N/A
<0.001

9.25± 10.0
27.9± 5.22
29.7(92)

8.34± 10.3
26.9± 5.24
29.2(39)

0.386
0.057
0.925

1.32± 1.15
25.5(79)

2.14± 1.54
58.8(79)

<0.001
<0.001
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P-value
<0.001
0.585
0.327

Table 2a: Descriptive characteristics within FIB-4 categories in HIV mono-infection.
Degree of fibrosis
Mild
Indeterminate
Severe
FIB-4< 1.45
FIB-4≥ 1.45-3.24
FIB-4≥ 3.25
Mean± S.D. or
Mean± S.D. or
Mean± S.D. or
%(n)
%(n)
%(n)
n=230
n=67
n=13
Descriptive
Characteristics
Age
44.5 ± 8.3a
48.0 ± 6.0a,b
49.4 ±4.9b
a
b
Gender (% Male)
58(138)
84(57)
77(10)a,b
Ethnicity,
n(%within FIB-4
category)
4.2(10)
11.8(8)
7.7(1)
White Non-Hispanic
20.8(49)
10.3(7)
0.0(0)
White Hispanic
68.2(161)
66.2(45)
76.9(10)
Black Non-Hispanic
4.2(10)
7.4(5)
0.0(0)
Black Hispanic
2.5(6)
4.4(3)
15.4(2)
Other
Disease Parameters
Log10(HIV viral load)
2.62± 1.27
2.83± 1.36
2.97± 1.49
Uncontrolled HIV viral
49.8(114)
51.5%
69.2%
load
(>75 copies/ml)
Uncontrolled HIV viral
41.8(96)
47.1%
53.8%
load (>200 copies/ml)
CD4 cell count
549.04 ± 371.38a,b 359.76 ± 235.60b
776.50 ± 1267.70a
3
(cells/mm )
CD4 cut off of 200
13.9(32)a,b
30.9(21)b
15.4(2)a
cells/ml
(% < 200)
FIB-4 index
0.96 ± 0.26a
1.83 ± 0.38b
5.32 ± 3.44c
Lifestyle
Characteristics
Drinks alcohol (%Y)
78.1(179)
83.8
69.2
AUDIT score
8.7 ± 9.8
10.2 ± 10.4
13.5 ± 12.4
AUDIT cut off of 8 or
39.7(91)
45.6
69.2
higher (%Y)
BMI (kg/m2)
28.32 ± 5.22a,b
26.49 ± 5.00a
27.09 ± 5.61a
2
BMI cut off ≥25 kg/m
71.7(170)
54.4(37)
61.5(8)
BMI cut off ≥ 28 kg/m2
53.2(126)
36.8(25)b
38.5(5)
BMI cut off ≥ 30 kg/m2
35.0(83)
20.6(14)b
15.4(2)
Cocaine use (Y/N)
27.7(64)
39.4(26)b
15.4(2)
Cocaine frequency,
n(% in each category)
1. No cocaine use
72.6(172)
60.3(41)
84.6(11)
2. Uses crack/cocaine
3.8(9)
8.8(6)
0.0(0)
a) Once per week
13.3(31)
14.7(10)
0.0(0)
b) > once per week
3.0(7)
8.8(6)
0.0(0)
c) Once per day
3.0(7)
2.9(2)
7.7(1)
d) > once per day
4.6(11)
4.4(3)
7.7(1)
P-value <0.05 is significant.
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P- value

0.001
<0.001
0.509

0.371
0.392
0.548
0.001
0.005
<0.001
0.402
0.164
0.089
0.034
0.024
0.043
0.035
0.096
0.749

Table 2b: Descriptive characteristics within FIB-4 categories in HIV/HCV co-infection
Degree of fibrosis
Mild
Indeterminate
Advanced
FIB-4< 1.45
FIB-4≥ 1.45-3.24
FIB-4≥ 3.25
Mean± S.D. or
Mean± S.D. or
Mean± S.D. or
%(n)
%(n)
%(n)
n=56
n=54
n=24
Descriptive
Characteristics
Age
49.1 ± 5.6a
52.5 ± 4.5b
51.3 ± 5.2b
Gender (% Male)
31(55.4%)
35(63.6%)
18(72.0%)
Ethnicity,
n(%within FIB-4
category)
16.1(9)
5.5(3)
4.0(1)
White Non-Hispanic
17.9(10)
14.5(8)
28.0(7)
White Hispanic
57.1(32)
76.4(42)
60.0(15)
Black Non-Hispanic
5.4(3)
3.6(2)
8.0(2)
Black Hispanic
3.6(1)
0.0(0)
0.0(0)
Other
Disease Parameters
Log10(HIV viral load)
2.72 ± 1.32
2.58 ± 1.29
3.26 ± 1.34
Uncontrolled HIV viral
55.4(31)a
52.7(29)a
80.0(20)b
load
(>75 copies/ml)
Uncontrolled HIV viral
44.6(25)
43.6(24)
68.0(17)
load (>200 copies/ml)
CD4 cell count
538.79 ± 319.67
525.62 ± 350.19
516.36 ± 350.15
(cells/mm3)
CD4 cut off of 200
16.1(9)
20.0(11)
16.0(4)
cells/ml
(% < 200)
FIB-4 index
1.09 ± 0.25a
2.07 ± 0.51b
4.66 ± 1.84c
Lifestyle
Characteristics
Drinks alcohol (%Y)
66.1(37)
65.5(36)
64(16)
AUDIT score
8.3 ± 10.4
7.8 ± 9.8
9.6 ± 11.7
AUDIT cut off of 8 or
37.5(21)
40.0(22)
40.0(10)
higher (%Y)
BMI (kg/m2)
26.55 ± 5.04
27.3 ± 5.48
26.56 ± 5.32
BMI cut off ≥25 kg/m2
50.0(28)
65.5(36)
52.0(13)
BMI cut off ≥ 28 kg/m2
42.9(24)
47.3(26)
32.0(8)
BMI cut off ≥ 30 kg/m2
25.0(14)
29.1(16)
20.0(5)
Cocaine Use
n(% in each category)
1. No cocaine use
72.2(40)
65.5(35)
73.9(18)
2. Uses crack/cocaine
27.8(15)
34.5(18)
26.1(6)
a) Once per week
12.5(7)
20.0(11)
12.5(3)
b) > once per week
1.8(1)
1.8(1)
4.0(1)
c) Once per day
5.4(3)
0.0(0)
4.0(1)
d) > once per day
1.8(1)
5.5(3)
4.0(1)
P-value <0.05 is significant.
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P- value

0.003
0.339
0.344

0.107
0.056
0.097
0.966
0.839
<0.001
0.984
0.777
0.958
0.329
0.227
0.440
0.660
0.636

Figure 1: ROC curves for adverse lifestyle factors in HIV mono- and HIV/HCV co-infection. The
curves indicate the sensitivity and specificity of each parameter (BMI, AUDIT, and crack/cocaine
use) to predict progression in FIB-4 over 24 months. The values with the best combination of
sensitivity and specificity were chosen as cut off points for individual lifestyle factors.
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Table 3: AUROC analysis for adverse lifestyle factors in HIV mono- and HIV/HCV co-infection to predict
progression of FIB-4 category over 24 months.
Lifestyle
Area under
P-value
Cut off tested
Sensitivity Specificity
factor
ROC (S.E)
(95% CI)
BMI
.650 (.059)
.023
Overweighta (25 kg/ m2)
86.4%,
31.8%
(.536, .765) Overweightb (28 kg/ m2)*
68.2%
59.1%
Obese (30 kg/ m2)
59.1%
68.2%
AUDIT
.565 (.069)
.325
Mild drinking (score of 1)
72.7%
32.0%
(.430, .700) Hazardous drinking
45.5%
66.0%
(score of 8)*
Alcohol dependence
31.8%
79.1%
(score of 13F/15M)
Cocaine
.428 (.089)
.423
Cocaine use Yes/No
25.0%
68.5%
Frequency
(.252,.603) Uses crack/cocaine
a) Once per week
16.7%
80.8%
b) > once per week
8.3%
91.8%
c) Once per day
0.0%
94.5%
Lifestyle
Area under
P-value
Cut off tested
Sensitivity Specificity
factor
ROC (S.E)
(95% CI)
a
2
BMI
.425 (.103)
.436
Overweight (25 kg/ m )
86.4%
31.8%
(.223, .627) Overweightb (28 kg/ m2)
68.2%
57.8%
Obese (30 kg/ m2)
59.1%
68.2%
AUDIT
.486 (.103)
.888
Mild drinking (score of 1)
54.5%
38.0%
(.285, .688) Hazardous drinking
36.4%
66.0%
(score of 8)
Alcohol dependence
26.4%
80.0%
(score of 13F/15M)
Cocaine
.500 (.128)
.999
Cocaine use Yes/No
60.0%
50.0%
Frequency
(.249, .751) Uses crack/cocaine
a) Once per week
20.0%
71.9%
b) > once per week
20.0%
84.5%
c) Once per day
0.0%
87.5%
a
Overweight category based on CDC cut off points42
b
Overweight category based on previous publications23,48,49
*indicates the cutoff value that best predicted progression in FIB-4 category over 24 months.
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Table 4: Association with FIB-4 index and continuous variables BMI, AUDIT score, and cocaine use in
HIV mono-infection.
Unadjusted model
Adjusted model*
Variable
β
t
P-value
β
t
P-value
BMI (kg/m2)
-0.005
-2.211
0.028
-0.003
-1.294
0.197
AUDIT score
0.002
2.047
0.042
0.003
2.291
0.023
Cocaine (Y/N)
-0.005
-0.183
0.855
0.006
0.154
0.800
*Multivariate linear regression model was adjusted for age, gender, viral load, CD4, and ART use.
P-value <0.05 is significant.
Table 5: ANOVA analysis showed independent effects of being overweight, drinking hazardously, and
using cocaine on FIB-4 index in HIV mono-infection.
Variable
F unadjusted
P-value
F adjusted*
P-value
AUDIT score ≥8
4.202
.041
5.216
.023
4.239
.040
3.543
.061
BMI≥28kg/m2
Cocaine use (Y/N)
0.493
.483
2.812
.095
*Model was adjusted for age, gender, viral load, CD4 cell count, and ART use.
P-value <0.05 is significant.

Figure 2: ANOVA analysis shows and interaction between BMI ≥ 28 kg/m2and crack/cocaine use
on FIB-4 index in HIV mono-infection.
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Figure 3: Associations between CD4 cell count and FIB-4 index within BMI categories. An
association can be observed between lower CD4 cell count and increasing liver fibrosis (FIB-4
index) in participants in the low BMI. However, there is no association between CD4 cell count
and FIB-4 in participants with high BMI due to the protective effect that BMI has on CD4 cell
count. Participants with low BMI had significantly lower mean CD4 values than those with high
BMI.
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Figure 4: Proportion of HIV mono-infected participants who progressed one category of liver
fibrosis over 2 years in each lifestyle group. Significantly more participants who were overweight
progressed a stage of liver fibrosis than those who had a lower BMI.
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Table 6: HIV mono-infection. Association between adverse lifestyle factors and the odds of progressing at
least one category of fibrosis over 2 years.
Variables
Unadjusted OR
P-Value Adjusted OR
P-Value
(95% CI) for progressing
(95% CI) for progressing
one FIB4 category
one FIB4 category
Model 1
Alcohol ≥ 8
1.638 (.668 - 4.018)
.281
2.085 (.758 - 5.735)
.155
Model 2
BMI ≥ 28 kg/m2
2.934 (1.132 - 7.605)
.027
3.797 (1.301 - 11.077)
.015
Model 3
Crack/Cocaine Use
.328 (.093 - 1.162)
.084
.288 (.076 - 1.095)
.068
(Y/N)
Model 4†
Alcohol ≥ 8
2.450 (.935 - 6.423)
.068
3.038 (1.010 - 9.135)
.048
BMI ≥ 28 kg/m2
2.907 (1.087 - 7.777)
.034
4.108 (1.360 - 12.403)
.012
Crack/Cocaine Use
.308 (.082 - 1.161)
.082
.228 (.057 - .918)
.038
(Y/N)
*Models were adjusted for age, gender, HIV viral load, CD4 cell count, and ART use.
†
Model controlled for age, gender, HIV viral load, CD4 cell count, ART use, and BMI.

Table 7: Association with FIB-4 index and continuous variables BMI, AUDIT score, and cocaine use in
HIV/HCV co-infection.
Unadjusted model
Adjusted model*
Variable
β
t
P-value
β
t
P-value
BMI (kg/m2)
0.003
0.725
0.470
0.004
0.981
0.329
AUDIT score
0.001
0.484
0.629
0.001
0.607
0.545
Cocaine (Y/N)
-0.028
-0.569
0.571
-0.048
-0.993
0.323
*Model was adjusted for age, gender, viral load, CD4 cell count, and ART use.

Table 8: ANOVA analysis showed independent effects of being overweight, drinking
hazardously, and using cocaine on FIB-4 index in HIV/HCV co-infection.
Variable
F unadjusted
P-value
F adjusted*
P-value
AUDIT score ≥ 8
.931
.336
1.046
.303
BMI ≥ 28 kg/m2
1.591
.209
.390
.533
Cocaine use (Y/N)
0.101
.751
.442
.507
*Model was adjusted for age, gender, viral load, CD4 cell count, and ART use.
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Figure 5: ANOVA analysis shows an interaction between BMI ≥ 28 kg/m2and crack/cocaine use
on FIB-4 index in HIV mono-infection.
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Figure 6: Proportion of HIV/HCV co-infected participants who progressed one category of liver
fibrosis over 2 years in each lifestyle group. None of the lifestyle groups showed a statistically
significant higher proportion of participants progressing in fibrosis stage over 2 years, perhaps
due to the smaller sample size of HIV/HCV co-infected participants analyzed longitudinally
(n=61).
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Figure 7: Mean BMI between cocaine groups in HIV mono- and HIV/HCV co-infection. Cocaine
users show no difference in mean BMI values. Mean BMI values for both cocaine users and nonusers fall into the “overweight” category.

Table 9: HIV/HCV co-infection. Association between adverse lifestyle factors and the odds of progressing
at least one category of fibrosis over 2 years.
Unadjusted OR
Adjusted OR
(95% CI) for progressing
(95% CI) for progressing
Variables
one FIB4 category
P-Value
one FIB4 category
P-Value
Model 1
Alcohol ≥ 8
0.857 (0.222 – 3.315)
0.823
0.766 (0.177 – 3.325
0.722
Model 2
BMI ≥ 28 kg/m2
0.671 (0.174 – 2.584)
0.562
0.581 (0.128 – 2.644)
0.482
Model 3
Crack/Cocaine Use 2.133 (0.570 – 7.985)
0.261
2.687 (0.627 – 11.513)
0.183
(Y/N)
Model 4†
Alcohol ≥ 8
0.540 (0.112 – 2.597)
0.442
0.412 (0.068 – 2.492)
0.334
BMI ≥ 28 kg/m2
0.818 (0.813 – 3.662)
0.793
0.775 (0.158 – 3.809)
0.754
Crack/Cocaine Use 2.735 (0.588 – 12.711)
0.199
3.764 (0.675 – 20.972)
0.130
(Y/N)
*all adjusted models controlled for age, gender, HIV viral load, CD4 cell count, and ART use.
†
Model controlled for age, gender, HIV viral load, CD4 cell count, ART use, and BMI.
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CHAPTER V: BIOLOGICAL MEDIATORS PREDICT LIVER FIBROSIS
PROGRESSION OVER TIME IN AN HIV MONO-INFECTED COHORT
Abstract
Background: As the HIV infected population is aging with the advent of effect
antiretroviral therapies (ART), significant morbidity and mortality can be attributed to
non-AIDS defining illnesses in people living with HIV (PLWH). While co-infection with
HIV and Hepatitis C (HCV) is a major contributor to liver disease progression, higher
prevalence of liver fibrosis is observed in HIV mono-infected populations. New and
effective direct acting antivirals that target HCV infection may also reduce the risk of
liver decompensation in HIV/HCV co-infection, encouraging research into independent
mediators of liver disease related to HIV mono-infection. Biological mediators that are
routinely high in HIV disease and associated with liver fibrosis in cell and animal models
include oxidative stress, hepatocyte apoptosis, transforming growth factor-beta1 (TGFβ1), and microbial endotoxin. The aim of this study is to associate biological mediators
of liver fibrosis in HIV mono-infected participants to predict development of liver
fibrosis over 2 years.
Methods: A subset of the Miami Adults Studies on HIV (MASH) cohort in Miami, FL
(n=65) was chosen for longitudinal analysis. Participants were grouped into categories of
liver fibrosis at baseline according to their FIB-4 score. Laboratory values for
malondialdehyde (MDA), percent oxidized glutathione (GSH), hepatocyte apoptosis
marker Cytokeratin 18 (CK-18), TGF-β1, and the microbial endotoxin lipopolysaccharide
(LPS) were measured in plasma using commercially available kits. Multivariate linear
regressions were used to find associations between biological mediator and FIB-4 index
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cross-sectionally. Logistic regression and General Estimating Equations were used to
describe associations between liver fibrosis progression and biological mediators of
fibrosis over 2 years. Mixed model analysis used repeated measures to describe the
associations between biological factors and liver fibrosis (FIB-4 index) with time as an
interaction. All models were adjusted for covariates that are known to influence liver
fibrosis.
Results: In this subset of 65 participants of the MASH cohort, 13.8% of HIV monoinfected participants progressed at least one FIB-4 stage from baseline to 2 years. High
% oxidized glutathione (≥ 24% at baseline) was associated with 4.342 times higher odds
of progressing in fibrosis category over time, after adjusting for covariates (adjusted OR
4.342 [95% CI 1.026 – 18.144]; P= 0.046). LPS showed a trend of increasing the odds of
progressing in liver fibrosis (OR 1.098 [95% CI 0.794 – 5.741]; P= 0.097], indicating a
small (9%) increase in the odds of liver fibrosis progression. CK-18 protein was
significantly associated with an increase in the odds of progressing FIB-4 category over 2
years (OR 1.008, [95% CI 1.001 – 1.015]; P=0.021), and a trend in progressing at least
one category of liver fibrosis over two years (OR 4.311 [95% CI 0.881 – 21.089]; P =
0.071). Percent oxidized glutathione was significantly associated with small probability
of progression of liver fibrosis in the adjusted model (OR 1.063 [95% CI 1.101 – 3.432]:
P=0.003). There were no significant associations in this subset between FIB-4 and
MDA, and TGF-β1.
Conclusions: Biological mediators associated with increased liver fibrosis may serve as
potential targets for future therapy, so it is important to identify biomarkers associated
with the progression of liver fibrosis in HIV mono-infection. Establishing cut off values
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for some biological mediators of liver fibrosis, such as LPS, may be useful to predict
liver fibrosis. Larger studies are warranted to investigate mediators of fibrosis in PLWH.
Keywords: HIV infection, liver fibrosis, FIB-4 index, liver disease, oxidative stress,
hepatocyte apoptosis, transforming growth factor-beta1, microbial endotoxin,
malondialdehyde, glutathione, MDA, GSH, TGF-β1, CK-18, LPS
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Introduction
Early initiation of antiretroviral therapy (ART) has significantly increased life
expectancy in people living with HIV (PLWH) in the United States and Canada.1 As this
population is aging, morbidity and mortality from non-AIDS defining illnesses has
increased.2,3 Liver disease is a major cause of mortality in PLWH, contributing to
between 14-18% of the deaths ascribed to non-AIDS related causes, mainly attributed to
HIV/hepatitis C (HCV) co-infection.2,4,5
Infection with HCV increases the odds of liver fibrosis progression and mortality,
however investigators have also reported increased liver-related mortality in HIV monoinfected populations when compared to non-infected populations,6-8 indicating that HIV
mono-infection may be an independent risk factor for liver disease. Furthermore, recent
developments in HCV direct acting antivirals (DAAs) offer a new line of defense against
liver decompensation in the HIV/HCV co-infected population,9,10 making it more
compelling to investigate factors associated with liver fibrosis in HIV mono-infected
populations.11 Liver fibrosis is used as a determinant of the seriousness of liver disease
and its prognosis.12 A useful tool for determining liver fibrosis in PLWH is the FIB-4
index that takes into account age, liver enzymes, and platelet count.13,14 Although with
lower sensitivity and specificity than liver biopsy, FIB-4 can distinguish between none or
mild fibrosis (equivalent to METAVIR stage F0 –F1), and presence of advance
fibrosis/cirrhosis (equivalent to METAVIR stage ≥ F2), and its main advantage is that it
is not invasive and uses biomarkers that are collected routinely to follow HIV-infected
patients.15,16

111

Pathogenesis of liver fibrosis in HIV is associated with biological mediators that
have been investigated in cellular and animal models. Liver fibrosis is a cellular
mechanism initiated by presence of injury to hepatocytes. It can be classified into
sequential phases based on the activation of hepatic stellate cells (HSCs): initiation phase
and perpetuation phase.17 The initiation phase refers to early events that render the
quiescent hepatic stellate cells (HSCs) responsive to a range of growth factors.17
Important fibrogenic stimuli in this stage include: reactive oxygen species,18-20 leading to
oxidative stress; apoptotic fragments, generated from hepatocyte cell death,21,22 and the
bacterial endotoxin lipopolysaccharide (LPS),23 resulting from bacterial products crossing
from the gut into the blood stream.17 The perpetuation phase involves proliferation and
migration of HSCs to the extra cellular matrix (ECM), where they synthesize and secrete
elevated levels of collagen and fibronectin, promoting fibrosis.24,25 The upregulation of
the cytokine transforming growth factor beta-1 (TGF-β1) is characteristic of the
perpetuation phase because it is released by Kupffer cells, platelets, and HSCs themselves
in the presence of fibrogenic stimuli.26 TGF-β1 is a key regulator of liver fibrosis because
it is required by HSCs to lay down fibrotic tissue.27 Anti-TGF-β1 strategies have been
proposed to reduce liver fibrosis by blocking its fibrogenic properties,28 including direct
neutralization of TGF-β1 and indirectly reducing TGF-β1 by targeting biological risk
factors such as oxidative stress,29 microbial translocation,30 and apoptosis.31
While clinical markers have been associated with liver fibrosis in HIV, such as
liver enzymes,32 HIV viral load,33 CD4 cell count,34 and age,35 few research studies have
investigated biological mediators that are increased in HIV mono-infected persons and
their impact on liver fibrosis over time. Biological mediators of advancing liver fibrosis
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and liver pathogenesis have been determined in animal and in vitro models,17 however,
human studies have not been conducted, although increased levels of individual markers
of fibrogenesis, such as increased oxidative stress,36,37 hepatocyte apoptosis,38
transforming growth factor-beta 1 (TGF-β1),39and bacterial endotoxin40 have been
demonstrated in HIV-infected populations. This study aims to investigate associations
between biological mediators that contribute to liver fibrosis in HIV mono-infection
longitudinally.
Methods
Study Design and Participants
The Miami Adult Studies on HIV (MASH) cohort is an ongoing research project
conducted in Miami, FL that follows HIV mono- and HIV/HCV co-infected participants
longitudinally. Participants signed informed consent upon screening and agreed to have
their data and biological samples stored for future analyses. A convenience sample that
included 65 HIV-mono infected participants was selected for longitudinal analyses at
baseline, 12 month, and 24 months. Out of 464 participants enrolled at the time of the
present study, 118 were excluded due to HCV co-infection, because the known
contribution of HCV to the progression of liver fibrosis. Participants were selected for
analysis if they had complete data sets, including all covariates and FIB-4 data at
baseline, 12 months, and 24 months. Subjects were excluded if baseline FIB-4 index was
≥3.25. Laboratory data for biological mediators were generated at Florida International
University using a repository of samples labeled with an identification number that was
not associated with personal or identifying patient information. The study was approved
by the Institutional Review Board at Florida International University.
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Biomarker Analysis
1. Measures of oxidative stress:
1.a. Malondialdehyde (MDA) is a widely accepted marker of lipid peroxidation,
which correlates well with liver fibrosis in other populations.37,41,42 MDA is measured
using a TBARS assay (Northwest Life Science Specialties, Portland, OR, USA). MDA
reacts with thiobarbituric acid (TBA) to form a complex that is highly absorbed at
532nm, which can be read spectrophometrically.43
1.b. Glutathione (GSH) is an important part of the endogenous antioxidant
system because it is the most abundant intracellular antioxidant, and directly participates
in quenching harmful peroxide radicals as well as recycling other antioxidants.18 GSH
represents antioxidant status by measuring the ratio of oxidized glutathione (GSSH) to
total glutathione (oxidized GSSH + reduced GSH). Measuring levels of reduced GSH
alone does not indicate oxidative stress levels because GSH measures vary across time in
an individual; however, a higher ratio of oxidized glutathione to total glutathione is
indicative of higher oxidative stress. Healthy values of oxidized glutathione are under
10% of the total glutathione pool.44 Percent oxidized glutathione is measured using a
colorimetric assay that measures total and oxidized glutathione (Arbor Assays, Ann
Arbor, MI, USA). Both MDA and % oxidized glutathione kits have been used in our
previous studies with the MASH cohort.36,43
2. Measures of Fibrogenesis:
2.a. The Apoptosense ELISA assay (Peviva, Nacka, Sweden) quantifies hepatocytespecific apoptosis. The assay uses the M30 antibody specific for the cytokeratin-18 (CK-
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18) protein in a sandwich ELISA kit with monoclonal antibodies specific for the caspasecleaved CK-18 protein.21,45-49
2.b.The fibrogenic cytokine TGF-β1 is determined using sandwich ELISA methods
from a commercially available kit. The Quantikine ELISA kit (R&D Systems,
Minneapolis, MN, USA) measures the activated form of TGF-β1 in plasma samples, and
has been used in previous studies.50,51
3. Measures of Immune Activation
The bacterial endotoxin lipopolysaccharide (LPS) is a major component of Gramnegative bacterial cells walls and can be quantitatively assessed to determine the degree
of microbial translocation.52 Plasma LPS levels are directly associated with the degree of
intestinal permeability following invasive surgery.53
3.a. The limulus amebocyte lysate (LAL) assay has been widely used for the
detection of endotoxin for approximately 30 years,54 and in HIV-related research.52,55-57
Recently, methods have been developed to measure LPS using the LAL Lonza kit in
plasma of HIV+ patients.55 Circulating LPS is measured using a chromogenic assay
(Lonza, Walkersville, MD, USA) using the EL800 microplate reader and GEN5 software.
Laboratory values were measured using residual plasma samples stored at -80°C until
analysis was conducted in duplicate. Acceptable results had coefficient of variation (CVs)
within 10% indicating a small variance between replicates; otherwise they were
reanalyzed.
Two groups (low/high) were generated using highest tertile value as a cut off pointfor
each biological marker. For example, a value that fell within the highest tertile was
placed in the “high” group for that biomarker.
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Index of Liver fibrosis
FIB-4 index is a non-invasive measure of liver fibrosis. Although liver biopsy is the
current gold standard for liver fibrosis staging using METAVIR scores, it is highly
invasive and unless needed for clinical diagnosis is associated with a high risk for
research purposes16 Specifically in HIV-infected patients, it is contraindicated because of
the increased risk of internal hemorrhage due to thrombocytopenia.15,16 FIB-4 index was
calculated using data collected by the MASH cohort using the formula:
[(AgeXAST)/(PlateletsX√(ALT))]. It has been used in previous studies in HIV infection
and validated in patients with HCV infection 13,14 and HIV/HCV co-nfection13 with
specificity of 94.7% and 90%, and sensitivity of 74.3% and 70%, respectively. For
baseline groups, participants were categorized as having no/mild fibrosis (FIB-4 index
<1.45, METAVIR stage F0-F1), indeterminate fibrosis (1.45 ≥ FIB-4 < 3.25) or severe
(FIB-4 ≥ 3.25 METAVIR stage ≥ F3-F4).58 The absence of advanced fibrosis was
determined with the cut off value of FIB-4 < 1.45 (METAVIR stage F0-F1) for crosssectional and longitudinal analyses.7,14,59 A participant qualified as progressing in at least
one METAVIR stage or category of liver fibrosis if their baseline FIB-4 score increased
from < 1.45 to greater than 1.45, or from between 1.45 – 3.25 to ≥ after 2 years of study
enrollment (Figure 1).
Statistical Analysis
Baseline characteristics for progressors and non-progressors were assessed using
Chi-square or Mann-Whitney U for non-parametric measures due to the unequal
variances between progressors and non-progressors. Student’s t-test evaluated differences
between descriptive characteristics for each biomarker at different time points. A test of
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proportions was conducted to determine the percent of participants who progressed in
each biomarker group (high vs. low) over 2 years. Logistic regressions were used to
determine the association between progressing at least one FIB-4 category over 2 years
with high/low levels of biological mediators at baseline. Mixed model analysis used
repeated measures to describe the associations between biological factors and liver
fibrosis (FIB-4 index) with time as an interaction. FIB-4 was the dependent variable and
the biomarkers of oxidative stress, fibrogenesis and immune activation were the
independent variables. Significant interactions were evaluated in sub-analyses and
predicted FIB-4 values were derived from General Estimating Equations and Mixed
Models when appropriate. All models were adjusted for covariates that are known to
influence liver fibrosis.
Covariates
Covariates included in the analysis are those associated with liver fibrosis in HIV
infection. They include: age,60gender,61,62 ethnicity,35 CD4 cell count (baseline),34HIV
viral load (baseline),33 and ART use.63,64
Results
Descriptive characteristics
Biological mediators were separated into tertiles and categorized as “high” if
values fell in the highest tertile. Table 1 shows the values for the tertile cutoff points for
each biomarker associated with liver fibrosis. Table 2 describes the baseline
characteristics for HIV mono-infected participants. In this HIV mono-infected subset,
13.8% (n=9) participants progressed at least one fibrosis category over 2 years of
enrollment in the study. The participants who progressed over 24 months were older at
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baseline, which trended towards significance (46.6±6.9 vs. 51.3+6.6 years, P=0.063).
There were no significant differences in biological factors associated with liver fibrosis
between FIB-4 category progressors and non-progressors at baseline. Table 3 shows
descriptive characteristics for participants within each biomarker group at baseline and 24
months. Participants with low MDA had significantly higher viral load at the end of the
study, and those with the high hepatocyte apoptosis (CK-18) were older. In participants
with the highest levels of oxidized glutathione, more people were obese, and a higher
percent identified as black non-Hispanic.
Biological markers associated with liver fibrosis progression over 2 years
The proportion of participants who progressed in FIB-4 stage over time is depicted in
Figure 2. A greater proportion of participants with high MDA (21.7%), and TGF-β1
(18.2%) progressed compared to those with low MDA (9.3%) and TGF-β1 (11.6%);
however, the differences in proportions are not statistically significant (P=0.138 and
P=0.469, respectively).
The major aim of the study was to determine associations between high levels of
biomarkers at baseline and the odds of progressing in FIB-4 category over 2 years.
Logistic regressions were used to describe the association between baseline biomarkers
(high/low) and the odds of progressing at least one category of FIB-4 (mild fibrosis: FIB4 >1.45, moderate fibrosis: FIB-4 = 1.45-3.24, severe fibrosis: FIB-4 ≥ 3.25) over 24
months. Results in Table 4 show that high % oxidized glutathione (≥ 24% at baseline)
was associated with 4.342 times higher odds of progressing in fibrosis category over
time, after adjusting for covariates (OR 4.342 [95% CI 1.026 – 18.144]; P= 0.046). LPS
showed a trend of increasing the odds of progressing in liver fibrosis (OR 1.098 [95% CI
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0.794 – 5.741]; P= 0.097], indicating a small (9%) increase in the odds of liver fibrosis
progression.
To evaluate the impact that biological mediators have on liver fibrosis progression
at each time point, a model was developed using logistic regression to predict the odds of
progressing in FIB-4 category. Figure 3a-e shows the predicted probabilities of
progressing at least one category of fibrosis based on having high and low biomarkers at
baseline, 1 year, and 2 years. Although none of the odds of progressing were statistically
significant, the figure illustrates that the estimated probabilities of progressing in liver
fibrosis are generally higher for participants with higher levels of biomarkers at each time
point.
Biomarkers may impact liver fibrosis progression linearly, i.e. the range of
biomarker values may matter more than having a high or low value. Logistic regression
models assessed the effect of biomarkers as continuous variables on the odds of liver
fibrosis progression over time. Results in Table 5 show that CK-18 protein is
significantly associated with an increase in the odds of progressing FIB-4 category over 2
years (OR 1.008, [95% CI 1.001 – 1.015]; P=0.021, however, this significance was lost
for CK-18 after adjusting for covariates.
Percent oxidized glutathione was significantly associated with small probability
of progression of liver fibrosis in the adjusted model, suggesting that there is an
interaction between glutathione and at least one of the covariates in the model that
contributes to progression over time (OR 1.063 [95% CI 1.101 – 3.432]: P=0.003).
Besides oxidized GSH, age was the only other variable in the model that contributed to
the model to increasing the odds of progressing by one FIB-4 category (OR 1.120 [95%

119

CI -.989 – 1.292]; P=0.072); however, there was no significant interaction between
oxidized GSH and age on progression of liver fibrosis (OR 1.031 [95% CI 0.836 –
1.271]; P=0.778).
Generalized Estimating Equation models adjusting for baseline values of
biomarkers were used to determine associations between odds of progressing at least one
fibrosis stage over 2 years. Table 6 shows that percent oxidized GSH is associated with
progressing at least one stage of liver fibrosis on a linear scale (OR 1.072 [95% CI 1.017
– 1.131]; P = 0.010) and also when using a high cut off value (OR 4.897 [95% CI 1.080 –
22.206]; P = 0.039). High levels of hepatocyte-specific apoptosis marker CK-18 were
associated with a trend in increasing odds of progressing in FIB-4 over 2 years (OR 4.311
[95% CI 0.881 – 21.089]; P = 0.071). CK-18 was not associated with liver fibrosis
progression on a linear scale, indicating that higher levels of CK-18 have a stronger
influence on liver fibrosis progression than lower levels.
Biological markers associated with FIB-4 index over 2 years
A mixed model approach to repeated measures was used to determine changes in
the biological variables and FIB-4 index over time. The mean values for each variable
are displayed in Table 6 at each time point. In this HIV mono-infected cohort, mean FIB4 values increased from baseline to 24 months. Although the result was not statistically
significant (P=0.403), the mean FIB-4 increased from mild fibrosis to moderate fibrosis,
which represents a clinical increase in liver disease. The biomarkers that significantly
increased over time were hepatocyte apoptosis (CK-18), pro-fibrogenic cytokine TGF-β1,
and bacterial endotoxin (LPS). ART use and ethnicity (being Black non-Hispanic)
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significantly interacted with time, which decreased the significance of the biomarkers,
suggesting that these covariates may interact with biomarkers in repeated measures.
Mixed models with time as a covariate analyzed whether biomarkers were good
predictors for FIB-4 index over 2 years. Figure 4a-e shows the predicted values of FIB-4
index between high and low biomarkers, while Table 7 displays the association between
biomarkers as continuous predictors on FIB-4 index. The most significant increase in
FIB-4 index was observed with hepatocyte apoptosis CK-18 as a predictor (β= 2.011,
S.E. 0.985, P=0.043) (Figure 5), indicating that another covariate significantly
contributes to liver fibrosis progression and supersedes any the effect of hepatocyte
apoptosis. In the adjusted model (β = 0.218. S.E. = 0.094, P= 0.023), HIV viral load
(log10(copies/mL) was the only significant variable that contributed to advanced FIB-4
index. A sub-analysis was used to investigate the relationship between CK-18 and HIV
viral load. The result showed an interaction, although not significant, between HIV viral
load and CK-18 hepatocyte apoptosis on FIB-4 index over time (β = 0.040, S.E. = 0.126,
P=0.075), which may highlight the relationship between HIV’s ability to infect
hepatocytes and cause apoptosis that leads to liver fibrosis.
Discussion
The aim of this study was to investigate biological mediators associated with liver
fibrosis in HIV mono-infected participants. Liver fibrosis is a growing concern in
PLWH,5 and cannot fully be attributed to co-infection with the hepatitis virus.6-8 The
ability of the HIV virus to infect hepatocytes,65,66 damage the intestinal barrier by
depleting gut associated lymphoid tissue,67,68 and cause immune dysregulation69,70
contribute to liver fibrosis, and may explain higher rates of liver disease in this
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population.2,4 Biological mediators associated with increased liver fibrosis may serve as
potential targets for future therapy, so it is important to identify biomarkers associated
with the progression of liver fibrosis in HIV mono-infection.
In this subset of 65 participants of the MASH cohort, 13.8% of HIV monoinfected participants progressed in FIB-4 stage from baseline to 2 years (i.e. from no
fibrosis and mild fibrosis, to indeterminate or severe, or from indeterminate to severe
fibrosis or cirrhosis). Our results are in line with previous research studies that use more
advanced categories of liver disease as outcomes. A study conducted by Sebastiani et
al.35 reported that 4% of HIV mono-infected subjects developed severe liver fibrosis over
a median of 4.9 years. Another study that included 132 HIV mono-infected subjects
reported 6.2% incidence of liver cirrhosis over 2.6 years.71
In the present study, high baseline values of oxidized glutathione and circulating
microbial endotoxin (LPS) were associated with increased odds of progression in liver
fibrosis stages after 2 years. Higher levels of oxidative stress, including excess
glutathione is associated with liver fibrosis in HIV-infection regardless of HCV disease
status.43 Our findings show higher % oxidized glutathione associated liver fibrosis
progression over time in HIV mono-infected participants. Notably, LPS was not
associated with FIB-4 index when analyzed as a continuous variable, but showed a trend
to predict liver fibrosis progressed with higher cut off values of endotoxin. This finding
is supported by Balagopal et al.68 who observed that the highest quartile values of LPS
cutoff values increased the odds of developing liver cirrhosis 19.0 times compared to
lower levels of LPS. However, a subset of this analysis showed that high LPS was not
associated with cirrhosis 12 months prior to progression,68 whereas our data show a trend
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of high levels of LPS and progression of liver fibrosis over 2 years. Establishing cut off
values may be important for certain biological mediators when predicting liver fibrosis
progression, because once a “tipping point” is reached, it may ultimately lead to liver
fibrosis progression. This phenomenon has been described by Cani et al.72,73 in metabolic
endotoxemia, whereby a threshold of LPS is reached that is associated with inflammatory
triggers, insulin insensitivity, and liver disease. In the context of HIV, LPS levels could
reach a dangerously high threshold in some patients that may trigger chronic immune
activation.52 Consistently high levels of LPS may decrease the ability of Kupffer cells to
clear endotoxin, making the liver more susceptible to fibrosis development over time.74,75
On the other hand, certain biological mediators may be more useful predictors of
liver fibrosis without the use of cut off points and liver fibrosis progression with cut off
points. Our results show that the marker for hepatocyte apoptosis (CK-18) was
associated with progressing in liver fibrosis category using a high cut off value and
linearly associated with FIB-4 index over 2 years as a continuous measure. Interestingly,
there was a slight interaction between CK-18 values and HIV viral load on FIB-4 index,
which may indicate that with high HIV viral load, infection of hepatocytes is most likely
more rapid, leading to apoptosis, and subsequently fibrosis.38
Average values of CK-18, TGF-β1, and LPS significantly increased in HIV
mono-infected participants over 24 months, however, the interaction between time, ART
use and black ethnicity decreased the statistical significance of the biomarkers. Mean
values for FIB-4 index increased from baseline to 24 months in the HIV mono-infected
cohort, and although the result was not statistically significant, there may be clinical
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implications because the average value of FIB-4 advanced from mild/no fibrosis to
moderate fibrosis.
A major limitation of this study is the small number of participants that
progressed in the stage of fibrosis determined with FIB-4. This is not surprising however,
as 24 months is not sufficient amount of time for a significant progression of liver
fibrosis to occur.71 Our data revealed trends that associated biological mediators with
liver fibrosis progression in HIV mono-infected persons with a small sample of liver
fibrosis progressors. A larger sample of HIV mono-infected participants followed for a
longer period of time may provide a larger number of people who progress in liver
fibrosis stage, and improve statistical significance. However, investigating these
biomarkers in humans offers a great insight into potential therapeutic targets for HIV
mono-infected persons at risk for developing liver fibrosis.
Conclusion
Our results indicate that the progression of liver fibrosis occurs in HIV monoinfection over time at least in a relatively small number of participants, in a fairly rapid
manner. In addition, higher levels of oxidative stress, hepatocyte apoptosis, and
microbial endotoxin are associated with liver fibrosis progression and FIB-4 index over
time in HIV mono-infected participants. These findings elucidate potential biological
processes that contribute to liver fibrosis progression in HIV mono-infection.
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Tables and Figures

Figure 1: Schematic describing FIB-4 index and METAVIR stage equivalent used for the study.
Participants who progressed at least one category of liver fibrosis over 2 years were considered
“progressors”. The cut off value used for statistical analyses was FIB-4 index ≥ 1.45 to establish
presence or absence of advanced fibrosis.

Table 1: Tertile cutoff values for biomarkers associated with liver fibrosis at baseline (n=65)
MDA (uM) GSH (% oxidized) CK-18 (pM) TGF-β1 (pg/mL) LPS (EU/mL)
Low tertile
0.438
19.6
90.0
1556.9
0.186
High tertile
0.617
27.9
100.4
5304.0
0.223
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Table 2: Baseline characteristics of participants who did and did not progress in FIB-4 category.
Did not progress in FIB-4
Progressed at least one
category
FIB-4 category
Mean±(S.D) or %(n)
Mean±(S.D) or %(n)
n=56
n=9
Age (years)
46.6± 6.9
51.3± 6.6
Gender (% male)
69.1(38)
66.7(6)
Ethnicity
83.6(46)
66.7(6)
(% non-Hispanic)
Log(HIV viral load)
2.41± 1.21
2.22± 0.90
CD4 cell count
553.7± 398.3
396.5± 169.2
(cells/mm3)
ART use (% yes)
89.1(49)
88.9(8)
BMI (kg/m2)
27.8± 5.1
29.6± 6.3
Alcohol intake
6.0± 7.4
8.4± 8.7
(AUDIT score)
Crack/cocaine use
26.8(15)
11.1(1)
(% yes)
FIB-4 index
1.30± 0.55
1.35± 0.29
Biological Markers
MDA (uM)
0.522± 0.196
0.641±0.269
GSH (% oxidized)
24.1± 9.2
28.6± 7.8
CK-18 (pM)
106.5± 47.5
129.5± 88.9
TGF-β1 (pg/mL)
4496.3± 4764.7
4863.3± 3495.3
LPS (EU/mL)
0.212±0.063
0.190± 0.059
P-value <0.05 is significant.
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P-value
0.063
0.884
0.227
0.644
0.250
0.986
0.348
0.392
0.311
0.814
0.115
0.173
0.469
0.826
0.334

Table 3: Characteristics of biological mediators of liver fibrosis from baseline to 24 months.
MDA
% oxidized GSH
CK-18
Mean±(S.D.) or %(n)
Mean±(S.D.) or %(n)
Mean±(S.D.) or %(n)
Variable
Low
High
Low
High
Low
High
n=43
n=22
n=46
n=19
n=43
n=22
Age (years,
baseline)
46.4±7.2
49.1±6.3
45.9±7.4
48.1±6.1
45.6±7.0* 50.4±5.8*
Gender (%
67.4(29)
71.4(15)
75.6(34)
52.6(10)
66.7(28)
72.7(16)
male)
Ethnicity
(% Black Non83.7(36)
72.7(16)
71.7(33)*
100(19)*
81.4(35)
72.7(16)
Hispanic)
Log10(HIV
viral load)
Baseline
2.48±1.19
2.21±1.12
2.34±1.06 2.50±1.42 2.43±1.16 2.29±1.20
24 months
3.06±1.47**
1.58±0.31** 2.62±1.43 2.42±1.37 2.62±1.39 2.39±1.45
CD4 cell count
(cells/mm3)
Baseline
532±423
530±277
548±408
492±296
524±418
545±290
24 months
788±1085
424±348
573±599
816±1315
520±588
952±1347
ART use (%Y)
Baseline
90.7(39)
85.7(19)
91.1(41)
84.2(16)
90.5(38)
86.4(19)
24 months
100(43)
100(22)
100(46)
100(19)
100(43)
100(22)
BMI (kg/m2)
Baseline
27.6±5.2
29.1±5.4
27.8±5.2
28.7±5.7
27.8±5.0
28.7±5.9
24 months
27.8±5.5
30.1±6.4
26.7±4.5* 32.1±6.7*
28.6±5.7
28.1±6.4
FIB-4
Baseline
1.39±0.58
1.15±0.42
1.28±0.46 1.37±0.65 1.29±0.54 1.34±0.47
24 months
1.34±0.66
2.27±5.08
1.82±3.55 1.30±0.89 1.77±3.65 1.44±0.73
P-values <0.05 are considered significant; *p<0.05, **p<0.001
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TGF-β1
Mean±(S.D.) or %(n)
Low
High
n=43
n=22

LPS
Mean±(S.D.) or %(n)
Low
High
n=43
n=22

47.5±6.3
71.4(30)

46.7±8.2
63.6(14)

46.8±7.7
69.0(29)

48.1±5.5
68.2(15)

76.7(33)

86.4(19)

79.1(34)

81.8(18)

2.29±1.08
2.60±1.32

2.57±1.32
2.35±1.74

2.60±1.32*
2.32±1.26

1.96±1.60*
2.97±1.58

523±408
518±553

549±317
1247±1709

460±270*
688±1012

672±508*
614±741

100(43)
100(43)

100(22)
100(22)

83.7(36)
100(43)

100(22)
100(22)

28.0±5.5
28.7±6.5

28.3±4.9
27.8±4.3

28.4±5.6
28.7±6.1

27.5±4.7
27.6±5.4

1.28±0.41
1.75±3.63

1.36±0.68
1.48±0.95

1.28±0.49
1.83±3.67

1.37±1.58
1.31±0.50

Figure 2: Proportion of liver fibrosis “progressors” within markers of oxidative stress, hepatocyte
apoptosis and immune activation. A higher percent of participants with high MDA and high
TGB-β1 at baseline progressed at least one category of FIB-4 over 24 months, however these
results were not statistically significant.
Table 4: Odds of progressing in FIB-4 category over 24 months with high baseline biomarkers in (n=65)
HIV mono-infected participants (n=9) progressed over 24 months.
Unadjusted model
Adjusted model*
Variable
β
OR
p-value
β
aOR
p-value
High MDA
0.332
1.394
0.646
0.569
1.766
0.488
High % oxidized
1.035
2.815
0.097
2.121
4.342
0.046
GSH
High CK-18
-0.332
0.717
0.646
-0.727
0.483
0.403
High TGF-β1
0.497
1.644
0.496
0.973
2.647
0.250
High LPS
0.182
1.200
0.801
0.914
1.098
0.097
*Controlled for age, gender, log10(HIV viral load) and CD4 cell count, and ethnicity.
Note: High baseline levels of oxidized GSH and microbial endotoxin (LPS) were associated with increased
odds of progressing at least one category of fibrosis over time.
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Table 5: Logistic regression associations between biomarkers (as continuous variables) and odds of
progressing FIB-4 category over 2 years.
Unadjusted
Adjusted*
Parameter (all time points)
Estimate
OR
P-value
Estimate
OR
P-value
MDA (uM)
1.648
5.197
0.147
1.079
2.942
0.465
GSH (% oxidized)
0.022
1.022
0.293
0.066
1.063
0.003
CK-18 (pM)
0.008
1.008
0.021
0.002
1.002
0.600
TGF- β1 (pg/mL)
0.001
1.001
0.431
0.001
1.001
0.738
LPS (EU/mL)
1.038
2.824
0.374
-2.485
0.083
0.230
*Controlled for age, gender, Log10(HIV viral load) and CD4 cell count, and ethnicity.
Table 6: GEE associations between biomarkers and odds of progressing FIB-4 category over 2 years.
Unadjusted
Adjusted*
Parameter (continuous)
Estimate
OR
P-value
Estimate
OR
P-value
MDA (uM)
-0.117
0.889
0.945
0.285
1.329
0.903
GSH (% oxidized)
0.047
1.048
0.064
0.070
1.072
0.010
CK-18 (pM)
0.004
1.004
0.533
0.008
1.008
0.299
TGF- β1 (pg/mL)
0.000
1.000
0.953
0.000
1.000
0.731
LPS (EU/mL)
-0.398
0.672
0.887
0.023
1.023
0.994
Parameter (high cut off)
Estimate
OR
P-value
Estimate
OR
P-value
High MDA
0.498
1.646
0.390
1.057
2.877
0.201
≥ 0.617 EU/mL
High % oxidized GSH
0.879
2.409
0.128
1.589
4.897
0.039
≥ 27.9%
High CK-18
0.884
2.421
0.123
1.464
4.311
0.071
≥ 100.4 pM
High TGF-β1
-0.857
0.424
0.400
-1.571
0.208
0.221
≥ 5304.0 pg/mL
High LPS
0.670
1.955
0.292
1.026
2.790
0.185
≥ 0.223 EU/mL
*Controlled for age, gender, Log10(HIV viral load) and CD4 cell count, and ethnicity, and baseline
parameter values.
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Figure 3a-e: Predicted probability of fibrosis progression at each time point associated with
low/high values of biomarkers at baseline. The figure shows that at each visit the predicted
probability of progressing in FIB-4 category over time based on having high/low biomarkers
(MDA, GSH, CK-18, TGF-β1, LPS) at each time point. Participants categorized with high
biomarkers have a higher predicted probability of progressing in FIB-4 category over time,
compared to lower biomarker groups, however, these results did not reach statistical significance.
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Table 7: Comparison of biomarkers at different time points (n=65).
Variables
Unadjusted
FIB4
Baseline
1.245 ± 0.530
12 months
1.431 ± 1.514
24 months
1.528 ± 2.851
P-value time = 0.403
MDA
Baseline
0.556 ± 0.223
12 months
0.574 ± 0.230
24 months
0.581 ± 0.218
P-value time = 0.700
GSH
Baseline
24.949 ± 8.879
12 months
22.832 ± 10.046
24 months
23.810 ± 10.262
P-value time = 0.412
CK-18
Baseline
108.426 ± 52.632a
12 months
95.628 ± 37.032b
24 months
117.625 ± 78.615c
P-value time = 0.006
TGF-β1
Baseline
5122.520 ± 6379.338a
12 months
10175.168 ± 8348.009b
24 months
15840.438 ± 11117.780c
P-value time = 0.001
LPS
Baseline
12 months
24 months

0.211 ± 0.063a
0.226 ± 0.096b
0.319 ± 0.195c
P-value time = 0.001

Adjusted*
1.245 ± 0.530
1.431 ± 1.514
1.528 ± 2.851
P-value time = 0.743
0.556 ± 0.223
0.574 ± 0.230
0.581 ± 0.218
P-value time = 0.687
24.949 ± 8.879
22.832 ± 10.046
23.810 ± 10.262
P-value time = 0.283
108.426 ± 52.632
95.628 ± 37.032
117.625 ± 78.615
P-value time = 0.438
5122.520 ± 6379.338
10175.168 ± 8348.009
15840.438 ± 11117.780
P-value time = 0.834
0.211 ± 0.063
0.226 ± 0.096
0.319 ± 0.195
P-value time = 0.380

CK-18 P-valueb,c=0.007
TGF-β1: P-valuea,b=0.001,
P-valuea,c=0.001, P-valueb,c=0.003
LPS: P-valuea,c=0.001, P-valueb,c=0.002
* Adjusted for age, gender, ethnicity, HIV viral load log10 copies/mL, CD4 cell count, and ART use.

Table 8: Mixed model associations between biomarkers (as continuous variables) and FIB-4 index over 2
years.
Unadjusted
Adjusted*
Parameter (all time points)
Estimate
S.E.
p-value
Estimate
S.E.
p-value
MDA (uM)
0.513
0.651
0.431
0.747
0.522
0.156
GSH (% oxidized)
-0.102
0.014
0.472
-0.001
0.011
0.899
CK-18 (pM)
2.011
0.985
0.043
0.235
0.816
0.773
TGF-β1 (pg/mL)
0.044
0.148
0.765
-0.019
0.313
0.637
LPS (EU/mL)
0.298
0.777
0.701
0.434
0.739
0.558
*Controlled for age, gender, HIV viral load log10 copies/mL and CD4 cell count, and ethnicity.
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Figure 4: Mixed models predict FIB-4 values based on high/low biomarkers at each time point.
Part a) shows low levels of MDA increasing FIB-4 index, b) shows interactions between high/low
GSH groups, c, d, and e) show high levels of CK-18, TGF- β1, and LPS show trends of
increasing estimated marginal means of FIB-4 index over time. Although the p-values did not
reach statistical significance, there are clear trends for high levels of CK-18, TGF- β1, and LPS to
predict an increase in FIB-4 index over 2 years.

Figure 5a and b: Association between CK-18 values and Predicted FIB-4 with time as a covariate.
The figure shows a) the significant relationship between the hepatocyte apoptosis marker CK-18
and predicted FIB-4 index, however, b) the significance is lost when controlling for covariates in
the model.
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CHAPTER VI: MEDIATORS OF LIVER FIBROSIS ASSOCIATED WITH
HAZARDOUS ALCOHOL USE, OBESITY, AND COCAINE USE IN
HIV-INFECTION
Abstract
Objective: Liver fibrosis is a leading cause of morbidity and mortality in people living
with HIV (PLWH). Co-infection with HIV and Hepatitis C (HCV) is a major contributor
to liver disease progression, because of the ability of HCV and HIV to specifically infect
hepatic stellate cells. Adverse lifestyle factors that are prevalent in PLWH include
hazardous alcohol use, high body mass index (BMI), and illicit drug abuse, such as
crack/cocaine use also may be significant contributors to liver fibrosis in HIV disease.
Hazardous lifestyle factors are associated with increased levels of biological mediators
associated with pathogenesis of liver fibrosis. This research aimed to investigate levels of
biological mediators of liver fibrosis that contribute to liver fibrosis within harmful
lifestyle factors using FIB-4 index as a non-invasive indicator in an HIV mono- and
HIV/HCV co-infected people.
Methods: After excluding participants with multiple adverse lifestyle factors, baseline
data was collected in n=67 HIV infected participants in the Miami Adults Studies on HIV
(MASH) cohort in Miami, FL. Hazardous drinking was assessed by AUDIT score ≥ 8,
obesity was considered ≥ 30 kg/m2, and positive cocaine use was collected using
participant self-report, and confirmed with urine toxicology test. Biological mediators of
liver fibrosis including malondialdehyde (MDA), percent oxidized glutathione (GSH),
hepatocyte apoptosis marker Cytokeratin 18 (CK-18), TGF-β1, and the microbial
endotoxin lipopolysaccharide (LPS) were measured in plasma using commercially
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available kits. Participants were grouped into categories of liver fibrosis at baseline
according to their FIB-4 score generated by the equation that uses common laboratory
values: [(AgeXAST)/(PlateletsX√(ALT))]. FIB-4 index < 1.45 ruled out advanced stage
of hepatic fibrosis (METAVIR stage equivalent F0-F1), or advanced liver fibrosis FIB-4
index ≥ 1.45 (METAVIR stage equivalent ≥F2). Student t-test and one-way ANOVA
were used to assess relationships between biological mediators of fibrosis between
lifestyle groups. Multivariate analyses and logistic regression were used to evaluate
associations between biological mediators and FIB-4 index within lifestyle groups.
Results: In the current study, higher levels of TGF-β1 was associated with higher liver
fibrosis in HIV+ cocaine users (β=0.858, P=0.027). High % oxidized GSH was
associated with liver fibrosis in obese subjects (β=0.563, P=0.018). Hepatocyte apoptosis
(CK-18) independently predicted a higher FIB-4 index in the group without harmful
lifestyle factors (β=0.435, P=0.015). MDA and TGF-β1 on liver fibrosis (F=3.171,
P=0.071), indicating that mechanisms of hepatic pathogenesis may be elucidated in larger
sample sizes of PLWH. There were no significant associations between MDA and LPS
and liver fibrosis within lifestyle groups, and liver fibrosis did not differ significantly
between lifestyle groups.
Conclusions: This study offers new insight into biological mediators of liver fibrosis
and their interaction with harmful lifestyle factors associated with HIV-infection.
Strategies to develop therapeutic targets, treatment options, and the utilization of
diagnostic markers may become more personalized when examining the manner in which
potential biomarkers are affected by individual lifestyle factors.
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Introduction
People living with HIV (PLWH) have longer lifespans with the successful use of
antiretroviral therapies.1 However, PLWH experience higher prevalence of noninfectious co-morbidities,2 which negatively impacts the quality of life of the HIVinfected patient, increases morbidity and mortality, and unduly burdens health care
systems.3-6 A major co-morbidity identified in HIV infection is liver disease,7-10 and a
main diagnostic component of liver disease is liver fibrosis.11 Hepatitis C co-infection
(HIV/HCV) is attributed to the rapid progression of liver fibrosis in HIV-infected
patients, and, there is increasing evidence that HIV mono-infection itself contributes to
the development of liver fibrosis.12-16 Thus, it is important to investigate the biological
mediators of liver fibrosis in both HIV mono- and HIV/HCV co-infected persons at risk
for developing liver fibrosis. Proposed biological mediators implicated in liver fibrosis
and HIV infection include increased markers of oxidative stress,17,18 pro-fibrogenic
cytokine TGF-β1,19-21 `microbial endotoxin lipopolysaccharide (LPS),22,23 and
hepatocyte apoptosis marker CK-18.24,25
Unhealthy lifestyle factors disproportionately affect PLWH in the United States,
including increased hazardous drinking,26,27 obesity,26,28,29 and cocaine use.30-32 Increased
liver fibrosis is associated with having a high body mass index (BMI), drinking
hazardously and using cocaine in the general population, as well as in the HIV-infected
patients.33-36 Furthermore, hazardous lifestyle factors are associated with increased levels
of biological mediators associated with pathogenesis of liver fibrosis. For example,
alcohol use and obesity independently increase circulating oxidative stress levels, which
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stimulate the hepatic stellate cells to produce TGF-β1, which perpetuates the cellular
framework of fibrosis.37,38
The combination of HIV infection and harmful lifestyle factors may advance
biological markers of liver fibrosis. The aim of this research was to investigate specific
biological markers associated with liver fibrosis in people with distinct harmful lifestyle
factors in the Miami Adult Studies in HIV (MASH) cohort.
Methods
Study participants and design
Data from a subsample of the MASH cohort consisting of 454 HIV infected
adults, with 29% of participants co-infected with HCV at the time of this cross-sectional
secondary analysis was used for these analyses. Participants attended visits at FIUBorinquen Research Clinic, Miami, FL every 3 months for the parent study. All
participants gave written consent to participate and have agreed to their information used
for future research at their baseline visit. Trained interviewers conducted patient
interviews and collected anthropometric information. Blood samples were collected at
baseline and annually via venipuncture by the study nurse and sent to a central laboratory
(Quest Diagnostics, Miami, FL) for common laboratory data, and to FIU laboratory for
processing and for specialized assays. The data used for this study was the cross-sectional
baseline information the MASH cohort. A subset of the cohort participants was used for
this study, who were categorized into different groups that included (i) Group 1:
hazardous drinking (not obese and no cocaine use); (ii) Group 2: obese only (mild alcohol
use, and no cocaine use); (iii) Group 3: cocaine use (mild alcohol use and not obese); and
(iv) Group 4: control group (low alcohol use, not obese, and no cocaine use). Baseline
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descriptive statistics and biological markers were characterized within and throughout the
groups and associated with FIB-4, an index of liver fibrosis. The study was approved by
the Institutional Review Board at Florida International University.
Measurements
The primary outcome of this study is stage of liver fibrosis. Laboratory data to
obtain FIB-4 index was sent to a central laboratory (Quest Diagnostics, Miami, FL) for
blinded analysis. FIB-4 index was calculated using the validated equation that include
age, liver enzymes (AST, ALT) and platelets [(AgeXAST)/(PlateletsX√(ALT))].39,40
Stage of liver fibrosis serves as an important prognostic factor for liver disease because it
defines the extent of liver disease advancement for therapeutic decisions.11 Although
liver biopsy is the current gold standard for liver fibrosis, it is highly invasive, carries a
high risk for research purposes.41 Specifically in HIV infected populations, it is
contraindicated because there is an increased risk of internal hemorrhage due to
thrombocytopenia.41,42 Sterling et al.39 have described the FIB-4 index, which consists of
alanine aminotransferase (ALT) level, AST level, PLT counts, and age, for assessing
fibrosis in a large cohort of patients with HIV/HCV co-infection. The FIB-4 index has
also been validated as an inexpensive and accurate marker of fibrosis in the context of
HCV mono-infection with a sensitivity of 74.3% and specificity of 80.1% (FIB-4 cut off<
1.45) to rule out advanced liver fibrosis.40 FIB-4 index also correlates to METAVIR
stage of fibrosis that corresponds to to liver biopsy measurements such that FIB-4 <1.45
is associated with a METAVIR stage of F0-F1 (no/mild liver fibrosis) and FIB-4 ≥ 1.45
is associated with METAVIR stage ≥ F2 (advanced liver fibrosis).43 FIB-4 index was
examined as a continuous variable or participants were categorized having the presence
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or absence of advanced hepatic fibrosis, as determined by the cut off value of FIB-4
index ≥1.45 (METAVIR stage ≥ F2) or FIB-4 < 1.45 (METAVIR stage F0-F1,
respectively).
Lifestyle groups were determined using data collected during the baseline
interview of the study. Information about alcohol consumption was obtained using the
Alcohol Use Disorders Identification Test (AUDIT), a questionnaire developed by the
World Health Organization to identify patients who drink hazardously with an AUDIT
score ≥8.44-47 Body mass index (BMI) was obtained by measuring height using a
stadiometer and weight on a calibrated scale when subjects were dressed in light clothing
and after removing shoes. Participants were categorized as being obese with BMI values
≥ 30 kg/m2.48 Interviewers utilized a drug-frequency questionnaire to obtain self-reported
crack/cocaine use, and the information was confirmed with urine toxicology. Positive
self-report or positive urine toxicology indicated that participants may be categorized in
the cocaine use group.
Covariates in analyses included variables that are known to be associated with
liver fibrosis in HIV, including age, gender, and ART use. HIV disease parameters (HIV
viral load, and CD4 cell count) were obtained from primary care physicians with the
consent of the participants at each visit.
Biological Mediators
Biological mediators served as independent predictors of liver fibrosis (FIB-4 index)
within lifestyle groups. A secondary aim of the study was to investigate the impact of
lifestyle factors on biological markers as dependent variables.
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Malondialdehyde (MDA) is a widely accepted marker of lipid peroxidation, which
correlates well with liver fibrosis in other populations.49-51 MDA is measured using a
TBARS assay (Northwest Life Science Specialties, Portland, OR, USA) whereby it reacts
with thiobarbiuric acid (TBA) to form a complex that is highly absorbed at 532nm, which
can be read spectrophometrically.
Glutathione (GSH) is an important part of the endogenous antioxidant system
because it is the most abundant intracellular antioxidant, and directly participates in
quenching harmful peroxide radicals as well as recycling other antioxidants.18 GSH
represents antioxidant status by measuring the ratio of oxidized glutathione (GSSH) to
total glutathione (oxidized GSSH + reduced GSH). Measuring levels of reduced GSH
alone does not indicate oxidative stress levels because GSH measures vary across
individual, however, a higher ratio of oxidized glutathione to total glutathione is
indicative of higher oxidative stress. Healthy values of oxidized glutathione are close to
10% of the total glutathione pool in tissues and 16% in plasma.52-54 Percent oxidized
glutathione is measured using a colorimetric assay that measures total and oxidized
glutathione (Arbor Assays, Ann Arbor, MI, USA).
Bacterial endotoxin lipopolysaccharide (LPS) is a major component of Gramnegative bacterial cells walls and can be quantitatively assessed to determine the degree
of microbial translocation.55 The limulus amebocyte lysate (LAL) assay has been widely
used for the detection of endotoxin for approximately 30 years,56 and in HIV-related
research.55,57-59 Recently, methods have been developed to measure LPS using the LAL
Lonza kit in plasma of HIV+ patients.57 Circulating LPS was measured in plasma using a
chromogenic endpoint assay (Lonza, Walkersville, MD, USA), Samples were heated to
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75 C for 15 min to reduce protein interference and diluted (1:10) then spiked with
endotoxin when values were undetectable, and read using the EL800 microplate reader
and GEN5 software.
Fibrogenic cytokine TGF-β1 uses ELISA methods from a commercially available
kit. The Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA) measures the
activated form of TGF-β1 circulating in plasma samples, and has been used in previous
studies in human plasma with a sensitivity of 15.4 pg/mL.60,61
Hepatocyte-specific apoptosis (CK-18) is quantified with the M30 Apoptosense
ELISA assay (Peviva, Nacka, Sweden) that uses the M30 antibody specific for the
cytokeratin-18 (CK-18) protein. Programmed cell death, or apoptosis, in hepatocytes has
been suggested as a mechanism for liver fibrosis because apoptotic bodies initiate
inflammation and activate hepatic stellate cells.62 Hepatocytes undergoing cell death
produce CK-18 and circulating levels are associated with hepatic injury and
fibrosis.24,25,63-66
Laboratory values for biological mediators were measured using residual blood
samples stored at -80°C until analysis in duplicate. Acceptable results had coefficient of
variation (CVs) within 10% indicating a small variance between replicates; otherwise
they were reanalyzed.
Statistical Analysis
Descriptive statistics were conducted by t-test or one-way ANOVA for
continuous variables, and Chi-square for categorical variables. Non-parametric equivalent
tests were employed when equality of variances were not met. Multivariate linear
regression was used to find associations within lifestyle groups for individual biological
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markers (MDA, % oxidized GSH, CK-18, TGF-β1, LPS) and liver fibrosis (FIB-4 index)
as the dependent variable. Logistic regression was used to examine binary outcomes of
biological mediators categorized into high/low categories and categories of lifestyle
groups.
Statistical models were adjusted for covariates that are known to affect liver
fibrosis in HIV infection including age, gender, CD4 cell count, HIV viral load, ART use,
and co-infected status. Covariates that were significantly associated with dependent
variables (i.e., FIB-4 index or biological mediators) were kept in the model for analyses.
Results
After removing subjects with missing variables, participants were categorized into
lifestyle groups that identified one single main characteristic as inclusion criterion. All
participants were HIV-positive and qualified for 1 out of 4 lifestyle groups. Group 1
eligibility criterion was drinking alcohol hazardously (AUDIT ≥8) but were not obese
and did not use cocaine. Group 2 main characteristic was having high BMI (≥30kg/m2),
had an AUDIT≤8, and did not use cocaine. Group 3 inclusion criterion was using
cocaine (self-report and urine toxicology), had BMI≤30kg/m2and AUDIT≤8. Group 4,
the control group, did not have any of the unhealthy lifestyle characteristics of the other
three groups.
The purpose of identifying participants with a single lifestyle factor was to
investigate the effect of one adverse lifestyle factor rather than a combination of two or
more, in order to isolate the main effect of that lifestyle factor on biomarkers and liver
fibrosis. Participants who did not fall into a lifestyle category or who had a combination
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of them were excluded from the analysis. A total of n=67 participants were included in
the study, shown in Table 1.
There were no statistical differences in baseline characteristics between the
lifestyle groups in this subset of the MASH cohort. After separating the groups into
categories, the sample size for the cocaine group was small due to the difficulty in finding
participants who had low AUDIT scores but reported using cocaine. Based on the
descriptive characteristics, there were significantly more women in the obese category,
and more men who drank hazardously (P=0.003). Mean MDA, % oxidized GSH, CK18, TGF-β1, and LPS did not vary between lifestyle groups (Table 2).
Biological markers associated with FIB-4 index within adverse lifestyle groups
According to multivariate linear regressions, age, gender and being co-infected
with HCV were significantly associated with liver fibrosis (Table 3). Regression models
were controlled for these covariates, along with CD4 cell count to consider disease status
when exploring associations with biological mediators and FIB-4 index within groups.
Biological mediators that increased with FIB-4 index included TGF-β1, hepatocyte
apoptosis marker CK-18, and % oxidized GSH.
TGF-β1 was significantly associated with FIB-4 in people who used cocaine
(β=0.858, P=0.027) when the model was controlled for covariates. TGF-β1 also showed a
trend in predicting FIB-4 index in the group that did not use unhealthy behaviors and was
not obese (β=0.326, P=0.064). Also in this group, CK-18 was independently associated
with FIB-4, and remained significant after controlling for covariates (β=0.435, P=0.015),
suggesting that apoptosis can predict FIB-4 in HIV+ subjects without unhealthy lifestyle
characteristics. In people who are obese, high oxidative stress (GSSH) is independently
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associated with increased FIB-4 index when controlling for covariates (β=0.563,
P=0.018).
Table 7 describes univariate and multivariate analyses examining the influence of
adverse lifestyle factors on biological mediators of fibrosis. Among the adverse lifestyle
groups, only the obese group showed trends of higher biomarkers of liver fibrosis.
Percent oxidized GSH and TGF-β1 both trended towards significance in obese
participants (F(6, 67)=2.940, P=0.092 and F(6,67)=3.24, P=0.077, respectively) after
adjusting for significant covariates. Obese participants had higher estimated means of %
oxidized GSH (28.2% vs. 23.5%) compared to the combined average of other groups.
Obesity does not have a direct influence on TGF-β1, instead, there is a significant
interaction between BMI ≥ 30 kg/m2 and being co-infected with HIV/HCV that
significantly increases TGF-β1 F(7, 67)=7.478, P<0.001, which may reveal a relationship
between these medical conditions and liver disease in HIV. Participants in the control
group (who did not exhibit a harmful lifestyle factor) had a lower association with
percent oxidized GSH F(6, 67)= 3.29, P=0.075; (estimated means: 23.0% vs. 26.9%);
however, the unadjusted FIB-4 index was significantly higher in participants without a
harmful lifestyle factor F(1, 67)=5.04, P=0.028. The estimated mean FIB-4 index was
higher in the control group compared to the combined means of the adverse lifestyle
groups (1.16±0.15 vs. 1.19 ± 0.14), however the effect was lost after adjusting for
covariates which indicates that another factor is significantly associated with FIB-4 index
in people without an adverse lifestyle factor. In fact, FIB-4 index is significantly
influenced by HCV coinfection in this model F(6, 67)=10.954, P=0.002, and there is a
slightly higher proportion of HIV/HCV co-infected participants in the control group

151

(32.3%) compare to the combined average of the other groups (13.9%), P=0.072. The
higher proportion of HIV/HCV co-infected participants in the control group may account
for significant associations with higher FIB-4 index in the unadjusted model.
The association between high levels of circulating biological mediators on FIB-4
index in people experiencing a harmful lifestyle factor was investigated using univariate
and multivariate analyses. In the obese group, the estimated mean FIB-4 index was lower
for those with low GSH vs high GSH (0.83± 0.20 vs. 1.33± 0.12), which was in
agreement with the linear regression data.
TGF-β1 showed a trend in predicting FIB-4 index in those who drank alcohol
hazardously (P=0.061) and are those who were obese (P=0.088). The estimated mean
FIB-4 values were lower in participants who drank alcohol hazardously and who had low
TGF-β1 compared to hazardous drinkers with high TGF-β1 (1.59±0.16 vs. 1.37± 0.12).
Conversely, the estimated mean for FIB-4 was higher for participants with high TGF-β1
levels in the obese group (0.43± 0.46 vs 1.20± 0.31). These results indicate that TGF-β1
can influence FIB-4 index differently under different harmful lifestyle conditions.
Associations between harmful lifestyle factor and odds of high biological mediators
of liver fibrosis
There were no significant associations between having high levels of biological
mediators and the odds of having advanced liver fibrosis within any lifestyle group, likely
due to the small sample sizes in the groups, however, factors associated with liver fibrosis
were associated with increased odds of having a harmful lifestyle (Tables 8 a-d).
Not having a harmful lifestyle condition was associated with 65% lower odds of
being in the control group, and this result remained slightly significant after adjusting for
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age, gender, co-infection status, and CD4 cell count (OR 0.350 [95% CI 0.122 – 1.007];
P=0.051), indicating that HIV+ subjects with harmful lifestyle factors had more oxidative
stress. Hazardous alcohol use decreased the odds of advanced liver fibrosis classification
by 87.1% and there was a trend in association between high lipid peroxidation (MDA)
and using cocaine in the adjusted model, however, it did not reach significance (OR
7.919 [95% CI 0.742 – 84.519]; P=0.087).
There was also slight interaction between high MDA and high TGF-β1 on FIB-4
index (F=3.171, P=0.071) in the control group with no adverse lifestyle factors. Figure 1
shows that FIB-4 index increased in participants with high MDA and high TGF-β1, with
the opposite trend in people with low levels of TGF-β1. No other significant interactions
between biological mediators were associated with FIB-4 index within lifestyle groups.
Discussion
Liver disease has now surpassed AIDS-defining illnesses as a leading cause of
morbidity and mortality in PLWH.67,68 Liver disease progression can be monitored using
measures of liver fibrosis.11 Harmful lifestyle factors tend to be more prevalent in HIVinfected populations, including alcohol abuse,26,27 obesity,26,28,29 and cocaine use,30-32
and these conditions are also associated with increased progression of liver
disease.34,35,48,69-71 Our findings show that biological mediators of liver fibrosis that are
high in HIV are also associated with liver fibrosis among PLWH with distinct harmful
lifestyle characteristics.
Although baseline characteristics do not vary significantly between lifestyle
groups, the ratio of oxidized GSSH:total GSSH (% oxidized GSH) is one of the few
biomarkers with established values in healthy subjects in the literature.52-54 Our data
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show that baseline measures of % oxidized GSH in plasma were significantly higher than
reported values in healthy individuals A one-sample t-test utilized a reported value of %
oxidized GSH in plasma healthy individuals taken from the literature (16.6%) compared
to this HIV+ sample. Glutathione values were significantly higher in all groups
(hazardous drinking P=0.002, obese group P<0.001, cocaine use P=0.004, control group
P=<0.001) compared to the healthy reference in the literature.53,54 Glutathione is
characteristically low in HIV populations, and research suggest replenishment of the
glutathione pool as a therapeutic target to improve HIV status.72
In the current study, higher levels of TGF-β1 was associated with higher liver
fibrosis in HIV+ cocaine users. In in vitro models, cocaine induces TGF-β1 production,
and in mice exposed to cocaine, TGF-β1 receptors are upregulated.73,74 Cocaine has also
been shown to increase HIV replication and inflammation in peripheral blood
mononucleocytes in a humanized mouse model,75 which may contribute to liver
fibrogenesis.
Hepatocyte apoptosis determined with circulating CK-18 independently predicted
a higher FIB-4 index in the group without harmful lifestyle factors, indicating that hepatic
apoptosis occurs in the context of HIV with the absence of harmful lifestyle conditions,
and may lead to liver fibrosis. This finding is not unexpected, because HIV-infection
itself may cause hepatocyte apoptosis due to its ability to infect hepatocytes through the
CCR5 receptor,14 and this pathogenesis is enhanced in HIV/HCV.76 Also in the control
group, an interaction between oxidative stress marker MDA and TGF-β1 showed a trend
to contribute to higher FIB-4 index, that is, high MDA and high TGF-β1 are associated
with higher FIB-4 values. The control group also had an association with increased odds
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of advanced stages of liver fibrosis, most likely due to the higher proportion of HIV/HCV
co-infected participants in the group. Taken together, these findings may represent the
interplay between oxidative stress as an importance initiator of fibrosis through the
activation of TGF-β1 to promote fibrosis in persons with HIV infection.77-79
This cross-sectional analysis of the MASH cohort may provide an indirect
narrative of the population. The finding that hazardous drinking is associated with a
decreased probability of having advanced liver fibrosis is counterintuitive at first glance,
however, it may be related to a higher proportion of HIV/HCV co-infected participants
and the higher FIB-4 value in the control group. Since the participants in the control
group, on average, have advanced stages of liver fibrosis (1.64 ± 1.11) and greater than
30% are co-infected with hepatitis C, it is likely that they were strongly advised by a
medical professional to stop drinking hazardously, and that they are aware of the damage
hazardous drinking has on the liver. In fact, a study that compared reported alcohol
consumption between HIV mono- and HIV/HCV co-infected patients showed that a coinfected patients reported restricted drinking habits to avoid medical problems.80 Rather
than conclude that probability of having advanced fibrosis is lower in hazardous alcohol
drinkers with HIV, we may reason that PLWH in the MASH cohort are less likely to
drink alcohol hazardously if they are co-infected with hepatitis C and have advanced
stages of fibrosis.
Our findings consistently demonstrate that people who were obese had a
significant and independent association between % oxidized GSH and liver fibrosis.
Obesity is significantly associated with oxidative stress in HIV negative cohorts;38,80
however few studies have investigated the combination of obesity and HIV with the
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impact of oxidative stress on liver fibrosis. Interestingly, a high level of oxidized
glutathione [GSSH/GSH+GSSH] is associated with a significantly lower odds of having
a healthy lifestyle, which supports the concept that unhealthy lifestyle factors
significantly contribute to higher oxidative stress in HIV-infected persons.
Although this study design had the advantage of isolating the effects of specific
lifestyle conditions on biological mediators of liver fibrosis, it also limited the sample
size of the study, which was fixed in this secondary analysis of specimens collected by
the parent grant. Few participants met the criteria to be in the group that only used
cocaine, even though high proportion of MASH cohort participants use cocaine (29%),70
the majority used it in combination with alcohol AUDIT scores ≥ 8, which disqualified
them for the group. Ultimately, the sample size limited the statistical analyses, however,
even with a small sample, our data shows differences in biological mediators between
lifestyle groups.
Conclusion
This study offers new insight into biological mediators of liver fibrosis and their
interaction with harmful lifestyle factors associated with HIV-infection. Strategies to
develop therapeutic targets, treatment options, and the utilization of diagnostic markers
may become more personalized when examining the manner in which potential
biomarkers are affected by individual lifestyle factors. More research may be warranted
to further investigate the impact of lifestyle factors on the interpretation of predictive
biomarkers of liver fibrosis, which is one of the most important co-morbidities associated
with non-AIDS related death in PLWH.
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Tables and Figures
Table 1: Descriptive characteristics of lifestyle groups.
Hazardous
Obese Group
Drinking Group
(mean±SD)
(mean±SD)
or %(n)
or %(n)
Covariate
n=13
n=15
Age (years)
45.1± 8.6
48.1± 6.1
Gender (% male)
92.3(12)b
26.7(4)a
Ethnicity
92.3(12)
86.7(13)
(% Black NonHispanic)
Co-infection status
15.4(2)
13.3(2)
(% HIV/HCV)
Log10(HIV viral load)
2.34± 1.08
2.22± 0.76
CD4 cell count
425.6± 246.9
726.2± 596.0
(cells/mm3)
ART use (%yes)
83.3(10)
93.3(14)
FIB-4 index
1.17± 0.39
1.19± 0.44

Table 2: Mean biological mediators between lifestyle groups.
Hazardous
Obese Group
Drinking Group
(mean±SD)
(mean±SD)
or %(n)
or %(n)
Biomarker
n=13
n=15
MDA (uM)
0.613± 0.213
0.545±0.228
GSH (%
24.9± 8.7
23.6± 6.9
oxidized)
CK-18 (pM)
141.9± 126.9
135.2± 74.4
2662.4± 2939.0
1988.1±1599.9
TGF-β1 (pg/mL)
LPS (EU/mL)

0.231± 0.060

0.239± 0.069

Cocaine Use
Group
(mean±SD)
or %(n)
n=7
45.7± 6.6
75.0(6)a,b
62.5(5)

Control
Group
(mean±SD)
or %(n)
n=31
46.7± 8.0
67.7(21)a,b
71.0(22)

P-value
0.758
0.003
0.244

12.5(1)

32.3(10)

0.353

3.01± 1.64
352.0± 261.6

2.25± 0.98
594.4± 292.4

0.361
0.083

87.5(7)
1.46± 0.74

80.6(25)
1.64± 1.11

0.722
0.241

Cocaine Use
Group
(mean±SD)
or %(n)
n=7
0.632± 0.140
27.0± 9.4
99.1± 35.8
4344.7±
3878.1
0.266±0.042

Control Group
(mean±SD)
or %(n)
n=31
0.546± 0.232
21.9± 6.8

P-value
0.636
0.217

114.6± 89.7
2507.9± 3147.3

0.651
0.329

0.259± 0.074

0.444

Table 3: Significant covariates associated with FIB-4 index in the regression model.
Covariate
β
t
Age
0.256
2.086
Gender (1 is Male)
0.265
2.201
Ethnicity (Black Non-Hispanic)
-0.112
-0.989
HCV Co-infected
0.420
3.667
Log10(HIV viral load)
0.052
0.387
CD4 cell count (cells/mm3)
-0.081
-0.714
ART use
0.020
0.155
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P-value
0.042
0.032
0.327
0.001
0.701
0.478
0.877

Table 4: Multivariate regression within lifestyle groups – associations between biological mediators and
FIB-4 index as the dependent variable.
4a. Hazardous alcohol use group (AUDIT score ≥8).
Unadjusted model
Parameter
β
t
P-value
MDA (µM)
-0.054
-0.465
0.643
[GSSH/GSSH+GSH] -0.286
-0.990
0.344
CK-18 (pM)
-0.148
-0.148
0.629
TGF-β1 (pg/mL)
0.118
0.394
0.701
LPS (EU/mL)
-0.059
-0.197
0.848

β
0.278
-0.240
-0.218
1.137
-0.694

Adjusted model*
t
P-value
0.835
0.428
-0.789
0.453
-0.712
0.497
0.744
0.478
-1.393
0.201

4b. Obese group (BMI ≥30 kg/m2).
Unadjusted model
Parameter
β
t
P-value
MDA (µM)
-0.193
-1.657
0.102
[GSSH/GSSH+GSH] 0.568
2.489
0.027
CK-18 (pM)
-.312
-1.186
0.257
TGF-β1 (pg/mL)
0.377
1.468
.166
LPS (EU/mL)
-0.028
-0.100
0.922

β
-0.403
0.563
-0.259
0.240
-0.127

Adjusted model*
t
P-value
-1.694
0.121
2.821
0.018
-1.080
0.306
0.847
0.417
-0.449
0.663

4c. Cocaine use group (Self-report and positive urine toxicology).
Unadjusted model
Parameter
β
t
P-value
β
MDA (µM)
-0.045
-0.290
0.773
-0.058
[GSSH/GSSH+GSH] -0.066
-0.445
0.659
-0.059
CK-18 (pM)
-0.308
-0.794
0.457
-0.008
TGF-β1 (pg/mL)
0.536
1.679
0.137
0.858
LPS (EU/mL)
0.191
0.477
0.650
-0.277

Adjusted model*
t
P-value
-0.306
0.762
-0.137
0.900
-0.017
0.988
4.049
0.027
-0.503
0.650

4d. Control group (low BMI, low AUDIT score, no cocaine use).
Unadjusted model
Parameter
β
t
P-value
β
MDA (µM)
-0.168
-1.960
0.311
-0.071
[GSSH/GSSH+GSH] -0.081
-0.942
0.348
-0.159
CK-18 (pM)
0.593
3.967
<0.001
0.435
TGF-β1 (pg/mL)
0.326
1.922
0.064
0.278
LPS (EU/mL)
0.176
0.960
0.345
0.113
*Model controlled for age, gender, co-infection status, and CD4 cell count.

158

Adjusted model*
t
P-value
-0.352
0.727
-0.925
0.364
2.593
0.015
1.603
0.121
0.635
0.531

Table 5: Binary covariates that influence biological mediators and FIB-4 index (n=67).
MDA
GSH
CK-18
TGF-β1
(µM)
(% oxidized)
pM
(pg/mL)
F
P-value
F
P-value
F
P-value
F
P-value
Covariate
0.14
0.708
0.25
0.618
0.69
0.407
2.16
0.147
Age ≥50 years
3.31
0.074
1.20
0.277
3.83
0.055
7.83
0.007
Gender (male)
Ethnicity
0.20
0.653
3.84
0.055
0.01
0.928
0.16
0.683
(Black
Non-Hispanic)
Co-infection
8.15
0.006
0.00
0.922
1.37
0.245
15.49
<0.001
status
(HIV/HCV)
HIV viral load
1.18
0.281
0.23
0.630
0.09
0.763
0.02
0.883
(≥75 RNA
copies/mL)
CD4 cell count
0.09
0.754
0.07
0.791
1.46
0.232
5.70
0.020
(<200 cells/mm3)
4.00
0.050
0.40
0.527
4.17
0.046
0.96
0.330
ART use (yes)

LPS
(EU/mL)
F
P-value

FIB-4 index
F

2.41
1.26
0.01

0.126
0.265
0.936

1.93
4.38
0.89

0.170
.041
0.348

1.38

0.245

14.10

<0.001

0.41

0.525

0.58

0.448

1.00

0.321

0.01

0.948

0.01

0.940

0.27

0.606

Table 6: Cut off values for biological mediators of liver fibrosis.
MDA (uM)
% oxidized GSH
CK-18 (pM)
TGF-β1(pg/mL)
LPS (EU/mL)
50% percentile
0.525
24.0
93.27
1539.2
0.228
(median value)
Any value that fell below the median qualified as a “low” biological marker. Values that were greater than or equal to the
median were considered a “high” biological marker.
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P-value

Table 7: Influence of adverse lifestyles on biomarkers of liver fibrosis.
Control Group

Hazardous drinking group
Unadjusted
Adjusted*

Obese group
Unadjusted
Adjusted*

Cocaine use group
Unadjusted
Adjusted*

Unadjusted

Adjusted*

F

F

F

F

F

MDA (µM)

0.37

Pvalue
0.545

[GSSH/GSSH+GSH]

0.01

0.988

0.06

0.813

3.64

0.061

2.94

0.092

0.08

0.786

0.17

0.678

3.25

0.076

3.29

0.075

CK-18 (pM)

0.77

0.383

0.66

0.420

0.24

0.629

1.56

0.216

0.45

0.503

0.87

0.356

0.46

0.501

1.04

0.312

TGF-β1 (pg/mL)

0.07

0.782

2.45

0.123

0.87

0.354

3.24

0.077

0.98

0.327

2.24

0.140

0.02

0.965

0.56

0.457

LPS (EU/mL)

0.03

0.866

0.02

0.878

1.24

0.269

1.50

0.225

0.82

0.37

0.17

0.685

2.79

0.100

1.22

0.275

FIB-4 index

1.23

0.271

1.95

0.168

1.25

0.268

0.01

0.973

0.33

0.567

0.41

0.525

5.04

0.028

2.16

0.147

Outcome variable

F
0.13

Pvalue
0.716

0.39

Pvalue
0.535

F
0.02

Pvalue
0.885

1.28

Pvalue
0.263

F
2.39

Pvalue
0.128

0.42

Pvalue
0.519

0.63

Pvalue
0.429

*Model controlled for gender, ethnicity, co-infection status, CD4 cell count, and ART use.
Outcome variables included biological mediators of liver fibrosis.
Table 8: High levels of biomarkers that influence FIB-4 index within lifestyle groups.
Hazardous drinking group
Obese group
Unadjusted
Adjusted*
Unadjusted
Adjusted*
Parameter

F

Pvalue
0.418

F

Pvalue
0.502

F

Pvalue
0.101

F

P-value

Unadjusted

Adjusted*

F

F

F

Pvalue
0.272

F

High MDA
0.70
0.50
3.12
1.69
0.225
1.46
3.44
≥ 0.525 EU/mL
High % oxidized
3.42 0.910 3.25
0.121
4.38
0.056 3.43
0.097
0.12
0.740
5.64
GSH ≥24.0%
High CK-18
0.03 0.871 0.05
0.819
0.02
0.964 0.16
0.700
0.81
0.400
0.33
≥93.27 pM
High TGF-β1
0.03 0.871 5.27
0.061
1.74
0.210 3.67
0.088
1.27
0.302
3.44
≥1539.2 pg/mL
High LPS
0.33 0.574 0.52
0.495
0.62
0.444 0.57
0.470
0.19
0.896
0.66
≥0.228 EU/mL
*Model controlled for gender, ethnicity, co-infection status, CD4 cell count, and ART use.
FIB-4 is dependent variable, each biological mediator was assessed separately within the respective lifestyle group.
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Control Group

Cocaine use group
Unadjusted
Adjusted*
Pvalue
0.204

2.77

Pvalue
0.106

0.73

Pvalue
0.420

0.254

0.47

0.495

0.01

0.960

0.667

1.65

0.208

0.13

0.724

0.204

0.52

0.473

0.95

0.339

0.564

2.06

0.161

1.56

0.224

Table 8: Associations between adverse lifestyle groups and odds of having higher biological factors of
liver fibrosis.
8a. Hazardous alcohol use group (AUDIT score ≥8)
Unadjusted model
Variable
OR
95% CI
P-value
High MDA
1.600
0.462 – 5.543
0.458
≥ 0.525 EU/mL
High %
0.926
0.274 – 3.131
0.901
oxidized GSH
≥24.0%
High CK-18
0.536
0.155 – 1.857
0.325
≥93.27 pM
High TGF-β1
1.260
0.373 – 4.262
0.710
≥1539.2
pg/mL
High LPS
0.794
0.235 – 2.684
0.710
≥0.228 EU/mL
High FIB-4
0.316
0.063 – 1.578
0.160
≥ 1.45
8b. High BMI group (BMI ≥30 kg/m2)
Unadjusted model
Variable
OR
95% CI
P-value
High MDA
0.524
0.162 – 1.695
0.280
≥ 0.525 EU/mL
High %
4.125
1.151 – 14.786
0.030
oxidized GSH
≥24.0%
High CK-18
1.143
0.360 – 3.631
0.821
≥93.27 pM
High TGF-β1
0.615
0.191 – 1.988
0.417
≥1539.2
pg/mL
High LPS
0.393
0.117 – 1.318
0.130
≥0.228 EU/mL
High FIB-4
0.706
0.195 – 2.522
0.595
≥ 1.45

aOR
1.175

Adjusted model*
95% CI
P-value
0.289 – 4.780
0.822

1.114

0.304 – 4.085

0.871

0.412

0.106 – 1.604

0.201

1.705

0.439 – 6.620

0.441

0.788

0.213 – 2.915

0.788

0.129

0.017 – 0.953

0.045

aOR
0.569

Adjusted model*
95% CI
P-value
0.143 – 2.261
0.423

3.743

0.899 – 15.587

0.070

1.908

0.480 – 7.576

0.359

0.390

0.088 – 1.721

0.214

0.347

0.862 – 27.998

0.135

2.084

0.400 – 10.856

0.383

8c. Cocaine use group (Self-report and positive urine toxicology)
Unadjusted model
Adjusted model*
Variable
OR
95% CI
P-value
aOR
95% CI
P-value
High MDA
6.429
0.728 – 56.798
0.094
7.919 0.742 – 84.519
0.087
≥ 0.525 EU/mL
High %
1.531
0.314 – 7.457
0.598
1.684 0.330 - 8.593
0.531
oxidized GSH
≥24.0%
High CK-18
1.333
0.274 – 6.492
0.722
1.439 0.272 – 7.617
0.669
≥93.27 pM
High TGF-β1
1.429
0.293 – 6.957
0.659
1.364 0.251 – 7.393
0.719
≥1539.2
pg/mL
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High LPS
≥0.228
EU/mL
High FIB-4
≥ 1.45

1.333

0.274 – 6.492

0.722

1.882

0.353 – 10.040

0.459

0.821

0.146 – 4.627

0.823

0.785

0.119 – 5.187

0.802

8d. Control group (low BMI, low AUDIT score, no cocaine use)
Unadjusted model
Adjusted model*
Variable
OR
95% CI
P-value
aOR
95% CI
High MDA
0.656
0.246 – 1.751
0.400
0.676 0.231 – 1.980
≥ 0.525
EU/mL
High %
0.333
0.121 – 0.921
0.034
0.350 0.122 – 1.007
oxidized
GSH ≥24.0%
High CK-18
1.014
0.356 – 2.883
0.980
1.210 0.456 – 3.213
≥93.27 pM
High TGF-β1 1.059
0.399 – 2.808
0.909
1.100 0.380 – 3.182
≥1539.2
pg/mL
High LPS
2.000
0.743 – 5.387
0.170
1.640 0.578 – 4.654
≥0.228
EU/mL
High FIB-4
2.581
0.886 – 7.521
0.082
2.738 0.752 – 9.971
≥ 1.45
*Model controlled for age, gender, co-infection status, and CD4 cell count.
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P-value
0.475
0.051
0.702
0.860
0.352
0.127

Figure 1: Interaction between MDA and TGF-β1 on estimating FIB-4 index. In HIV-infected
persons with no adverse lifestyle conditions, the combination of high oxidative damage (MDA)
and high TGF-β1 and may increase liver fibrosis.
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CHAPTER VII: SUMMARY AND CONCLUSIONS
With the introduction of effective antiretroviral therapy (ART),1 and an aging
HIV+ population,2 liver disease is now a leading cause of non-AIDS related morbidity
and mortality in PLWH,3-6 creating new health burdens in this population and for the
society.
The present study investigated the interplay between adverse lifestyle factors that
are prevalent in people living with HIV (PLWH), biological mediators of liver damage,
and a non-invasive measure of liver fibrosis (FIB-4 index) in HIV mono- and HIV/HCV
co-infected study participants.
Adverse lifestyle factors that disproportionately affect morbidity and mortality
among PLWH include hazardous drinking,7,8 high body mass index (BMI),7,9,10 and illicit
drug use including crack/cocaine.11-13 These lifestyle factors have been previously shown
in both HIV-infected and HIV- non-infected populations to be to cause liver disease as
reflected by increased liver fibrosis.14-17
The results of this investigation in the Miami Adult Studies of HIV (MASH)
cohort show that, in people with HIV mono-infection, the odds of progression of liver
fibrosis significantly increase over 2 years and that the process was associated with
harmful lifestyle factors. Having an Alcohol Use Disorders Identification Test (AUDIT)
score ≥8 was independently associated with higher liver fibrosis (FIB-4) index in HIV
mono-infection and 3.04 higher odds of increasing at least the FIB-4 equivalent of one
METAVIR stage of liver fibrosis over 2 years after adjusting for BMI, age, gender, CD4
cell count, HIV viral load, and ART use (OR 3.038 [95% CI 1.010 – 9.135]; P=0.048).
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The results of the present study in the MASH cohort show that having a high
body mass index (≥ 28 kg/m2) was also associated with higher FIB-4 index in HIV monoinfection (OR 2.934 [95% CI 1.132 – 7.605]; P=0.027). The relationship between BMI
and liver fibrosis in HIV infection has not been thoroughly explored. Studies have shown
that high BMI may be protective in HIV, a phenomenon known as the “obesity paradox”
whereby high BMI is associated with higher CD4 cell counts.18,19 Additionally, higher
CD4 cell count is associated with better outcomes of liver fibrosis because of improved
immune function.20,21 The results of the present study demonstrate the combined effect of
BMI and CD4 cell count on liver fibrosis in HIV mono-infection in the MASH cohort.
Decreased CD4 cell count was associated with higher liver fibrosis in participants with
lower BMI (< 28 kg/m2). On the other hand, CD4 cell count showed no association with
liver fibrosis in participants with higher BMI, likely due to the strong fibrogenic
influence of BMI on the liver. It is possible that any beneficial effect of CD4 cell count to
lower liver fibrosis are masked by the fibrogenic effect of high BMI when participants
are close to obesity.
The potent impact of BMI on liver fibrosis was revealed through the paradoxical
associations between cocaine use and FIB-4 index. There is a significant association
between the use of crack/cocaine and liver fibrosis (OR 0.228 [95% CI 0.057 – 0.918];
P=0.038). However, PLWH are less likely to be obese if they use crack/cocaine due to
the anorectic effect of this illicit drug. Since higher BMI is strongly associated with liver
fibrosis, lower BMI in those who use crack/cocaine leads to a seemingly paradoxically
lower liver fibrosis, compared to PLWH who do not use crack/cocaine. When the
analyses were stratified by BMI, there is was a strong interaction between BMI and
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crack/cocaine use that shows that cocaine increases FIB-4 index, a marker of liver
fibrosis, when adjusting for this interaction, such that the combined impact of BMI and
cocaine use is associated with advancing liver damage. To our knowledge, this is the
first time a relationship between crack/cocaine use, BMI, and liver fibrosis has been
reported in HIV mono-infected subjects.
Although there were no independent associations with liver fibrosis and
hazardous alcohol use, high BMI, or crack/cocaine use in the HIV/HCV co-infected
group, BMI could predict higher FIB-4 in participants who were older than 50 years.
BMI also had a significant interaction with crack/cocaine use in HIV/HCV co-infected
subjects, and this interaction significantly increased the odds of progressing FIB-4 stage
by a factor of nearly five (OR 4.985 [95% CI 1.130 – 21.993];P=0.034). The impact of
crack/cocaine and BMI on liver in HIV/HCV co-infection may be enhanced compared to
HIV mono-infection because of the underlying pathophysiology of HIV/HCV coinfection, so that the liver is more susceptible to facilitators of fibrogenesis.
The biological mediators of liver fibrosis were also investigated and we found
them to be elevated in HIV infection, including oxidative stress, such as malondialdehyde
(MDA) and % oxidized glutathione (GSH),22,23 the hepatic apoptosis marker Cytokeratin
18 (CK-18),24 transforming growth factor-beta1 (TGF-β1),25 and the microbial endotoxin
lipopolysaccharide (LPS).26 Our results show that high glutathione and LPS are
associated with progression of liver fibrosis over time in HIV mono-infection. This is a
unique finding because these biological mediators have not been found to predict liver
fibrosis progression over time in HIV mono-infected subjects in previous studies.
Interestingly, the effect that oxidative stress and microbial translocation had on liver

173

fibrosis was only revealed in combination with the clinical and demographic factors that
contribute to liver fibrosis. This suggests an interaction between biological mediators
and covariates of disease stage, treatment and host characteristics, such as age, gender,
CD4 cell count, and ART use that enhance liver fibrosis. Further research needs to be
conducted to investigate these interactions and target conditions that increase the effect of
the fibrogenic biomarkers on liver fibrosis. The mean values of TGF-β1 (P-value time =
0.001), CK-18 (P-value time = 0.006), and LPS (P-value time = 0.001) increased
significantly from baseline to 24 months. This indicates that biological mediators of
fibrosis may increase over time in HIV mono-infection. Furthermore, mean FIB-4 index
increased from mild fibrosis (1.24 ± 0.53) or the equivalent METAVIR stage F0-F1 to
more advanced stage of fibrosis (1.52 ±2.85) or the METAVIR equivalent ≥ F2 over 24
months in 65 mono-infected participants, and although the result was not statistically
significant, clinically, it indicates a trend in liver fibrosis progression in HIV monoinfection.
A cross-sectional analysis revealed the individual adverse lifestyle characteristics
with specific biological mediators that increased liver fibrosis. Subjects who were obese
had a significant positive association between % oxidized glutathione and higher FIB-4
index (β=0.563, P=0.018).
Obesity is associated with higher oxidative stress even in HIV-negative
populations,27,28 and this is the first report of the significant effect of increased oxidative
stress on liver fibrosis specifically in obese HIV mono-infected subjects. The marker for
hepatocyte apoptosis was independently associated with liver fibrosis in people who did
not have any of the investigated adverse lifestyle conditions (β=0.435, P=0.015),
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indicating that hepatic apoptosis may be an important driver of liver fibrosis in HIV
mono-infection.
Taken together, the findings of these studies describe interrelationships between
HIV disease status, lifestyle, and biological mediators of fibrosis that are elevated in HIV.
In addition, the results show that biological mediators of fibrogenesis were elevated
among PLWH with different lifestyle conditions, and that there may be important
interactions between lifestyle conditions and the biomarkers of mediators of liver fibrosis
that may account for higher rates of liver disease in HIV mono-infection. More research
is warranted to develop personalized therapeutics for this population to curb the growing
burden of liver disease as a co-morbidity.
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Table 1: Summary of hypotheses and major findings
Hypothesis #
Hypothesis
Major Findings
1
Adverse Lifestyle
AUDIT score was an independent predictor of liver fibrosis (FIB-4 index) in HIV mono-infection. Being
factors (high BMI,
overweight (BMI ≥ 28kg/m2) and drinking alcohol hazardously were independently associated with
drinking alcohol, and
increased FIB-4 in HIV mono-infection, but not co-infection. Having a high BMI independently increased
cocaine use) are
the odds of progressing in FIB-4 category by a 3.797 times (P=0.015) in the adjusted model. Drinking
associated with higher hazardously also increased the odds of progressing FIB-4 index significantly by 4.108 times over 2 years in
liver fibrosis measured HIV mono-infection (P=0.048). Crack/Cocaine use was associated with a 4.390 significantly lower odds of
with FIB-4, in HIVprogressing in FIB-4 index, (P=0.038) due to an interaction with BMI in HIV mono-infection. When
mono and HIV/HCV
controlling for BMI, the effect of cocaine loses significance.
co-infection.
None of the lifestyle factors were independently associated with FIB-4 index in HIV/HCV co-infection,
however, the interaction with cocaine and BMI significantly increased FIB-4 index by a factor of nearly 5
(P=0.034).
We can reject the null hypothesis that states there is no association with adverse lifestyle factors and liver
fibrosis in HIV mono-infection; however, we cannot reject the null hypothesis in HIV/HCV co-infection.
2
Increased oxidative
None of the biological mediators could independently predict liver fibrosis progression over 2 years. High
stress, microbial
baseline measures of % oxidized glutathione (aOR 4.342, P=0.046) and circulating microbial endotoxin LPS
translocation,
(aOR 1.098, P=0.097) are associated with increased odds of progressing at least one category of liver fibrosis
hepatocyte apoptosis,
over 2 years, however, GSH was only significant in models adjusting for covariates and LPS only showed a
and TGF-β1
trend towards statistical significance. Increasing levels of hepatocyte apoptosis marker CK-18 are
independently increase significantly associated with progressing in stage of liver fibrosis and FIB-4 index over 2 years (β= 2.011,
the risk of liver
P=0.043), and high levels are associated with odds of progressing in FIB-4 category (OR 1.008, P=0.021)
fibrosis over time (2
but these findings lose significance in multivariate models adjusting for age, gender, HIV viral load, CD4
years) in HIV monocell count, and ethnicity.
infection.
We cannot reject the null hypothesis that high levels of biological mediators of fibrosis care associated with
increased liver fibrosis over 2 years. Secondary analyses show associations between increasing biomarkers
over time, and FIB-4 index in HIV mono-infected population.
3
Oxidative stress,
Circulating levels of oxidative stress were significantly and independently associated with an increase in
microbial
liver fibrosis index (FIB-4) in obese HIV+ subjects.
translocation,
Higher hepatocyte apoptosis marker CK-18 independently predicts an increase in liver fibrosis in HIV+
hepatocyte apoptosis,
subjects with no adverse lifestyle conditions.
and TGF-β1 are
TGF- β1 is associated with a trend in the increase of liver fibrosis in cocaine users (β=0.858, P=0.027) and a
increased HIVtrend in interaction between MDA and TGF-β1 (F=3.171, P=0.071) on increasing FIB-4 index in the control
infected participants
group.
who have high BMI,
We cannot reject the null hypothesis, because there were significant biomarkers associated with FIB-4 index
drink or abuse alcohol, in the control group that did not have adverse lifestyle factors, suggesting that HIV infection and/or
or use cocaine
HIVHCV co-infection contributes to liver fibrosis; however, our results suggest that biological mediators
compared to controls.
that potentiate liver fibrosis may differ slightly between subjects with different lifestyle conditions.
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CHAPTER VIII: STRENGTHS AND LIMITATIONS
The results for this study may guide future research to develop personalized
diagnostic and therapeutic targets of liver fibrosis in people living with HIV. This is the
first study to examine the relationships between adverse lifestyle factors that
disproportionately affect the HIV population and biological mediators that are higher in
PLWH with liver fibrosis, a non-AIDS co-morbidity.
The strengths of this study include capturing longitudinal data of an HIV+ cohort
who use cocaine and drink hazardously, which are lifestyle factors associated with low
study retention.1 HIV mono-infection is associated with higher rates of liver disease and
mortality compared to the non-infected population,2 and this study highlights significant
lifestyle factors and biological mediators that may generate new therapeutic approaches
to treatment. Further investigations are needed to confirm these findings in a larger
cohort with adequate sample size.
Design and Sample Size
The main limitation of this research are derived from its design as a secondary
analysis of data. The laboratory data for biological mediators, however, were generated
for the purpose of this work. Ideally, an experimental design for this research would
include more participants who progressed in the FIB-4 categories, and who use cocaine
combined with a low AUDIT score to be able to separate the effects of cocaine from that
of the alcohol, and have adequate sample size for testing each hypothesis.
Methods
Plasma samples were used for laboratory analyses of biological mediators. The
limulus amebocyte lysate (LAL) assay (Lonza, Walkersville, MD, USA), has been
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widely used for the detection of endotoxin for approximately 30 years,3 and in HIVrelated research, however, plasma is not the recommended sample type due to possible
presence of inhibitory proteins.4-7 Recently, methods have been developed to measure
LPS using the LAL Lonza kit in plasma of HIV+ patients.4 A large coefficient of
variance (CV > 20%) was initially observed, for our samples, suggesting that the assay
was not generating accurate results for the samples. After developing methods to treat
samples with high CVs, the results improved, but it would be beneficial to corroborate
LPS results with a surrogate marker of microbial translocation such as sCD14 that is
associated with the LPS-binding protein.8
Although liver biopsy is the current gold standard for staging liver fibrosis by
using METAVIR scores, it is highly invasive and it is risky and ethical to perform the
procedure for research purposes only.9 Specifically in HIV patients, repeated biopsies are
contraindicated because of the increased risk of internal hemorrhage due to
thrombocytopenia.9,10 The FIB-4 index is a non-invasive measure of liver fibrosis that is
calculated using data collected by common laboratory values using the formula:
[(AgeXAST)/(PlateletsX√(ALT))]. Cut off points for liver fibrosis categories are: (FIB-4
<1.45) none/mild fibrosis, (1.45≤ FIB4 ≤3.25) moderate to severe fibrosis, and (FIB-4
>3.25) cirrhosis that correspond to METAVIR scores of liver fibrosis F0-F1, F2-F3 and
F4, respectively.11,12 The study may have benefitted by using a second non-invasive index
of fibrosis, such as APRI, to reveal different associations for risk factors of liver fibrosis
in HIV-infected subjects. For example, Mendeni et al.13 found that progression of liver
fibrosis occurred in 8.3% of their HIV-infected sample when using FIB-4 categories of
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liver fibrosis. In the same sample, the proportion of subjects who were categorized as
having progressed in stage of liver fibrosis increased to 31% using APRI score.
Hepatitis C infection (HCV) is a significant contributor of liver fibrosis in HIVinfection.14-16 The data in the parent study had limited information about HCV treatment
history, genotype, and viral load. Future studies should take into account HCV variables
when developing a research design. Despite these limitations, our results offer new
insights into associations and interactions between biological mediators of liver fibrosis
and adverse lifestyle factors and their relationship with HIV-infection.
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CHAPTER IX: FUTURE RESEARCH
A greater part of the literature in HIV and liver fibrosis examines hepatitis C
(HCV) as a primary source of fibrosis,1-3 however, our study strongly suggests that
adverse lifestyle factors play a role in increasing prevalence of liver fibrosis in HIV
mono-infection and may have interactions to increase fibrosis in HIV/HCV co-infection.
Biological mediators of liver damage that are elevated in people living with HIV
(PLWH) are associated with increased liver fibrosis development over time, and this
relationship may be further examined for time-dependent associations with liver disease.
Our research suggests that oxidative stress, hepatocyte-specific apoptosis, profibrogenic
cytokine TGF-β1, and microbial translocation contribute to liver fibrosis differently
under different lifestyle conditions, which provides a link between elevated biological
mediators in HIV, adverse lifestyle conditions prevalent in HIV+ populations, and the
development of liver fibrosis. Future research could aim to identify specific markers of
liver fibrosis concerning PLWH who are experiencing adverse lifestyle conditions, and to
elucidate and explain specific mechanisms by which these interactions drive liver
fibrosis.
Initial studies using new direct acting antivirals (DAAs), such as Sofosbuvir and
Ribavirin, show high cure rates in HIV/HCV co-infected populations,4,5 and although
DAAs are not widely available to PLWH due to multiple barriers,6,7 future research could
study the effects of DAAs on liver hepatotoxicity, especially in combination with HIV
antiretroviral therapies. A high cure rate of HCV in HIV-infected populations may
warrant more research into liver fibrosis in HIV mono-infected populations in future
studies.
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Although the size of this study was relatively small, our significant findings may
encourage research into complex biological relationships arising from health and
behavioral conditions in HIV. Finally, this research highlights the potential for
personalized treatment of risk factors associated with FIB-4, a non-invasive liver fibrosis
index in HIV mono- and HIV/HCV co-infection. Studies examining best approaches to
translate these findings into recommendations for PLWH are warranted.
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